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Abstract 
ADAMTS13 regulates the multimeric size of von Willebrand factor (VWF). Its function 
is highly dependent upon Ca^^ ions. In the present work, using the initial rates of 
substrate (VWF115, VWF residues 1554-1668) proteolysis by ADAMTS13 pre-
incubated with varying Ca^ concentrations, a high affinity functional ADAMTS13 
binding site was suggested with KD(app) of ~70|aM, corroborating a previously 
reported study. When Glu83 or Asp173 (residues involved in a predicted Ca^^ binding 
site in the ADAMTS13 metalloprotease domain) were mutated to alanine, 
dependence of proteolysis of VWF115 was unaffected, but ADAMTS13 activity 
against full-length VWF was severely compromised. Consequently, a candidate Ca^^ 
binding site relating to the KD(app) was sought and identified in close proximity to the 
ADAMTS13 active site, potentially comprising Glu184, Asp187 and Glu212. 
Mutagenesis of these residues within this site to alanine dramatically increased the 
KD(app) for Ca^'^of ADAMTS13 cleavage of VWF115, and for D187A and E212A also 
reduced the V^ax of initial rates to -25% normal. Kinetic analysis of the Asp187 
mutant in the presence of excess Ca^* revealed a -13 fold reduction in specificity 
constant, kca/Km, contributed by changes in both Km and kcat. These results 
demonstrate that a major influence of Ca^* upon ADAMTS13 function is mediated 
through binding to a high affinity site adjacent to its active site cleft. 
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Chapter 1 
Introduction 
1.1 Introduction to Haemostasis 
Haemostasis is a regulated process, maintaining blood flow through the vascular 
system, preventing blood loss at sites of vessel injury. At these sites three events 
occur to prevent blood loss: 1) vasoconstriction to reduce blood flow; 2) formation of 
a primary platelet plug, which rapidly limits blood loss, but is unstable; 3) stabilisation 
of the platelet plug through the coagulation cascade, and the resulting formation of 
thrombin which converts soluble fibrinogen to fibrin. This third process locks the initial 
platelet plug into a meshwork, holding it in a firm haemostatic plug. 
1.2 Von Willebrand Factor 
Primary haemostasis involves the formation of a platelet plug following vessel injury. 
Platelets form this plug through their interactions with the vessel wall and with von 
Willebrand factor (VWF)^'^, VWF is a large (>250kDa) multimeric multi-domain 
glycoprotein® with two main functions in haemostasis, to form a bridge between 
damaged vessel wall and platelets, and to stabilise and protect blood clotting factor 
Vll l^ 
1.2.1 VWF synthesis and secretion 
1.2.1.1 Tissue distribution and sites of synthesis 
VWF is found in plasma, endothelial cells (EC), megakaryocytes and the 
subendothelial matrix. Biosynthesis of VWF is limited to EC and megakaryocytes in 
vivo.^ In EC, VWF is either secreted via a constitutive pathway or stored in Weibel-
Palade bodies until cellular signals induce its release. VWF in megakaryocytes is 
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stored in the a-granules of mature platelets. It was recently shown that most of the 
continuously secreted VWF derives from post-Golgi secretory vesicles, being held 
before release in these storage pools, presumed to be Weibel-palade bodies®'^ . The 
majority of circulating VWF is derived from the endothelium®. Evidence also suggests 
that expression of VWF may vary between vascular beds, in particular between veins 
and arteries. Porcine studies showed the presence of VWF consisitently in most 
venous EC but not in most arterial EC® and similar studies in mice confirmed this 
difference in venous and arterial distribution of VWF^°. VWF has also been shown to 
be involved in the formation of atherosclerotic plaques in lesion-prone sites of the 
arterial tree, through its ability to strongly tether platelets and EC, possibly providing 
a docking site for monocyte recruitment to the sub-endothelial space^\ 
1.2.1.2 Gene structure and transcriptional regulation 
The VWF gene is located on chromosome 12 near the tip of the short arm^^. 
Following transcription, RNA product is spliced to remove 51 introns. Exon 1 encodes 
a 5' untranslated sequence, exons 2-18 encode a signal and propeptide sequence 
and exons 19-52 encode for the mature VWF subunit (Fig. 1.3). Regulation of VWF 
expression has been investigated using the promoter sequence linked to a reporter 
gene where the promoter sequence was comprised of base pairs -487 to +247 
(numbered relative to the transcription start site). This promoter was sufficient to 
mediate endothelial specific expression of the reporter gene in transfected cells 
studied in vitro^^. 
1.2.1.3 Dimerisation and multimerisation 
Pre-pro-VWF undergoes extensive post-translational modifications in the 
endoplasmic reticulum (ER), as well as dimerisation and multimerisation later on in 
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the Golgi network '^^ '^ ®. The pre-pro-VWF contains a signal peptide of 21 amino acids 
that directs the protein to the rough ER where it is cleaved. N-linked glycosylation 
occurs, involving the addition of sugar structures to 16 predicted asparagine 
residues^®. This glycosylation is essential for subsequent dimerisation, which occurs 
in the ER^^. Dimers of VWF monomers are formed by intermolecular disulphide 
bonds in the cysteine knot (CK) region of adjacent VWF molecules (Fig.1.1)^^"'®, with 
subsequent exit from the ER being dependent on this dimerisation and 
glycosylation^°. It is suggested that sequences near the carboxyl terminus (in the CK 
domain) are responsible for retention of monomers until dimerisation is complete^. In 
the absence of dimerisation, VWF is retained specifically by ER regulatory proteins 
with subsequent degradation of remaining VWF monomers^^'^^. 
VWF dimers are transported to the Golgi for modification of N-linked glycans by 
trimming and addition of further sugar groups, creating complex glycan structures^^. 
Further glycan structures are added in the Golgi with ten 0-linked glycans added to 
serine and threonine residues^®. Pro-VWF dimers are polymerised in the Golgi 
network by utilising additional disulphide bonds near to the N terminus (Fig. 1.1). 
Disulphide bonding occurs specifically between D3 domains^®'^ "^  and has been found 
to be heavily dependent on two specific residues, Cys1099 and Cys1142^®. 
Multimerisation is heavily dependent on the presence of Ca^^ ions and acidic pH 
found within the Golgi network. In addition, evidence for protein disulphide isomerase 
activity, which catalyzes the formation of native disulphide bonds, specifically 
conferred by a CXXC motif^ '^^ ® has been found in the propeptide^^. This pro-peptide 
is eventually cleaved by furin^®, after which it remains non-covalently associated with 
VWF, until secretion. The largest VWF multimers secreted into the blood may contain 
over 40 subunits and be as long as the combined diameters of a several platelets, 
with a potential molecular weight of a ~20000kDa^®. Fig. 1.2 illustrates the distribution 
of VWF multimers in plasma. 
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Figure 1.1 Dimerisation and Multimerisation of VWF 
Within the ER, VWF dimers are formed by intersubunit disulphide bonds between cysteine residues located in the C-
terminal region of each mature VWF monomer. Multimerisation of pro-VWF dimers occurs in the post-Golgi by the 
formation of intermolecular disulphide bonds between cysteine residues located at the N-terminal ends of adjacent 
molecules. Following multimerisation, the propeptide is cleaved by furin, and remains non-covalently associated with 
VWF. Adapted from Sadler (1998)®' 
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Figure 1.2 Subunit composition of VWF in plasma 
Electrophoresis of normal non-reduced plasma VWF in SDS-1% agarose gel (left panel) separates VWF 
multimers according to their size. The sample was applied on top of the gel. After electrophoresis, the 
proteins were electrotransferred to nitrocellulose and the bands of VWF were detected using 
peroxidase-labeled rabbit IgG against human VWF. The bottom band, having the most rapid anodic 
mobility, corresponds in size to the dimer (500 kDa) of the VWF polypeptide subunit (middle panel). 
Each slower migrating band is one dimer larger than the faster one. The arrow (right panel) 
schematically illustrates the decrease of the functional activity (binding affinity for collagen or platelet 
receptor GPIb) in small molecular forms of VWF. Adapted from Furlan (1996) 
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1.2.1.4 Secretion 
Once VWF has undergone these post translational modifications in the ER and Golgi, 
the mature product can take either of two pathways, secretion or storage. It is 
secreted constitutively and is stored in Weibel-Palade bodies, which are unique 
storage granules in the or it may be stored in a-granules in megakaryocytes, 
being released after platelet activation^'^. The majority of mature VWF synthesised in 
ECs is constitutively secreted (-95%), and is made up of low to medium molecular 
weight species^®. The highest molecular weight multimers are those that remain 
stored in Weibel-Palade bodies, and these are the most biologically active®®. VWF 
undergoes helical packing into tubules, which are held in place by Ca^^ and pH-
dependent (acidic pH) contacts between the propeptide and dimeric D'D3 domains®^. 
These tubules can be viewed using electron microscopy^®. In this state, the VWF 
tubules may be thought of as constrained springs. In contrast, upon secretion, 
release from Weibel-Palade bodies and the increase in pH to neutral weaken these 
constraints allowing tubules to unfurl into flowing blood without tangling®^. These ultra 
large multimers (UL-VWF), once secreted, are cleared with a half life of 12-20 hrs. 
Weibel-Palade bodies are only found in ECs and they store VWF and other co-
localised proteins in longitudinally arranged tubular structures®® '^ ". Exactly how VWF 
is targeted to Weibel-Palade bodies is unknown but it is suggested that VWF itself is 
involved in their formation, since ECs of mice and pigs deficient in VWF were also 
deficient in Weibel Palade bodies'^ ^ '^ .^ It is hypothesised that it is the multimerisation 
of VWF in the trans Golgi network specifically that leads to the formation of these 
bodies since only cells that synthesise multimeric forms of the protein can form 
Weibel-Palade body-like structures, although some studies have contradicted these 
findings'^ ®'*'^ . There is strong evidence that the propeptide is essential for the 
formation of storage granules as VWF expressed lacking this fragment is unable to 
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form them^®. VWF and associated Weibel-Palade body proteins are secreted through 
translocation of these bodies from the cytoplasm to the plasma membrane and 
subsequent fusion of these organelles with the membrane. Agonists of VWF release 
include thrombin, histamine, fibrin, complement components, leukotrienes and 
oxidative stress'^ ®"''®. These agonists function specifically by raising the cytosolic Ca^ "^  
concentration'^®"^\ and stimulating downstream Ca^^ signalling pathways, leading to 
release. Regulated secretion of VWF can also be induced by adrenalin, adenosine or 
DDAVP (1 -deamino-8-D-arginine vasopressin)®^'®^, which has been used in the 
treatment of von Willebrands disease (VWD)®'*. Physical activity also raises plasma 
VWF levels, as both elevated sheer stress and hypoxia cause ECs to secrete VWF 
from storage®®'® .^ 
1.2.2 VWF structure and function 
Mature VWF multimers may contain a variable number of VWF monomeric subunits. 
The monomeric VWF protein of 2050 residues consists of domains arranged as 
shown in Fig. 1.3®. The multimeric nature of VWF can be visualised using agarose 
gel electrophoresis under non reducing conditions with subsequent Western blotting 
(Fig. 1.2f^. Each pro-VWF monomer is comprised of five types of repeating domain: 
four D domains and a truncated D domain, three A domains, three B domains, two C 
domains and a CK domain. 
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Figure 1.3: Domain structure of pre-pro VWF 
A,B,C,D and CK indicate the five structural domains. Amino acid residues are numbered consecutively 1-2813, 
beginning with the initiation codon. Residues 1-22 indicate the signal peptide; Residues 23-763 indicate the 
propeptide; 764-2813 show the mature subunit polypeptide. Intersubunit disulphide bonds are shown by S-S. Also 
shown are: factor VIII binding site, GPIba site, ADAIVITS13 cleavage site (Y1605-M1606), collagen binding site and 
GPIIb-llla binding site, (adapted from Sadler, 1998^) 
1.2.2.1 D domains 
The VWF propeptide (D1-D2) is required for multimerisation, with mutation in this 
region resulting in failure of N-terminal dimerisation^®. The propeptide region of 
several enzymes has been shown to be involved in the correct folding of the mature 
protein, acting as a molecular chaperone^®'®°. This is also the case with VWF, with 
the propeptide functioning to fold VWF into the correct orientation for disulphide 
bonding^V The D' and D3 domains represent the N-terminal portion of the mature 
VWF monomer. The D domains are rich in cysteine residues, and there is 
appreciable sequence similarity between them, with the position of most of the 
cysteine residues being conserved. This suggests a similar tertiary structure of each, 
since cysteine residues are commonly involved in disulphide bonding and hence 
stabilisation of folds®^. This propeptide region together with D' - A1 domains is 
necessary for the efficient storage of UL-VWF multimers in tubules in Weibel Palade 
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bodies, contributing also to actual tubule formation®®. It is thought that this tubular 
storage is vital to prevent entanglement of these very long multimers prior to release. 
As well as mediating adhesion of platelets to the subendothelium, VWF also serves 
as a carrier for factor VIII, protecting it from inactivation by activated protein C and 
preventing activation by factor X a ^ ^ . VWF also acts a cofactor for the cleavage of 
the factor VIII light chain catalysed by thrombin®®. The factor VIII binding site has 
been localized to the D' and D3 domains of VWF®®®^ . Factor VIII circulates with VWF 
in a non-covalently associated complex, with Kd of 200-400 pM®®'^ °, but this affinity is 
compromised when VWF is bound to collagen decreasing to ~ 5nM^\ 
The D' and D3 domains have also been suggested to participate in binding to P-
selectin, leading to the anchoring of VWF to the endothelium^^, and also to its 
recruitment to Weibel-palade bodies^®. Anchoring through avps integrin has also 
been shown to be responsible for anchoring VWF strings to the endothelium under 
physiological conditions of Ca^ and Mg^^, and it has been suggested that both 
anchoring mechanisms may have roles in vivo^''. 
1.2.2.2 A domains 
A1, A2 and A3 domains are homologous in VWF and span residues 1260-1874^®. 
A1 and AS contain an intramolecular disulphide bond which forms a loop region. 
Crystal structures for both have been d e t e r m i n e d T h e A1 domain contains the 
GPIba binding site, through which platelets are able to adhere to VWF multimers^®. 
GPIba is a component of the platelet GPIb-IX-V complex^®, which, with VWF, 
supports platelet adhesion to laminin®°. Residues in the A1 domain are important for 
this interaction®^ particularly Asp1277-Glu1305®^. This region is also thought to 
interact with the D'D3 region as it was demonstrated to be in close proximity to the 
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A1 domain when VWF was in a soluble conformation®^. The A1 domain contains a 
heparin binding site®"* and binding sites for sulphatides, suggesting possible 
interactions of VWF with matrix glycosaminoglycans®^ Collagen also binds to the 
VWF A domains and two types, type I and type III, are involved. Type III collagen is 
found in the subendothelium and becomes exposed after surface injury of the 
endothelium, whereas type I collagen is found deeper in the vessel wall and only 
becomes exposed after more extensive vessel damage. Both A1 and A3 domains 
contain collagen binding sites^'^, although the major collagen binding site is located 
in the A3 domain®®. It is proposed that initial binding of collagen to VWF occurs 
through the A3 domain, which then causes VWF to unfold under the influence of 
shear stress, allowing exposure of the A1 domain collagen binding site®®. The highest 
molecular weight VWF species have the greatest collagen-binding capacity, since 
they contain more collagen binding sites, binding with Kd 1-7nM. 
The A2 domain contains the ADAMTSIS (A disintegrin and metalloprotease with 
thrombospondin repeats 13) cleavage site, the cleavage of which converts large 
VWF multimers into smaller, less platelet adhesive forms. ADAMTS13 cleaves 
specifically between Tyr1605-Met1606. Under normal conditions this cleavage is 
slow due to the globular conformation adopted by VWF in addition to the particularly 
complex folding of the A2 domain®". Unfolding and cleavage requires high shear 
stress conditions in vivo or the use of denaturants in vitro^\ 
1.2.2.3 D4 and B domains 
These domains form the region between the A3 domain and the C1 domain of VWF. 
There has been little published on this region of the VWF molecule and no specific 
functional role has yet been assigned for either domain. Expression of recombinant 
VWF with the D4 domain deleted had no effect on VWF multimeric structure and did 
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not alter binding to collagen type 11!®^ . Further studies on these domains are needed 
to ascertain whether they have any specific function in VWF. 
1.2.2.4 C domains and the CK domain 
The C and CK domains are located at the C-terminal end of the VWF monomer. C1-
C2 spans residues 2255-2645 and has sequence homology to cysteine-rich domains 
found in thrombospondin and procollagen®^. The C1 domain contains a binding site 
for GPIIpllla integrin on the surface of activated platelets. The CK domain spans the 
final residues of VWF from 2724 to 2813 and contains the intersubunit disulphide 
bonding site important for dimerisation, which, together with the D3 site, allows 
efficient multimerisation of VWF into large and ultra-large multimers. This CK domain 
contains a common dimerisation motif found in many growth factors of the neutrophin 
family^. 
1.2.2.5 VWF and primary platelet plug formation 
In normal circulation, VWF is generally in a globular form and it only becomes 
unfolded on anchoring to the subendothelial matrix and when subject to shear force. 
In this globular form, VWF does not interact with circulating platelets as none of its 
platelet binding sites are exposed. An early haemostatic event following a disruption 
of the endothelium involves VWF binding to exposed subendothelial matrix proteins, 
mainly collagen. High molecular weight VWF multimers are released from the 
Weibel-Palade bodies in ECs in the apical direction. Once released they are stopped 
from escaping into the circulation by binding to subendothelial collagen and EC 
attachment®''. Blood flow induces shear stress upon the tethered VWF, which then 
causes it to unfold, adopting an elongated structure. This elongated VWF exhibits 
greater affinity for the GPIb-IX-V receptor complex on the surface of circulating 
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platelets due to the exposed A1 domain binding site, resulting in their tethering at the 
sites of vascular damage and formation of a primary platelet plug®®. VWF function is 
therefore heavily dependent on the fluid shear stress of circulating blood. Provided 
VWF is unfolded by shear forces, platelets that encounter it can be tethered at the 
endothelial surface and become attached. These platelets become activated and 
immobile causing them to change shape and activate other platelets®®. It has been 
observed that in the absence of shear stress, only a small percentage of VWF 
molecules are unfolded, while the majority are coiled into a 'ball'®^. The larger the 
VWF multimer, the more readily it unravels. Once platelets have adhered to sites of 
vascular injury, further platelets are recruited by the above mechanisms and by 
fibrinogen interacting with GPIIBIIIa. This latter interaction forms the predominant link 
between aggregated platelets at low shear stress i.e. in the venous circulation®^. At 
high shear stress fibrinogen alone is not enough to hold a stable platelet plug 
together and VWF is also required®®'^ °°. It has also recently been suggested that UL-
VWF secreted by ECs and subsequently anchored to them, can covalently associate 
with VWF muitimers in plasma to form longer, thicker, string-like VWF structures, 
involving thiols exposed on the surface of VWF multimers^°^"^°^. 
1.2.3 Von Willebrand Disease (VWD) 
1.2.3.1 Type 1 VWD 
VWD is the most common inherited human bleeding disorder with symptoms 
including nose bleeding, skin bruising, prolonged bleeding, oral cavity bleeding and 
excessive menstrual bleeding^. VWD is categorised as qualitative (type 2) or 
quantitative (type 1 & 3)^ °'^  deficiencies. In type 1 VWD, the distribution of VWF 
muitimers is unchanged but all molecular forms are proportionally reduced (Fig.1.4). 
It is frequently caused by frameshift, nonsense mutations or deletions that overlap 
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with those involved in type 3 VWD. These result in reduced secretion with normal 
multimer distribution, possibly by impairing intracellular transport of VWF subunits. 
1.2.3.2 Type 3 VWD 
Type 3 VWD is a recessive disorder where there is a very low level of detectable 
VWF protein (in some cases completely absent) (Fig.1.4), affecting both its role in 
primary and secondary haemostasis. The mutations involved are usually frameshift 
or nonsense, leading to incomplete protein or impaired folding and often overlap with 
type I deficiency mutations^"®. 
A non-processed VWF pseudogene is located on chromosome 22 (22q11) which is 
~29kb in length, spanning exons 23-34 of the functional VWF gene and has 97% 
sequence homology with the region on chromosome 12 encoding domains A1-A2-A3 
(see Fig. 1.3). This pseudogene has several missense, nonsense and splice site 
mutations that prevent the generation of a functional transcript. In some patients with 
von Willebrand's Disease (VWD), characteristic sequences of the pseudogene have 
been found in the VWF gene, possibly from localized gene conversion^". 
1.2.3.3 Type 2 VWD 
Type 2 VWD involves qualitative VWF defects with impaired platelet adhesion or 
factor VIII binding. Type 2A shows selective absence of large VWF multimers 
(Fig.1,4), necessary for efficient haemostasis. It is usually passed on as a dominant 
disorder involving a single amino acid substitution within the A1 and/or A2 domains. 
Two distinct molecular mechanisms may be involved in causing the type 2A VWD 
phenotype, caused by one of two types of mutation. Group I mutations are 
associated with impaired assembly and secretion of normal VWF multimers^°® 
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(Fig.1.4). Group II mutations are associated with normal processing and secretion of 
VWF multimers, but then the large and intermediate weight multimers are lost in the 
plasma due to increased susceptibility to cleavage by ADAMTS13 (Fig.1.4)^°^"^°®. The 
A2 domain of VWF is likely to be in a highly folded conformation that normally hides 
the cleavage site. Hence, it is possible that mutations in this region cause the domain 
to become partially unfolded, and so allow easier access of ADAMTS13 to the 
cleavage site. Type 2B is characterised by increased affinity of the mutant form for 
platelets®. This leads to spontaneous binding of large VWF multimers to platelets 
followed by clearance of the complex, resulting in only small circulating multimers 
(Fig.1.4). These small multimers though, appear to bind platelets in such a way as to 
inhibit their interaction with connective tissue^"®. Type 2M, in contrast, involves 
impaired ability of the mutant VWF to bind to platelets without deficiency of high 
molecular weight multimers. Assembly and secretion are normal, but mutations in the 
A3 domain cause impaired binding to platelets or subendothelium^°®'"°.Type 2N 
involves a mutation which disrupts the binding site for factor VIII, usually due to 
mutations in the D'-D3 factor VIII binding region, and hence leads to bleeding via 
disruption of the downstream coagulation cascade^ " 
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Figure 1.4 Multimer patterns in VWD 
Samples of plasma from a normal Individual (N) and from patients with VWD types 1, 2A, 2B, and 3 
were electrophoresed through a 1.3% agarose/SDS gel and VWF was detected by Western blotting. 
Adapted from®°. 
1.2.4 Regulation and modification of VWF function 
1.2.4.1 Cleavage by ADAMTS13 
The highest molecular weight VWF multimers are the most biologically active, and 
their size must be carefully regulated to prevent abnormal thrombus formation. This 
is achieved in plasma by ADAMTS13, which cleaves at the Y1605-M1606 bond in 
the VWF A2 domain, generating 176kDa and 140kDa fragments in monomers"^ 
More recently, ADAMTS13 has been suggested to have a disulphide bond reduction 
activity on VWF^°^, but this requires confirmation. 
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1.2.4.2 Influence of Thrombospondin-1 
Thrombospondin-I (TSP-1) has been suggested to regulate VWF multimeric size. 
Administration of TSP-1 to mice resulted in reduction of VWF multimeric size""*. 
TSP-1 has been shown to interact with the VWF A3 domain"'^'''^®, and it has also 
been suggested that ADAMTS13 binds to a potential primary site in the same 
domain"®. This suggests that TSP-1 may compete with ADAMTS13 for binding to 
VWF and inhibit ADAIVITSI 3-mediated proteolysis. 
1.2.4.3 VWF levels in human plasma 
The average plasma VWF concentration is ~10|ig/ml (~40nM), although the normal 
distribution of plasma VWF concentration across the population shows a wide range. 
Low levels or deficiency of VWF have long been established as a contributing factor 
in VWD^°. Elevated levels may represent a risk factor for myocardial infarction and 
venous thromboembolic disease"^'"®. Both genetic and environmental factors may 
influence VWF levels in plasma. Three single nucleotide polymorphisms in the 5' 
promoter region of the VWF gene have been shown to affect plasma VWF 
concentration: CfT at 1234, A/G at 1185 and G/A at 1051"®. Increasing age, female 
gender, exercise, malignancy, infection or inflammation can increase VWF levels 
also"^. VWF levels have also been shown to vary across ethnic groups with 
Caucasians and Indians having significantly lower levels than African-Americans^^"' 
As previously mentioned, individuals with type 1 VWD have reduced VWF levels 
and those with type III VWD have almost complete VWF deficiency as a result of 
mutation. As well as the VWF gene, other gene loci can exert major quantitative 
effects on plasma VWF levels. The best known example are the ABO blood groups. 
ABH antigenic determinants have been identified on the A/-linked glycans of 
circulating VWF according to the blood group of the ind iv idual Ind iv iduals with 
blood group O have generally 20-30% lower levels of VWF compared to non-0 
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groups^^'^. Levels are highest in AB individuals followed by group B, group A. This 
has been attributed to a shorter VWF survival in plasma in individuals with blood 
group but also to increased susceptibility of VWF from blood group O 
individuals to cleavage by ADAMTS13^^®. N-linked glycans also affect the 
susceptibility of VWF to ADAMTS13 cleavage. Removal of the N-linked glycan at 
position 1574 resulted in higher affinity binding to ADAMTS13 and increased 
cleavage^^^. 
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1.3 ADAMTS13: the VWF Cleaving Protease 
The highest molecular weight VWF multimers have the greatest potential to 
aggregate platelets and this must be carefully regulated to prevent unwanted platelet 
aggregation. A metalloprotease that regulates VWF multimeric size was identified as 
the 13'^ member of the ADAMTS family^^®""^". 
1.3.1 ADAM and ADAMTS family metalloproteases 
ADAMTS1 was initially identified in 1997 as a new type of metalloprotease disintegrin 
family protein with thrombospondin type 1 m o t i f s ^ a f t e r which a large number of 
proteases sharing similar domain organization were described. The ADAMTS family 
now includes 19 proteases with various physiological functions. The wide variety of 
ADAMTS protein functions include: cleavage of matrix proteoglycans called 
aggrecans, which are found in high amounts in cartilage (ADAMTS 1,4,5,8,9,1 
collagen processing (ADAMTS2, 3, 14)^ 38,139^  inhibition of angiogenesis (ADAMTS1, 
2^ 40,141^  possibly gonadal development based on orthology with Gon-1 (ADAMTS9, 
20)^ ^® and VWF cleavage (ADAMTS13). ADAMTS6 has not yet been assigned a 
function^''^. ADAMTS12 has been found to associate with and degrade a cartilage 
matrix protein^"® and ADAMTS16 is capable of cleaving og-macroglobulin in human 
ovarian follicles^'^'^. Other family members (ADAMTS6,7,10,18,19) have no known 
function as yet. The ADAMTS family represents a branch of the M12B ADAM (A 
Disintegrin and metalloprotease-like or adamalysin) subfamily. The adamalysins 
belong to the family of metzincins (zinc-dependent proteases), which include matrix 
metalloproteases (MMPs), astacins and serralysins^"®'^ '*®. They are named as such 
because of the zinc ion located in their active sites and a conserved methionine 
downstream from the catalytic site, which generates a characteristic "Met-turn". 
ADAMTS and ADAM family members show a high degree of similarity in the 
organisation of their domains (Fig. 1.5). They both contain a signal peptide, 
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propeptide, metalloprotease domain, disintegrin-like domain and a cysteine-rich 
domain. ADAM proteases are usually transmembrane proteins, whereas ADAMTS 
family members are secreted enzymes. ADAM metalloproteases also differ in that 
they have an epidermal growth factor (EGF)-like domain whereas a spacer domain 
and at least one Thrombospondin Type 1 repeat (TSP-1) are present in the ADAMTS 
sequence, together with additional C-terminal domains. ADAMTS13 shows the 
highest degree of divergence from any other ADAMTS family member, due to two C-
terminal CUB domains but also by the presence of a much smaller propeptide. 
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Figure 1.5 Schematic diagram of ADAM and ADAMTS metalloproteases and of ADAMTS13 
SP indicates signal peptide; pro, propeptide; protease, metalloprotease (location of zinc-binding motif shown in red); 
disintegrin, disintegrin domain; dis-like, disintegrin-like domain; cysteine-rich, cysteine-rich domain; TSP, 
thrombospondin type-1 motif; EGF, epidermal growth factor-like domain TM, transmembrane domain; CUB, CUB 
domain. 
(Adapted from Levy et al (2005) "^) 
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1.3.2 ADAMTS13 Structure and Function 
The VWF-cleaving protease gene was identified in 2001, and the deduced protein 
sequence indicates a structure very similar to that of other ADAMTS proteases, but 
with unique modules suggestive of distinct f u n c t i o n s ^ A D A I V I T S 13 domain 
structure comprises a classical signal peptide, propeptide, metalloprotease domain, 
disintegrin-like domain, TSP1 repeat, cysteine-rich domain and Spacer domain, 
characteristic of all ADAMTS proteins. Thereafter, 7 additional TSP1 repeats occur 
followed by two CUB (C1r/C1s, Urinary EGF and Bone morphogenetic protein) 
domains (Fig. 1.5). Plasma ADAMTS13 has a molecular weight of ~190kDa^''®. It is 
one of the largest members of the ADAMTS family '^*®'^ ®". The ADAIVITS 13 gene 
contains 29 exons, and the translation product consists of 1427 amino acids. 
ADAMTS 13 is expressed predominantly in the liver and secreted into the blood as an 
active enzyme and circulates at a concentration of ~5nM^^ ® 
1.3.2.1 ADAMTS13 propeptide 
Other ADAMTS proteases have propeptides up to -250 residues in length and 
contain 2 or 3 cysteine residues, which are thought to maintain enzyme latency by 
coordinating the active site Zn^^ ion. The ADAMTS13 propeptide has only 41 
residues with one cysteine, not in a typical "cysteine switch" environment. The 
propeptide ends with the sequence RQRR, which would suggest the presence a furin 
cleavage site. Other ADAMTS family propeptides are cleaved in this way either in the 
Golgi or on the cell surface '^^ ®. In other metalloproteases, the propeptide is essential 
in assisting in protein folding and maintaining enzyme latency^®\ Unlike most other 
ADAMTS proteases, ADAMTS13 remains active when secreted without propeptide 
removal, and its functional importance remains to be defined^^ '^^ ^®. 
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1.3.2.2 The metalloprotease domain 
The metalloprotease domain contains the active site of the protease. The folding of 
the domain is stabilized by conserved disulphide bonds in the ADAMTS family 
members. In ADAMTS13, disulphide pairing between cysteines 155-208, 202-281 
and 242-265 is also predicted '^^ ®. Like other ADAMTS family members, ADAMTS 13 
contains a characteristic metalloprotease domain containing three His residues that 
coordinate a catalytic Zn^^ ion in the active site. The His residues are in a sequence 
(HEXXHXXGXXHD) that is highly conserved^''®. There is also a conserved Met 
residue at amino acid position 249 in the ADAMTS13 protein sequence. A model of 
the crystal structure of Adamalysin II, a closely related metalloprotease, is shown in 
Fig. 1.6, illustrating the catalytic VWF-cleaving ability of ADAMTS13 is 
highly dependent on divalent cations, demonstrated by the observation that 
ethylenediaminetetraacetic acid (EDTA), which chelates such ions, renders 
ADAMTS13 completely inactive. One reason for this is the removal of the active site 
Zn^^ ion, whose coordination in the active site is essential for hydrolysis of the target 
peptide bond^ "^ ®. Here, the catalytic glutamic acid (Glu) in the enzyme active site 
reacts with the water molecule coordinating the Zn^^ ion, polarising it through 
hydrogen bonding, which promotes its nucleophillic attack on the carbonyl of the 
substrate scissile peptide bond^®®'^ ^^ . As well as Zn^* ions, lack of Ca^^ ions 
dramatically impairs the proteolysis of VWF^^®. 
Studies using C-terminal truncated mutants of recombinant ADAMTS13 have shown 
that the metalloprotease domain alone cannot efficiently cleave plasma VWF or a 
short A2 domain peptide, VWF73 (residues 1596-1668)^ "*®'^ °^'^ ®®. However, one of 
these studies demonstrated that the metalloprotease alone was able to cleave a 
short VWF substrate (VWF73) after long incubation periods (16-24 hrs), but at a 
different site than the Y1605-M1606 bond. These studies indicate that the 
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metalloprotease domain alone is insufficient for efficient recognition and specific 
cleavage of VWF. Additional downstream domains therefore must contribute to 
cleavage efficiency and perhaps substrate specificity. 
Figure 1.6 Model of Adamalysin II 
This model was generated from tlie Protein Database crystal structure 1IAG, and molecular modeling using Pymol. 
Tills structure shows the catalytic ion (grey) coordinated by three histidine residues (blue). 
1.3.2.3 The disintegrin-like domain 
The function of the disintegrin-like domain of ADAIVITSIS is not clear. Disintegrins 
have an important role in cell-cell and cell-matrix interactions by binding to the 
integrins on cell surfaces^®°'^ ®V They also prevent association of platelets with 
adhesive potential, and block their aggregation. In the snake venom 
metalloproteases, this domain binds to platelet integrin receptors. ADAM15 has been 
shown to interact with integrin allb(33 specifically via its disintegrin-like domain^®°. 
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However, these interactions with integrin require a specific RGD integrin recognition 
sequence which is not present in any ADAMTS family m e m b e r ^ T o date, it is 
unclear if this domain has a specific function or just a structural role. Although some 
mutations have been found in this region which contribute to inherited ADAMTS13 
deficiency (see section 1.3.4.1), it is unclear if they affect ADAMTS13 activity or 
merely impair secretion ®^2,i63 recently, ADAMTS13 has been suggested to be 
important in attenuating thrombus growth on diseased arteries under high shear 
stress, and antibodies against the disintegrin-like domain were specifically used to 
augment thrombus formation in these areas^®'^ . A study on various ADAMTS13 
truncation mutants demonstrated that ADAMTS13, containing only the 
metalloprotease and disintegrin domain, was inactive against full-length VWF^^°. 
Recent studies in our laboratory, however, have demonstrated that ADAMTS13, 
containing only these two domains, is active against the short VWF substrate 
VWF115, whereas the metalloprotease domain alone is not (de Groot et al, 
unpublished). 
1.3.2.4 Thrombospondin type-1 repeats (TSP-1s) 
TSP-ls were initially identified in TSP-1, a multifunctional protein present in platelet 
a-granules and released upon activation. TSP-1 regions commonly have positively 
charged patches with a high affinity for charged glycosaminoglycans and CD36 
receptors present on the surface of microvascular ECs The TSP-ls are seen 
in a wide variety of proteins, mainly in secreted proteins, and sometimes in the 
extracellular portion of transmembrane proteins, and appear to be involved in 
intercellular communication, migration of cells through the extracellular matrix and 
tissue remodelling in some tissues^®^. Most proteins with TSP-ls have been shown to 
be expressed in the developing nervous system, often in directing nerve cell 
migration^®^ ADAMTS13 has eight TSP-ls, the first one being located between the 
36 
disintegrin-like domain and the cysteine-rich domain. The other seven are located 
between the spacer domain and the two C-terminal CUB domains (Fig. 1.3). These 
latter seven TSP-ls contain the conserved sequence CSX(S/T)CG. The first TSP-1 
contains a specific sequence WXXW, which is often glycosylated in other TSP-1-
containing proteins '^^ ®. N-linked glycosylation has been found in ADAMTS13, with 10 
putative sites, some of which have been found to be important for secretion of the 
enzyme^®®. Like their role in other TSP-1-containing proteins, these repeats in 
ADAMTS13 may be responsible for localising ADAMTS13 to the surface of ECs by 
binding to glygosaminoglycans and to CD36. In support of this hypothesis, anti-CD36 
antibodies have been frequently found in patients with thrombotic thrombocytopenic 
purpura (TTP) which is a disease associated with ADAMTS13 deficiency (see section 
1.3.4). Alternatively, ADAMTS13 TSP-ls could be involved in VWF interaction, in 
manner similar to plasma TSP-1, which has been reported to bind to the A3 domain 
of Further studies are required to clarify these possibilities. 
1.3.2.5 Cysteine-rich domain 
This domain is rich in cysteine residues, as the name would suggest. The domain 
serves an unknown function in ADAMTS13. In ADAMTS4 the cysteine-rich and 
spacer domains bind sulphated glycosaminoglycans^®"'^ ®®. It is known that snake 
venom metalloproteases target VWA (VWF A-like) domains using their cysteine-rich 
domains, and can even target VWF in this way. It is possible that ADAMTS13 
cysteine-rich domain functions in a similar way, and so may be important in the 
interaction with the VWF A domains^^°. It also contains a potential integrin-binding 
sequence (RGD), although mutations of this sequence do not impair secretion or 
function of ADAMTS13 in vitro^'^^. This domain could, however, be important in 
ADAMTS13 activity as a polymorphism, P475S, in the Japanese population was 
identified and reported to reduce activity with normal secretion^^\ 
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The best evidence for an important role of the cysteine-rich domain of ADAMTS13 
has been provided by kinetic analysis of recombinant ADAMTS13 constructs. These 
have revealed that the TSP-1, Cysteine-rich, and spacer domains of ADAMTS13 
interact with segments of the VWF A2 domain between Gln1624 and Arg1668, and 
together these exosite interactions increase the rate of substrate cleavage by -300-
fold^^^. 
1.3.2.6 Spacer domain 
The spacer domain appears to be very important for efficient interaction of 
ADAMTS13 with VWF. Successive deletions of the CUB, TSP1 2-8 and spacer 
domains progressively lower proteolytic activity of the enzyme it has 
recently been found that the ADAMTS13 spacer domain binds to an exosite near the 
C terminus of the VWFA2 domain, with deletion of the spacer domain or VWF exosite 
reducing the rate of substrate cleavage -20 fold^^^. 
Furthermore, some missense mutations have been mapped to the spacer domain, 
being associated with congenital ADAMTS13 deficiency, although not all have been 
fully characterised '^^ ®'^ '^^ . Some patients with acquired ADAMTS13 deficiency develop 
autoantibodies against this region^^ '^^ ^®. In vitro experiments have shown that a 
monoclonal antibody against the cysteine-rich/spacer domain completely abolishes 
ADAMTS13 binding and cleavage of VWF, and also of a short substrate, VWF73^^® 
1.3.2.7 CUB domains 
The proximal carboxyl terminus is suggested to be responsible for substrate 
recognition and specificity, whereas the middle and distal parts are less critical, at 
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least under static conditions. The CUB domains may, however, be important for 
ADAMTS13 docking to VWF under flow^^ '^^ ^®. Several natural strains of 
phenotypically normal mice express a C-terminal truncation of ADAMTS13 after the 
seventh TSP-1, which implies that these domain, at least in mice, are not essential 
for ADAMTS13 function in vivo^^^. CUB domains are unique to ADAMTS13 in the 
ADAMTS family of metalloproteases, but are characteristic of another 
metalloprotease family that includes BMP-1 and mTolloid, both of which contain an 
astacin-like metalloprotease domain followed by an EGF like domain and up to five 
CUB domains^"*®. In these proteins the CUB domains interact with ligands and so 
contribute to substrate recognition and binding. Most CUB containing proteins are 
thought to be involved in developmental processes such as embryogenesis or 
organogenesis^^^. 
Autoantibodies against the CUB domains have also been found in patients with 
acquired TTP, but it is unknown whether they lead to impaired ADAMTS13 function 
or depletion Mutations in the CUB domains have also been reported in patients 
with congenital jjpi62,i8o recently, naturally occurring mutations of the CUB 
domains in ADAMTS 13 have been shown to impair secretion and particularly stability 
upon secretion^®\ 
1.3.2.8 ADAMTS13 function and interaction with VWF 
ADAMTS13 cleaves the peptide bond Y1605-M1606 in the A2 domain of VWF^°^ 
(Fig. 1.7) , regulating its multimeric size. In vivo, its activity is dependent upon the 
shear forces of flowing blood acting upon VWF to unravel it into an accessible 
conformation^®^, while in vitro, denaturants are required (Gdn-HCI or urea), along with 
long incubation times for cleavage to occur^ ®®. This suggests that the conformation of 
VWF is critical to determining the cleavability of VWF. Shear stress and denaturants 
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must induce changes in the conformation that expose the cleavage site, which is 
otherwise buried deep within the folded molecule. As mentioned previously, 
circulating VWF appears as a folded globular molecule by electron microscopy^®''. 
However, newly released VWF expressed by ECs after stimulation has been shown 
to form extremely long string-lit<e structures on the surface of ECs under flow 
conditions. These string-like structures are cleaved rapidly in the presence of normal 
plasma, but not ADAMTS13-deficient plasma, suggesting that this is a primary site of 
ADAMTS13action'®®'®®. 
With these findings it is possible to propose a model of VWF-ADAIVITS13 interaction 
in terms of location: ADAMTS13 circulates in plasma in an active form, so regulation 
of cleavage is mainly dependent on VWF conformation. VWF is normally present in 
plasma in a globular, folded form, which cannot either interact with platelets or be 
cleaved by ADAMTS13. However, in the presence of high shear stress, VWF can 
unravel, exposing the ADAMTSIS cleavage site. ADAMTS13 proteolysis prevents 
unwanted thrombus formation in the normal circulation in this way. A second site of 
ADAMTS13 action is on the surface of ECs where the newly secreted UL-VWF 
multimers emerge. Following EC stimulation, VWF is secreted from Weibel Palade 
bodies with high haemostatic potential. This UL-VWF tethers to ECs, and unravels. 
These unraveled, elongated strings have exposed A2 domain cleavage sites which 
ADAMTS13 can then bind to, leading to immediate proteolysis, providing a 
mechanism to avoid UL-VWF hyperactivity and spontaneous platelet adhesion. 
These models then raises the hypothesis that ADAMTS13 may need to anchor to the 
EC, possibly by binding to glycosaminoglycans and/or EC receptors via TSP-1s 
and/or CUB domains. In terms of the physical interaction between VWF and 
ADAMTS13, a two site model was proposed by Tao et al in which ADAMTS13 
circulates in plasma in equilibrium between a closed state (where an initial CUB-1 
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binding site is exposed but a second cryptic binding site is hidden) and an open state 
(where both sites are exposed). The closed conformation is favored when 
ADAMTSIS is in solution, and it is proposed that the open conformation is assumed 
only when ADAMTS13 binds to UL-VWF via its CUB-1 domain, after which the 
interaction can be stabilised by the binding to a second site. 
An additional role has recently been found for ADAMTS13 in the down-regulation of 
inflammation by preventing excessive leukocyte rolling and leukocyte adhesion, 
which are VWF-dependent processes^®®, highlighting the importance of ADAMTSIS 
cleavage of VWF not only in thrombosis but also inflammation. 
ADAMTSIS i 
COOH 
140 kDa 176 kDa 
Figure 1.7 VWF Y1605-M1606 cleavage site 
Schematic representation of VWF cleavage by ADAMTS13, with a close up of the A1, A2 and A3 domains. The 
ADAMTS13 cleavage site (Y1605-M1606) is located in the A2 domain and highlighted in blue. Adapted from 
Sadler(1998)^ 
1.3.3 Synthesis and secretion 
1.3.3.1 Tissue distribution and sites of synthesis 
ADAMTSIS has been shown to be synthesised and secreted mainly in hepatic 
stellate cells^®®, but more recent findings have shown that ADAMTSIS mRNA has 
also been detected in many other tissues including cultured ECs, as well as 
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megakaryocytes and platelets^®". Studies by Shang et aP®^  on ECs in culture showed 
that ADAIVITSIS and VWF appear to be partially co-localised to the ER, Golgi 
network and some secretory granules, as one would expect of secretory proteins. It 
is also suggested that this initial co-localisation in the ER may be provide an early 
regulatory step for VWF multimer size. ADAMTS13 is thought to be expressed 
apically in these cells, towards the lumen of the vessel. This apically secreted 
ADAMTS13 in the vascular endothelium may contribute significantly to the plasma 
level of the enzyme^ 
1.3.3.2 Gene structure and transcriptional regulation 
The human ADAMTS13 gene is located on chromosome 9 at position 9q34. It spans 
~37kb and contains 29 exons^® .^ ADAMTS13 mRNA is ~5kb and encodes a 1427 
amino acid protein, with a predicted molecular weight of 145 kDa, which differs from 
the observed molecular weight of purified plasma ADAMTSIS (180-200kDa)^^®'^^°. 
The molecular weight may be predicted from the number of amino acids, but the 
discrepancy between expected and observed molecular weight of ADAMTS13 is due 
to glycosylation, as there are ten potential glycosylation sites^ ^^ '^ ®®. ADAMTS 
proteases undergo N-terminal processing by a signal peptidase during translocation 
across the ER membrane, and then removal of the pro-peptide^®^. Alternative splicing 
occurs in ADAMTS13 processing. Several variant transcripts have been identified 
that truncate the protein after the metalloprotease domain, spacer domain or first 
CUB domain '^^ ®. This alternative splicing may account for the different sized 
transcripts found in placental and skeletal muscle. No other related gene product has 
been found. 
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1.3.3.3 ADAMTS13 secretion 
ADAMTS13 is constitutively secreted into the blood as an active enzyme. As 
mentioned previously (section 1.3.3.1), there is evidence to suggest that it may be 
secreted apically toward the lumen of vessels in ECs in vitro'^\ which appears to be 
dependent on the CUB domains as removal of these domains abolishes apical 
sorting. An increasing number of common polymorphisms have also been reported in 
ADAMTS13, particularly in the second CUB domain and the spacer region, leading to 
a reduced secretion of the mutated protein^®^. 
1.3.4 Thrombotic Thrombocytopenic Purpura (TTP) 
T I P is a rare but life threatening condition which has been found to be linked to high 
levels of UL-VWF^®^. It was first described in 1924 by Eli Moschowitz, who observed 
a young girl presenting with fever and haemolytic anemia, rapidly leading to coma 
and death^®'^ . It was in 2001 that the cause of high levels of UL-VWF was finally 
demonstrated to be due to a deficiency in the metalloprotease, ADAMTS13, that 
cleaves VWF into smaller fragments^®^. TTP is characterised by intravascular 
destruction of red blood cells and clearance of platelets resulting in anaemia and 
thrombocytopenia. Microthrombi are observed in small blood vessels of multiple 
organs and are rich in platelets and VWF. Such microvascular thrombosis often 
results in renal failure and neurological dysfunction^® '^^ ® .^ The annual incidence of 
TTP has been estimated to be four cases per million people in the United States but 
this appears to be increasing^®®'^ ® .^ Untreated TTP is almost always fatal, but plasma 
exchange/infusion therapy has reduced mortality from 90% to less than 20%^®®. 
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1.3.4.1 Familial TTP 
In 2001, Levy et aP®® reported a study in which 12 mutations in the ADAIVITS13 gene 
were identified in patients with TTP. Now more than 80 mutations have been 
documented in familial TTpisz,171,174,180,199-203 Affected patients are usually double 
heterozygous or homozygous carriers of mutated alleles, and when the parents were 
heterozygous, they were always asymptomatic^"". Familial TTP is rare, and usually 
presents in infancy or in childhood^"®. 75% of the missense mutations are found in 
the N-terminal part of ADAMTS13 up to the spacer domain, and 60% of the 
mutations discovered are missense. The other 40% are nonsense, frameshift or 
splicing mutations and result in truncated forms of the protein. The majority of 
mutations cause reduced ADAMTS13 s e c r e t i o n ^ T h r e e mutations have also 
been found which reduce ADAMTS13 activity; 1) P475S is a common polymorphism 
found in the Japanese population, located in the Cysteine-rich domain" \ 2) 
Q449stop (identified in the same study) possessed lower enzymatic activity than 
P475S, and is truncated after the first TSP-1^^\ 3) T196I found in the 
metalloprotease domain, has been reported to have less than 23% VWF-cleaving 
activity, compared to wild-type^®^. No patient described so far ever had null mutations 
on both alleles, suggesting that a complete deficiency of the enzyme may be lethaP°®" 
This is consistent with the observation that low levels of residual VWF-cleaving 
activity were detectable in all patients with TTP studied. 
1.3.4.2 Acquired TTP 
The more common form of TTP is acquired, and is associated with normal secretion 
and function of ADAMTS13. A circulating IgG inhibitor compromises its level and 
function. It usually occurs in individuals between 20 and 60 years old °^®. In 1998, 
inhibitory antibodies were identified for the first time in a patient with acquired TTP^^°. 
44 
Since then, autoantibodies inhibiting the activity of ADAIV1TS13 have been detected 
in most patients with acquired -rTpi^ s,176,211-214 epitope specificity of anti-
ADAIVITSIS antibodies has been investigated^^^'^^®, with the result that in most cases, 
the autoantibody response is polyclonal, directed at several epitopes of the molecule. 
Recent studies have shown that they are most commonly directed against the 
cysteine-rich/spacer domains^°^, suggesting that antibodies against this region are 
sufficient to induce acquired ADAMTS13 deficiency. 
1.3.4.3 Current treatments for TTP 
TTP is a life threatening disease, and mortality is high (>90%) if untreated. Plasma 
exchange has proved a useful and effective method for the treatment of acquired 
forms of the disease®°'^ '^ ^ .^ It replaces defective ADAMTS13, but also removes 
autoantibodies. B cells have been found to be key players in eliciting the immune 
response in auto-immune diseases^^®. The infusion of plasma containing normal 
ADAMTS13 every three weeks combined with Rituximab, an anti-CD20 monoclonal 
antibody that specifically depletes B cells is sufficient to avoid recurrent episodes of 
-|-jp205 patjgp^s with familial TTP usually do not require plasma exchange as they 
respond well to plasma infusions that partially restored ADAMTS13 levels. 
1.3.4.4 ADAMTS13 and other thrombotic microangiopathies 
TTP can be characterized by microangiopathic haemolysis and thrombocytopenia, 
but other conditions can lead to similar phenotypes including: bone marrow 
transplantation^^®'^^®, pregnancy^^°, autoimmune disorders (systemic lupus 
erythematosus)^^\ neoplastic disorders^^^"^^^, liver cirrhosis, some acute 
inflammatory disorders and postoperative period^ '^^ . Decreased levels of ADAMTS13 
have also been found in some of the above mentioned conditions, although in some 
cases decreased ADAMTS13 is likely to be a side effect of the disease rather than a 
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cause. Two other thrombotic microangiopathic diseases have also had decreased 
levels of ADAMTS13: disseminated intravascular coagulation and 
haemolytic uremic syndrome Levels of ADAMTS13 in these 
conditions are generally 20-50% of normal, rather than the 5-10% levels seen in TTP. 
HUS presents with similar symptoms to TTP usually caused by infections from 
E.Coli, Shigella dysenteriae and other related bacteria that produce shigatoxins. 
Acute renal failure is the principle abnormality in HUS, whereas this condition is 
usually mild (if present at all) in TTP. 
1.3.4.5 ADAMTS13 activity assays 
Laboratory based assays were developed to identify severe ADAMTS13 deficiency 
(typical of TTP but distinguishable from the levels found in HUS or other thrombotic 
microangiopathies). There is a great deal of variability in the methods used in 
different laboratories, but studies have been carried out to attempt to standardise 
these different methods. The most reliable procedures have been the collagen 
binding assay (CBA), immunoblotting of VWF multimers and ristocetin cofactor 
activity The CBA assay is an ELISA, based on the preferential binding of high 
molecular weight VWF multimers to collagen^^\ The plasma sample to be analysed 
is diluted to various concentrations, along with the standard plasma pool. Both are 
added to normal human plasma in which the ADAMTS13 has been previously 
inactivated by EDTA and dialysed. The cleavage reaction is performed in the 
presence of urea and initiated by addition of BaCl2. The sub-samples are added to a 
microtiter plate previously coated with collagen type III. The binding is measured 
using a peroxidase-conjugated anti-VWF antibody. Proteolytic degradation of VWF 
leads to generation of low molecular weight multimers which show impaired binding 
to collagen so the course of the cleavage reaction over time can be measured as a 
progressive decrease in collagen binding. Immunoblotting of VWF multimers involves 
purified VWF incubation with dilutions of the plasma to be tested and normal human 
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plasma. Cleavage is performed in the presence of CaClg or BaCIa, and stopped at 
different time points with EDTA. The extent of VWF degradation is measured as a 
loss of high molecular weight multlmers, assessed by SDS-1.4% agarose gel 
electrophoresis, followed by Western blot using anti-human VWF antibody^®®. VWF 
Ristocetin cofactor activity tests the ability of VWF to bind to platelet GPIba in the 
presence of ristocetin, measuring the agglutination of platelets. Ristocetin dimers 
bind to both VWF and platelets leading to their cross-linkage, and higher molecular 
weight VWF multimers show higher ristocetin cof actor activity. Disappearance of high 
molecular weight multimers after incubation with the plasma sample containing 
ADAMTS can be followed over time by the diminishing ristocetin cof actor activity, and 
can be compared with that obtained using a plasma standard^®®. 
Newer diagnostic techniques have been developed using smaller VWF fragments as 
substrates for ADAMTS13. Kokame et reported a fluorescence energy transfer 
(FRET) assay for ADAMTS13 activity, using a fluorescent VWF substrate where two 
amino acids have been modified. One of these amino acids is excited at 340nm and 
energy of fluorescence is transferred to the second modified amino acid, quenching 
that energy. When the Y1605-M1606 bond is cleaved by ADAMTS13, the quencher 
is no longer able to absorb the fluorescence which is then emitted at 440nm. In this 
way the cleavage reaction can be monitored over time following the increase in 
emission of fluorescence at 440nm. 
1.4 as an enzyme cofactor 
Ca^^ plays a wide variety of vital roles in biological processes. Like other divalent 
metal cations it can bind to a number of proteins influencing their biological activity 
and stability. The distinct chemical properties of Ca^^ allow it to act as an activator of 
biological processes both intracellulary and extracellularly, particularly in signal 
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transduction patliways^^^'^^®. There are many different types of Ca^^-handling proteins 
including Ca^^'-binding proteins, Ca "^" pumps, channels and proteins that may be 
less significantly altered by a brief binding of Ca^^. Different types of Ca^^-binding site 
may be involved in each case^^^. Because of its potency as a biological messenger 
and activator, the concentrations of Ca "^" in the cytoplasm and in the extracellular 
fluid must be tightly controlled. In plasma it is maintained at around 1.25mM free 
ADAMTS13 is known to be dependent on Ca^. This interaction is the main 
focus of this thesis. In what follows, in preparation to discussing my work, I will 
discuss the nature of Ca.^ * binding sites in proteins. 
1.4.1 Features of binding sites 
Metal binding sites can be varied in their geometry, coordination numbers and ligand 
preferences (including backbone carbonyl oxygens; side chain groups of Asp, Asn, 
Cys, Glu, Gin, His, Met, Ser, Thr and Tyr residues)^'^^^'^^^^"^. Metal ions are 
positively charged and act as electrophiles, seeking out electron pairs, usually having 
large ionic volumes so they can accommodate many ligands around them at the 
same time^"^". A common feature shared by many metal binding sites is that they 
comprise an inner shell of hydrophilic ligands and an outer shell of carbon-containing 
hydrophobic groups, creating an area of high hydrophobicity contrast^^'^'^'^'^ (see 
Fig. 1.8). It is thought that metal ions bind specifically to these areas because they 
have highly symmetrical electron distributions attracting electron pairs around the ion 
in a shell format. In proteins these electron pair donors are oxygen, nitrogen and 
sulphur atoms. Nearly all Ca "^" binding sites described contain an inner shell of 
oxygens clustering round 2.1-2.7 A from the Ca^^ ion with a second shell 3.2-3.8 A 
away populated by carbons, supporting the coordinating oxygens of the inner shell^ '"'^ . 
It has also been shown that a third shell 4-4.8 A away from the ion contains nitrogens 
in significant amounts, usually from amide groups, but no preferential clustering of 
particular atoms is seen > 5 A away^'''*. The same factors that cause these ligands to 
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bind metal ions also cause them to bind water^'^^. This hydrophobicity contrast can be 
illustrated graphically by a radial distribution plot, giving the mean Aa of protein 
atoms at a distance R from ion binding sites (Fig. 1.9) 2*2. Here, Ao represents the 
affinity of the protein atom for water, with Ao <0 for hydrophilic atoms and Ao >0 for 
hydrophobic atoms. From Fig. 1.9 it can be observed that the atoms closer to the ion 
are hydrophilic whereas those further away are hydrophobic, creating an area of high 
contrast. The outer hydrophobic sphere will also restrict flexibility of the site, reducing 
entropy of binding^'^^. In this way, it is possible for hydrophobicity contrast 
measurements to be used to detect possible metal binding sites in proteins with 
known crystal structures. Analysing 3D charge clusters in the protein model is 
another way to identify possible sites of ion interaction^'^®. Acidic clusters are known 
to coordinate certain cations and these may have evolved to provide more specific 
interactions than hydrophobic interactions could provide, since the latter would 
comprise one hydrophobic shell with no hydrophobicity contrast, whereas acidic 
clusters have intrinsic hydrophobicity contrast because of their hydrophilic negatively 
charged side chains^''®, with aspartic acid more commonly seen in Ca^^ binding sites 
than glutamic acid^® .^ Charge clusters are seen in many enzyme active sites, where 
the charge distribution is designed to stabilise the transition state of the catalysed 
reaction relative to the substrate^'*". Here, it is essential that the reactants are brought 
into the correct orientation and metal ions can assist in this process, binding groups 
in a rigid manner, and helping to control enzyme action^'^". Metal ion coordination is 
better than a hydrogen bond in aligning a functional group, due to the flexibility of 
hydrogen bonds. 
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Figure 1.8 Hydrophobiclty contrast of metal binding sites 
a) schematic illustration of the hydrophobicity contrast function, C. For a uniform hydrophobicity distribution there is 
no contrast (C=0 so the charge distribution in the site is even). The metal ion binding site shows a distribution with 
hydrophilic groups in the inner shell and hydrophobic groups in the outer shell so the hydrophobicity contrast function 
C is positive. The hydrophobic binding site shows a distribution with hydrophobic groups in the inner shell and 
hydrophilic groups in the outer shell so the hydrophobicity contrast function, C, is negative (adapted from Yamashita, 
1990^"^. b) Example of hydrophobicity contrast in a known Ca^* binding site, CaOl in matrix metalloprotease 12. This 
Ca^* ion (green) is coordinated by 6 oxygen atoms (red) from coordinating ligands, comprising the inner hydrophilic 
shell. The carbon atoms (grey) to which the oxygen atoms are bound comprise the outer hydrophobic shell (Adapted 
from Gossas and Danielson^"®). 
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Figure 1.9 Radial distribution functions for mean Ao, values around metal binding sites in proteins 
Tile mean value of Aa is plotted against the distance R from the metal site. Here Aa represents the affinity of the 
protein atom for water (atomic solvation parameter), with Ao < 0 for hydrophillc atoms and Ao >0 for hydrophobic 
atoms. (Adaptedjjj from Yamashlta et al, 1990 
ions have a strong tendency to bind oxygen ligands with preferred coordination 
numbers between 6 and 8^^°. This means the specific geometry of coordination can 
be any of Octahedral (coordination no. 6), pentagonal bipyramidal (coordination no. 
7) or square antiprismic (coordination no. 8) (Fig.1.10)^^®. There may also be 
additional capping ligands with coordination numbers of 9 or 10, although the 
average coordination number of Csi * ions in proteins is 6 or 7^^. Pentagonal 
bipyramidal geometry has Ca-0 bond lengths of 2.4 A with a narrow range, and a 
value with an open range of 120° in the O-Ca-0 angle to accommodate the great 
variations in different Ca^ binding sites"°. ,235 
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a) Octahedral 
b) Pentagonal Bipyramldal 
c) Square Antiprismic 
Figure 1.10 Types of coordination geometry around a ion 
a) Octahedral coordination of a Ca^* ion (purple) by 6 oxygen atoms (green) at the corners of an octahedron around 
the ion, b) Pentagonal bipyramldal coordination of a Ca^* ion (purple) by 7 oxygen atoms (blue), c) Ca^* (purple) 
coordinated by 8 oxygen atoms (green) at the corners of a square antiprism. (Taken from^^®) 
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In crystal structures of proteins, ions usually have six or seven oxygen ligands 
with the average ion binding 1.5 water molecules as oxygen electron donors^'^°. 
This is a fairly low number of water molecules compared with other cations binding in 
proteins, and may be due to the fact that Ca^^ tends to be bound to sites with less 
solvent exposure than, for example, |\/|g2+ 236,237.247 
Three types of Ca^ binding site have been identified: those that supply the ligands 
for the Ca^* ions from a continuous short sequence of amino acids are termed Class I 
sites e.g. EF-hand proteins, which generally consist of two Asp acid residues (or one 
Asp acid and one Asn), one Glu acid residue, one main chain carbonyl group and 
water molecule^'^°; Class II sites have one ligand supplied by a part of the amino acid 
sequence far removed from the main binding sequence^®® e.g. Neutrophil 
collagenase; and Class III sites have all the ligands supplied by amino acids remote 
from one another in the sequence^^^'^^^e.g. Adamalysin II. Helices and sheets do not 
usually provide ligands to the Ca^* ion in type I sites, since they have well-defined 
structures and so would not be able to provide all ligands in a continuous sequence. 
Conversely, the turn/loop motif is more flexible and as such is more often involved in 
Ca^+ binding^^®'^ ^^. The class of the binding site is also indicative of the dissociation 
constant with class I sites having the lowest values and hence the highest affinities 
for Ca^"". Also, conformational changes induced by the binding of Ca^^ may utilise 
some of the binding energy released by the Ca "^" -protein interaction and so reduce 
the observed binding affinity, which is more likely to occur with class III sites^® .^ 
Another method of classification of Ca^^ binding proteins is as EF-hand or non-EF-
hand. EF-hand proteins are widespread and control many cellular processes and 
Ca^^ levels within the celP^^. The canonical Ca^^ binding site loop is narrowly defined 
in EF-hand proteins, involving a highly conserved loop, flanked by two helices (helix-
loop-helix). The conserved loop provides seven oxygens from side chains of Asp, 
Asn, Glu and water in a pentagonal bipyramidal arrangement^^®'^'^". EF-hand proteins 
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have very strong affinities (lOOnlVl-liilVI) and also display strong selectivity for 
over Mg^ since the intracellular concentration of Mg^* is over 10'' fold higher 
than Ca^'', so this strong selectivity is essential^ ^®'^ ®®. 
It is useful to be able to predict Ca^ binding sites in proteins. NMR techniques have 
allowed an appreciable increase in solution structures, but they cannot provide the 
Ca^^- binding coordination. X-ray crystallography has been a major tool in visualising 
Ca^'^-binding sites, but those with lesser affinity remain undefined by this method as 
Ca^^ does not remain in the site during the crystallisation process^''\ Various 
statistical programmes have been used to try and accurately predict these sites but 
they are computationally complex and do not have the required speed and accuracy 
for routine application^'^^'^''®. Also, Ca^'^-binding sites are extremely heterogeneous in 
terms of their coordination geometry and structural architecture, as previously 
described^'*''. Therefore, they are used in conjunction with more indirect methods 
such as enzyme functional assays with and without Ca^. 
1.4.2 Examples of Ca^'^-binding sites and their role in metalloproteases 
Thermolysin-like proteases are a group metalloproteases with a single catalytic Zn^^ 
ion and between two and four Ca^^ ions, which stabilise the structure of the 
protein^''®. The Ca "^" ions largely contribute to the heat stability of many of these 
proteins allowing the conformation to be maintained at temperatures which would 
otherwise denature the enzyme. MMPs commonly bind two or more Ca^ "^  ions. An 
example is MMP12, which binds three Ca^^ ions and a ion in addition to the 
catalytic Zn^^ ion, which are believed to stabilise the structure of the metalloprotease 
domain '^*®. The three-dimensional structure of MMP12 show that the three Ca^^ 
binding sites are different, site 1 having ideal octahedral geometry and binding with 
the closest contacts and tightest affinity, site 2 adopting a pentagonal bipyramidal 
structure with the help of two water molecules, and site 3 octahedrally coordinated 
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also with two additional water molecules. Site 1 is the highest affinity site while site 3 
is considered to be a low affinity site (site 2 is intermediate in affinity for Ca^* 
between site 1 and site 3)^"®. There is a proposed correlation between the number of 
water molecules contributing to ion binding and the affinity of the site. The reason for 
the presence of different C a ^ binding sites with different affinities is attributed to the 
different specific environments in which MMP12 can be located and different 
activating circumstances, such as sites of inflammation, where [Ca^T may be 
several-fold higher than normal^ "^®. MMP12 can also remain inactive in areas of low 
[Ca^^] because of this mechanism, and so be tightly regulated in places where it 
would othen/vise have a deleterious effect. 
MMP26 is another MMP with well defined Ca^^ binding sites, having one of high 
affinity (K^ ~ 63nM) and one lower affinity site (Ky ~ 120|jM) '^^ ®. Like MMP12, MMP26 
is regulated by surrounding [Ca^T, being inactive at normal intracellular levels, but 
activating in a two stage mechanism, first when intracellular levels transiently rise 
from ~500nM to ~5nM from extracellular signals, and secondly on release from the 
cell to the extracellular environment with a [Ca^^ of ~1.25mM '^^ ®. Binding of Ca "^" ions 
to MMP26 not only regulates enzymatic activity but also modulates tertiary structure 
resulting in changes in total hydrophobic surface area, indicating a large 
conformational change due to Ca^^ binding, and providing a mechanism whereby 
Ca^^ binding to an area outside of the active site can induce a change in structure of 
the active site itself in an ailosteric fashion. 
1.4.3 Ca=+ and ADAMTS13 
As ADAMTS13 is a member of the M12B metalloprotease family its metalloprotease 
domain can be modelled on the known crystal structure of Adamalysin II (Fig. 1.6)). It 
can be predicted from this model that there may be a Class III type Ca^^ binding site 
in a similar position to that observed in Adamalysin II, on the opposite side of the 
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molecule to the active site. This putative site was predicted by Zheng et al, 200V®® 
and Anderson et al, 2005^®°. As a preliminary experiment for my study of the role of 
cations in ADAMTS13 activity, recombinant enzyme was expressed and purified and 
its activity tested against a short VWF substrate (VWF115) with Ba^^ and Ca^^ ions. 
This experiment suggested that Ba^" ions may be as capable as Ca "^" ions of 
enhancing the activity of ADAMTS13 (Fig 1.11). However, in this preliminary 
experiment, no attempt was made to titrate the cations or the rate of change of 
cleavage with cations. 
ADAMTS-i: 
(nM) 
- 40 40 40 40 40 40 40 40 40 
NaCI (mM) - - 20 50 100 150 20 150 20 150 
Crf^(mM) . - . - . . 5 5 . . 
BdUmM) - - - - - - - - 5 5 
16.9kDa ^ 
lOkDa P 
Figure 1.11: Influence of Ca^*/Ba^* upon proteolysis of VWF115 proteolysis by ADAMTS13. 
40nM ADAMTSIS was incubated witii varying concentrations of NaCI, CaCig or BaClg, as indicated. Reactions were 
started by addition of VWF115 (a 16,9kDa recombinant VWF A2 domain fragment). At time 0, no lOkDa cleavage 
product was detected by Western blotting for VWF115 amino-terminal Xpress epitope. In the absence of Ca^*/Ba^* 
after 10 minutes, irrespective of NaCI concentration, a small amount of lOkDa cleavage product was detected. 
However, after 10 minutes in the presence of 5mM Ca^* or Ba^*, a marked increase in proteolysis was observed, as 
determined by significantly elevated amounts of lOkDa cleavage product and a corresponding reduction in full-length 
16.gkDa VWF115 
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1.5 Aims of Thesis 
The aim of my thesis was to examine and characterise the role of in ADAMTS13 
function. I began with the hypothesis that Ca^^ would enhance ADAMTSIS by 
interacting with the metalloprotease domain. However, it was necessary in initial 
experiments to clarify precisely the functional role of Ca^^, and other cations. I 
then attempted to identify sites of interaction, focusing on the metalloprotease 
domain. In the work that follows, I have used recombinant ADAMTS13 and VWF 
fragments to explore potential Ca^^ binding sites and their effects upon ADAMTS13 
function. Because my focus has been on function, I have used a VWF fragment that 
is readily cleaved by ADAMTS13. This allowed me to use kinetic methods to assess 
functional occupancy of putative Ca^^ binding sites in the metalloprotease domain. 
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Chapter 2 
Materials and methods 
2.1 Generation of ADAMTS13 and ADAMTS mutants 
2.1.1 ADAMTSI3 vector 
Full-length ADAMTS13 cDNA was kindly donated to our laboratory by Baxter, 
Austria. The stop codon was then removed and this cDNA was then cloned in-frame 
into the mammalian expression vector pcDNA3.1myc/His by Dr Jonathan Lam prior 
to the start of this investigation. pcDNA3.1 is a 5.5kb mammalian expression vector 
with a multiple cloning site preceding the myc epitope and 6-His tag at the C-
terminus, an ampicillin resitance marker and a cytomegalovirus (CMV) promoter to 
drive gene expression. This construct was used to generate putative calcium binding 
site mutants in ADAMTS13. A list of the mutant constructs generated is shown in 
table 2.3. 
ADAMTSI3 cDNA myc epitope 
• g c S a o o S - o r a c n - Z 
pcDNA3.1/ 
myc-His® 
A, B , C 
5.5 kb 
Figure 2.1 Schematic representation of pcDNA 3.1/myc-His vector 
Important features of the vector encoding recombinant full-length ADAMTS 13 include the cytomegalovirus promoter 
(Pcmv) to drive transcription, a C-terminal myc-epitope for detection of recombinant protein by western blotting, a C-
terminal poiyhistidine tag (Hise) for protein purification, a SV40 promoter for efficient expression of neomycin 
resistance gene used for selecting mammalian clones, a pUC origin for high copy number replication of the vector in 
E.Co//and an ampicillin resistance gene for selection of bacterial clones. 
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2.1.2 Site directed mutagenesis 
The QuikChange® XL site-directed mutagenesis kit (Stratagene) was used to mutate 
various acidic residues encoded by the pcDNA3.1 ADAIViTSIS myc/6xHis expression 
vector, to investigate the effect of these residues on binding. Mutagenesis was 
carried out using the GeneAmp PGR system 2700 (Applied Bioscience, UK). Primers 
(Thermo Electron Gorporation, UK Electron Gorporation, Germany) containing the 
desired base change were purchased and their purity assessed by High Performance 
Liquid Chromatography (HPLG) analysis. PGR reactions were set up according to 
Table 2.1 with the conditions outlined in table 2.2. 
Reagents (Stratagene) Volume (|jl) 
pcDNA3.1 ADAMTS13 myc/His (50ng) 1 
Sense oligonucleotide primer (125ng) 1 
Antisense oligonucleotide primer (125ng) 1 
dNTPs mix 1 
10X reaction buffer 5 
Double distilled deionised water (ddHgO) 40 
Pfu Turbo DNA polymerase (2.5U/ |il) 1 
Total Volume 50 
Table 2.1 PGR reaction for generating ADAMTS13 mutant constructs 
PGR reaction volumes for site directed mutagenesis using the Quik-change site directed mutagenesis kit 
(Stratagene). Reactions were set up according the manufacturers instructions. 
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Segment Temperature (°C) Time Cycles 
1 95 1 min 1 
2 95 1min 18 
60 50 seconds 
68 10 minutes 
3 68 7 minutes 1 
Table 2.2 PCR conditions used to generate ADAMTS13 mutant constructs 
PGR reaction conditions were set up according ttie manufacturers instructions (Stratagene). 
Following PCR, the reaction mix was treated with 1|al Dpnl (10U/|il) for 2 hrs at 37°C 
to digest the methylated parental DNA strands. Dpn-digested vector was then 
transformed into XL-10-gold ultracompetent £.Co//cells (Stratagene, USA). Briefly, 
45|il XL-10-Gold E.Coli cells were thawed slowly on ice and pre-incubated with P-
mercaptoethanol (Stratagene, USA) for 10 mins to enhance cell membrane 
permeability. 4pl of the Dpnl treated plasmid DNA was then added to the mixture 
and incubated on ice for 30 minutes. Thereafter cells were heat-shocked for 30 
seconds at 42°C, rapidly chilled once for 2 minutes before incubating with 300^1 of 
pre-warmed SOC complete medium (Invitrogen, UK) for 1 hour at 37°C on a rotating 
platform (250rpm). 200|il of the liquid culture was then spread onto a Luna Bertani 
(LB) agar plate containing 100|_ig/ml ampicillin (Sigma,UK) and incubated at 37°C 
overnight. 
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ADAMTS13 mutant construct Made by 
Glu83^Ala Dr C.K.N.K. Chion 
Asp173—>Ala Dr C.K.N.K. Chion 
Asp284^Ala Dr C.K.N.K. Chion 
Glu83/Asp173->Ala M. Gardner & Dr C.K.N.K. Chion 
Asn162-^Aia M. Gardner 
Glu164-^AIa M. Gardner 
Asp166^Ala M. Gardner 
Glu184^Ala R. De Groot 
Asp187-^AIa R. De Groot 
Glu212^Ala M. Gardner 
Table 2.3 List of ADAMTS13 mutant constructs prepared and used in the present study 
2.1.3 Plasmid miniprep - Isolation of Plasmid DNA from E. Coli cells 
For small scale plasmid extractions, isolated transformed bacterial colonies were 
added to 5ml liquid LB containing 100|ig/ml ampicillin with shaking at 250rpm 
overnight at 37°C. After incubation the culture was centrifuged for 5 minutes at 
SOOOrpm and the supernatant decanted. Vector DNA was then purified using the 
plasmid miniprep kit (Qiagen,UK). Briefly, the cell pellet was resuspended in 250|il 
PI lysis buffer containing RNase A before being mixed gently with buffer P2 for 5 
minutes. During this step, bacterial phospholipids and cell membrane proteins are 
solubilised in sodium dodecyl sulphate (SDS) whilst chromosomal/plasmid DNA and 
proteins are denatured by the alkali conditions of the P2 buffer. 350|il N3 buffer was 
added to neutralise the alkali conditions and reconstitute the cell lysate in a high salt 
environment. This resulted in a white precipitate being formed consisting of 
denatured proteins, chromosomal DNA, cellular debris and SDS. After centrifugation 
at 13000rpm for 10 minutes, the supernatant was passed over a QIAprep spin 
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column and centrifuged for 1 minute. The flowthrough was discarded and 750^1 PE 
buffer containing ethanoi was centrifuged through the column for 1 minute at 
13000rpm. The flowthough was discarded and residual PE buffer removed by 
centrifugation as before. To elute the plasmid DNA from the mini-column, SOjjl EB 
buffer was added to the column and left to stand for 1 minute before eiuting the DNA 
by centrifugation as before. 
2.1.4 DNA sequencing 
Sequencing of the ADAMTS13 cDNA was carried out with specific sequence primers 
(Table 1, Appendix 1). 1|ag plasmid DNA was added to 3.2 pmol sequencing primer 
and the final reaction volume made up to 10|il. DNA sequencing was performed at 
the Hammersmith Hospitals Genetic Core facility using an ABI 3700 DNA analyser 
(Perkin-Elmer, UK). Alignment and analysis of the sequencing results were 
performed using Seqman (DNAstar, USA) software. 
2.1.5 Subcloning of mutant fragment into wild type vector 
2.1.5.1 Restriction enzyme digestion 
1ng DNA was added to 1U restriction enzyme (New England biolabs, USA), 
restriction enzyme buffer and bovine serum albumin (BSA) to digest plasmid DNA. 
The reaction volume was made up to 20^1 with ddHgO and incubated at 37°C for 
1hour. 
2.1.5.2 Agarose gel electrophoresis 
To visualise and separate DNA fragments according to their size, agarose gel 
electrophoresis was used. Agarose (Biomed, UK) (0.8%w/v) was dissolved in ddHaO 
by mixing and boiling in a microwave. Sjil SYBRsafe dye (Sigma, UK) was added, 
mixed and the gel poured and allowed to set at room temperature for 30 minutes. 
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DNA was mixed with 5xDNA loading buffer (Appendix 2), loaded onto the gel and run 
at 90V for 30 minutes. DNA bands were visualised using a UV lightbox (Fotoprep II, 
Fotodyne). 
2.1.5.3 Extraction of DNA from Agarose gel 
Once the DNA bands could be visualised they were excised from the gel and purified 
using a gel extraction kit (Qiagen, UK). Gel slices were resuspended in 3 volumes 
QG buffer to 1 volume gel (1 volume =100mg/100|al QG buffer), and incubated at 
50°C for 10 minutes. One volume of Isopropanol was added to improve recovery. 
The entire sample was centrifuged through a Qiaquick spin column (Qiagen, UK) for 
1 minute at 13000rpm and the flowthrough discarded. During this step, DNA is 
adsorbed onto a silica- membrane on the column whilst contaminants pass through. 
SOOjil QG buffer was added to remove traces of agarose and centrifuged at 13000 
rpm for 1 minute. The flowthrough was discarded and the column washed with 750|il 
PE buffer by centrifugation as before. The flowthrough was discarded and residual 
PE buffer removed by centrifugation as before. DNA was then eluted with 30pl EB 
buffer and the approximate concentration determined by comparing the band 
intensity with the 1 kb ladder (New England Biolabs, USA) on a 0.8% w/v agarose gel. 
2.1.5.4 Ligation of DNA 
To ligate DNA fragments, The DNA insert was incubated with the vector backbone at 
a ratio of 5:1 insert;vector molar ratio in the presence of 1U T4 DNA ligase 
(Invitrogen, UK), 5X T4 DNA ligase buffer (pH7.5) made up to lOpJ with ddHgO. The 
reaction was incubated for 1 hr at room temperature or 4°C overnight as appropriate. 
2.1.6 Transformation of XL-10 ultracompetent cells 
After ligation of DNA fragments into the plasmid vector, 1 |il ligation mix was added to 
20pl chemically ultracompetent XL-10 cells (Invitrogen, UK) on ice for 30 minutes. 
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heat-shocked at 37°C for 30 seconds and placed back on Ice for 2 minutes. The cells 
were suspended in 250|il pre-warmed SOC medium and incubated for 1hr at 37°C 
with shaking at 250rpm. The entire cell suspension was centrifuged, resuspended in 
100^1 SOC medium and plated on LB agar plates containing 10O^g/ml ampicillin. The 
pUC18 vector (Invitrogen, Uk) was used as a positive control for transformation 
efficiency. The restriction enzyme digested backbone vector lacking the insert was 
transformed as a negative control. 
2.1.7 Preparation of glycerol stock 
To store transformed bacterial E.Coli cells, 700^1 liquid cultures was mixed and 
vortexed with 300^1 glycerol (Sigma, UK) to prevent ice crystals forming and stored at 
-70°C. 
2.1.8 Large scale plasmid maxiprep preparation of plasmid DNA from E.Coli 
cells 
For stable or transient transfection of mammalian cells, large amounts of plasmid 
DNA were required. For this, larger cultures (50ml to 100ml) were grown. The vector 
containing the desired construct was streaked onto an LB agar plate containing 
100|j.g/ml ampicillin and incubated overnight at 37°C. An isolated colony was 
inoculated into 5ml liquid LB containing 10Opg/ml ampicillin and incubated for Shours 
shaking at 250rpm at 37°C. 500^1 was then taken, placed into 100ml liquid LB 
containing lOOng/mi ampicillin and grown overnight at 37°C with shaking at 250rpm. 
The Endofree plasmid maxi-prep kit (Qiagen, UK) was then used to obtain endotoxin 
free plasmid DNA. The culture was centrifuged at 9000 rpm for 15 minutes at 4°C , 
the supernatant decanted and the pellet resuspended in 10 ml PI buffer containing 
RNase A. The cells were lysed with 10ml P2 buffer and incubated at room 
temperature for 5 minutes. 10 ml chilled P3 buffer was added to neutralize the 
alkaline conditions and mixed gently. This precipitates proteins, genomic DNA and 
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detergent whilst plasmid DNA remained in solution. This was poured into the QIAfilter 
cartridge and 2.5ml ER buffer added for 30 minutes on ice to prevent 
lipopolysaccharide (LPS) molecules from binding to the anion-exchange resin of the 
Qiagen-tip 500 column. Plasmid DNA under low-salt (pH 7) conditions binds to the 
column. The column was equilibrated with 10ml QBT buffer under low-salt (pH 7) 
conditions before the filtered lysate was applied to the column and allowed to enter 
by gravity flow. The Qiagen tip was washed with 60 ml QC buffer and the DNA eluted 
with 15 ml high salt QN buffer, DNA was then concentrated and desalted with 10.5 ml 
isopropanol and centrifuged at ISOOOxg for a further 10 minutes and the supernatant 
discarded. The DNA pellet was air-dried for 5 minutes and re-suspended into 1ml 
endotoxin free ddHgO. Plasmid DNA was then stored at -20°C. 
2.1.9 Determination of DNA concentration 
Plasmid DNA concentration was quantified using the UV-1601 Shimadzu 
spectrophotometer (Shimadzu, Japan). In general, DNA was diluted 50 fold in ddHaO 
and the optical density (OD) was read at 260nm and 280nm to measure DNA 
concentration and purity. DNA concentration was calculated using the equation DNA 
(Hg/ml) = OD at 260nm x 50 (Beer's law-absorptivity constant) x dilution factor. The 
DNA purity was measured by determining the absorbance ratio of 260nm/280nm. A 
ratio of 1.8 corresponded to a pure DNA preparation, whilst a lower ratio suggested 
protein contamination and a higher concentration of RNA. 
2.2 Expression of ADAMTS13 and ADAMTS13 mutants 
2.2.1 Cell culture 
All cell culture was carried out in class II flow cabinets and all surfaces and flasks 
used in the flow cabinet thoroughly cleaned with 70% ethanol to prevent 
contamination of cell lines. Each cell line was grown in humidified incubators 
65 
(BIOHIT, Biological Instrumentation Service, Lancashire, UK) set to 37°C, in an 
atmosphere containing 5% CO2. Each incubator contained a tray with an aqueous, 
saturated solution of copper sulphate (BDH), which maintained humidity and prevent 
contamination by other bacteria. Frozen cells were kept in a liquid nitrogen container, 
at a temperature around -180°C. Cultured cells were visualised under an inverted 
microscope CK2 (Olympus, Japan). 
2.2.2 Expression of recombinant ADAMTS13 
Human Embyonic Kidney (HEK) 293 or HEK293T (transformed with SV40 large T 
antigen) cell lines (American Type Culture collection, USA) were used for expression 
of recombinant ADAMTS13, either stably or transiently respectively. HEK293 cells 
(for stable transfection of recombinant ADAMTS13) or HEK293T cells (for transient 
transfection of recombinant ADAMTS13) stored in dimethyl sulphoxide (DMSO) 
(SIGMA) in liquid nitrogen were thawed at room temperature and centrifuged at 100 
xg for 5 minutes, in order to remove residual DMSO and dead cells. The medium was 
decanted and the cell pellet resuspended in fresh growth medium consisting of Eagle 
Minimal Essential Medium (EMEM) (Sigma) supplemented with 10% Fetal Bovine 
Serum (FBS) (Biosera), 5mM Penicillin/Streptomycin (Invitrogen), 5mM L-Glutamine 
(Invitrogen) and 1 x non-essential amino acids (NEAA) (Sigma). Cells were then 
seeded into small (T25) tissue culture flasks (Nunc) and incubated at 37°C and 5% 
CO2 until they had reached the desired confluence. Once cells had reached full 
confluence on the flasks, adherent cells were passaged and seeded into larger tissue 
culture flasks. Cells were washed twice with autoclaved phosphate buffered saline 
solution (PBS) (Sigma), detached from the surface using 0.25% trypsin/EDTA 
(sigma). Trypsin was added in the amount necessary to cover the cell layer and the 
excess was immediately removed. The cells were then incubated for 5 minutes at 
37°C. Trypsin was inactivated by adding serum containing growth medium and the 
cells seeded into a larger tissue culture flask (Nunc). 
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2.2.3 Stable transfection of HEK293 cells 
Stable transfection allows the identification and growth of cells that have stably 
integrated plasmid DNA into one or more of the host's chromosomes. After DNA 
transfection, cells are subjected to selective pressure. Subsequently, colonies that 
are resistant to the selective antibody are isolated. Plasmid DNA containing 
ADAMTS13 wild-type or mutant constructs E83A, D173A and D284A were stably 
transfected into HEK293 cells by Dr. C.K. Chion prior to the start of this project. The 
mutant construct E83A/D173A was stably transfected into HEK293 cells using the 
lipofectamine reagent (Invitrogen), a liposome preparation formulated from cationic 
lipids. Briefly, 2 x 1 0 ^ HEK293 cells were seeded into a 3.5cm^ (6 well) dish and 
grown in 2ml of growth media for 24 hrs at 37°C with 5% COg until cells were 30-50% 
confluent. 4|jg of plasmid DNA was mixed with 100pl Optimem serum-free medium 
(Invitrogen) and in a separate reaction Ipg lipofectin was mixed with lOOpI Optimem. 
Both reactions were incubated at room temperature for 30 minutes. The two solutions 
were then combined and incubated at room temperature for 15 minutes, during which 
the HEK293 cells were washed twice with 2ml sterile PBS buffer and resuspended in 
1.8ml Optimem. The Lipofectin/DNA mix was then added to the cells and incubated 
overnight at 37°C with 5% CO2 until fully confluent. HEK293 cells were then 
trypsinised and seeded onto a 10cm^ dish with growth medium containing SOOpg/ml 
of the antibiotic geneticin G418 (Sigma), which is a neomycin analogue used for 
selection. A non-transfected line was used as a negative control to indicate when 
clones could be selected. Screening of high expressing clones was done using an 
ADAMTS13 ELISA (section 2.6.2) and verified by western blotting (section 2.6.6). 
Selected clones were expanded progressively in T25, T75, T175 cm^ and T175 cm^ 
triple flasks (Nunc). Cells were grown to 80-90% confluence, after which the growth 
medium was replaced with Optimem supplemented with a protease inhibitor cocktail 
(Sigma), including six protease inhibitors; aprotinin, 4-(2-aminoethyl) benzenesulfonyl 
fluoride, bestatin hydrochloride, N-(trans-epoxysuccinyl)-L-Leucine-4-
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guanidinobutylamide, leupeptin hemisulfate salt and pestatin A. This cocktail has a 
broad specificity for serine, cysteine and acid proteases and aminopeptidases and it 
is useful to prevent the degradation of the secreted proteins. The conditioned 
medium was then collected and filtered through a 0.5mm Nalgene filter to remove 
cell debris. 
2.2.4 Transient transfection of HEK293T cells 
Plasmid DNA containing ADAMTS13 wild-type or mutant constructs N162A, E164A, 
D166A, E184A, D187A and E212A were transiently transfected into HEK293T cells 
that were 80-90% confluent, at a concentration of ~ 2iig/ml, using 20ml\/l 
polyethyleneimine (PEI) reagent according to supplier's protocol (Sigma). Fresh 
conditioned medium (Gibco) was added 6 hours post-transfection, incubated at 37°C 
and 5% COg for 3 days, and then concentrated using the Labscale "TM TFF system 
(Milipore) with the Pellicon XL lOkDa filter. 
2.2.5 Cryopreservation of cell lines 
For long tem storage of mammalian cell lines, cells were trypsinised and resuspended 
in growth medium without 5mM Penicillin/Streptomycin. 10% dimethyl sulphuroxide 
(v/v) (Sigma, UK) was added to protect cells from rupturing by preventing formation 
of ice crystals at low temperatures. The cell suspension was aliquoted into 1ml 
cryovials (Nunc, Germany), placed in a container with 200ml isopropanol and stored 
at -70°C overnight. These were then transferred and stored in liquid nitrogen. 
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2.3 Purification of ADAIVITS13 
2.3.1 Desalting of conditioned media 
The concentrated conditioned medium was desalted in 5L 20mlVl Tris-HCI (pH7.8), 
500mM NaCl and 20mM Imidazole in preparation for purification by Ni^'^-chelating 
chromatography overnight at 4°C. Desalting was carried out in snakeskin dialysis 
tubing with lOkDa Molecular weight cut off. 
2.3.2 Nickel chelating chromatography 
ADAMTS13 was purified using a 5ml HiTrap chelating column (Amersham 
Pharmacia, UK), which allows HIs-tagged fusion proteins to bind on account the high 
affinity of His for ions. After equilibrating with 20mM Tris-HCI (pH7.8), 500mM 
NaCI and 20mM imidazole, the desalted conditioned medium was passed over the 
column, washed with 20mM Tris-HCI (pH7.8), 500mM NaCI and 20 mM imidazole. 
And eluted with 20mM Tris-HCI (pH7.8), 500mM NaCI and 500mM imidazole. Peak 
fractions during the elution were collected, pooled and dialysed in 20mM Tris-HCI 
(pH7.8) overnight at 4°C. Elution of ADAMTS13 was monitored by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) with Coomassie staining and 
Western blotting using the anti-myc mAb (Invitrogen, UK). 
2.4 Expression and purification of VWF115 
2.4.1 Expression of 6xHls-tagged VWF115 in Rosetta E-coli cells 
The VWFA2 domain fragment, VWF115, has been previously generated in the lab, 
and contains an N-terminal 6xHis Xpress epitope tag. This fragment comprises VWF 
residues Glu1554 to Arg1668 and spans the cleavage site for ADAMTS13 (Y1605-
M1606) which is exposed rather than burled in this fragment. 1^1 construct was 
added to 20pl Rosetta DE3 E. Coli cells (Novagen), which were thawed on ice for 5 
mins. The cells were then heat-shocked for 30 seconds at 42°C and the tubes 
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immediately transferred to ice. 80pl room temperature SOC medium was added to 
the tubes, which were then capped tightly and taped on their sides in a shaking 
incubator at 37°C for 1hour, after which the full volume of the tube was plated on a 
pre warmed LB agar plate. The plate was incubated overnight at 37°C. The next day 
12ml LB broth with 100|ig/mi ampicillin was inoculated with a single colony from the 
plate. The culture was grown for 3-4 hours at 37°C with shaking (250rpm) to an 
OD600 of between 0.6-1.0. At this point a glycerol stock was made (see section 
2.1.10). 1L 2x YT broth was inoculated with the culture, and this new culture grown 
out at 37°C with shaking (250rpm) for 2-6hours until the cells had reached an OD600 
of -0.6. 1M IPTG was then added to a final concentration of ImM to induce 
expression of recombinant protein. Cultures were grown overnight with shaking at 
250rpm at 37°C. Cells were harvested by centrifugation (lOOOOrpm for 20 minutes at 
4°C). Cell pellets were then frozen at -80° until cell lysis and inclusion body 
preparation. 
2.4.2 Isolation and washing of Inclusion bodies 
Bacterial cell pellets were resuspended at room temperature in Bugbuster reagent 
(Novagen) to disrupt the cell wall and liberate soluble proteins. This was achieved 
through pipetting and gentle vortexing, using 5ml reagent/g wet cell paste. 
Resuspended mixtures were transferred to 50 ml tubes and Ip l benzonase nuclease 
was added per 1 ml Bugbuster reagent. RLysozmye was added to help lyse the cells 
at a final concentration of IKU/ml. Cell suspensions were incubated at room 
temperature on a shaking platform for 30 minutes at a slow setting. Insoluble debris 
was then pelleted by centrifugation at SOOOxg for 30 minutes at 4°C. Supernatant was 
removed and frozen for later analysis of this soluble fraction. The inclusion body 
pellet was then resuspended using 5ml Bugbuster reagent /g wet cell paste. The 
mixture was pipetted up and down and vortexed to obtain an even suspension (this 
was critical to obtaining a high purity preparation by solubilising and removing 
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contaminating proteins). rLysozyme was then added to a final concentration of 
1 KU/ml, vortexed gently and Incubated at room temperature for 5-10 minutes. 6 
volumes of 1:10 diluted BugBuster reagent (In deionized water) were added to the 
mixture and vortexed for 1 minute. This suspension was then centrifuged at 5000xg 
for 15 minutes at 4°C to collect the inclusion bodies. The pellet was resuspended as 
before, and centrifuged as before. This step was repeated. Finally, the pellet was 
resuspended in 2ml 1:10 diluted reagent and transferred to 2ml tubes and 
centrifuged at 1 GOOOrpm for 15 minutes at 4°C. The supernatant was removed and 
the pellet containing the inclusion bodies frozen at -70°C until use. 
2.4.3 Purification and refolding of 6xHis-tagged VWF115 from inclusion bodies 
Inclusion body pellets were resuspended in -6ml solubilisation buffer (20mM Tris-HCI 
(pH7.8), 0.5M NaCI, 20mM Imidazole, 8M Urea), and mixed for 2 hours at room 
temperature on a rotating platform at a slow setting. The suspension was centrifuged 
at 15000rpm at 4°C and the supernatant removed to a fresh tube. Any remaining 
particles were removed by passing the solution through a 0.22|im filter. A 1 ml MP* -
His Trap column (lOmg capacity) was prepared by passing 10ml distilled water over 
at a rate of ~1 ml/minute. 5ml 0.1M NiS04 was then passed over at 0.5ml/minute to 
ensure the column was fully saturated with ions. The column was then washed 
with a further 10ml distilled water. Purification was carried out on FPLC (Akta, GE 
Healthcare) using the pre-prepared -His Trap column to bind the solubilised 
inclusion bodies. The protein was refolded using an 8M to OM urea linear gradient. 
Elution was performed with 500mM Imidazole, after which VWF115 was dilaysed in 
20mM Tris-HCI (pH7.8) and its concentration determined using the bicinchoninic acid 
(BCA) Total Protein Assay Kit (Perbio, UK) (see section 2.6.1). 
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2.5 Purification of VWF from Haemate P 
2.5.1 Gel filtration 
Haemate P® (ZLB Behring, Germany) is a commercial VWF/FVIII concentrate that 
was used to obtain large quantities of plasma derived, full length VWF. This 
preparation was resuspended in 10 ml of H2O and centrifuged at 4000 xg for 5 mins. 
The resuspended Haemate P® was then loaded onto a Sephacryl-400 gel filtration 
column (Amersham Pharmacia, UK) (600mm x 26mm, 320ml volume) that had been 
pre-equilibrated with 2 column volumes of Buffer A (lOOmM NaCI, 20 mM Tris-HCI, 
pH7.4). The column was eluted at a flow rate of 1ml/min and twenty two 10ml 
fractions were collected (A1-C3). Fractions A10-C2 were pooled for further 
purification by heparin-Sepharose affinity chromatography. 
2.5.2 Heparin-Sepharose Affinity Chromatography 
To further purify VWF, a heparin-sepharose column was equilibrated with 2 column 
volumes of Buffer A, then gel filtered fractions A10-C2 were passed over the column 
at a flow rate of 0.4ml/min. After sample loading was complete, the column was 
washed with Buffer A until the baseline had returned to zero. VWF was eluted from 
the column with elution buffer (300mM NaCl, 20mM Tris-HCI, pH 7.4). Three 10ml 
fractions were collected and dialysed into 20mM Tris-HCI, pH 7.4 overnight at 4°C. 
VWF concentration was determined by VWF antigen ELISA (section 2.6.3), 
multimeric composition was analysed by VWF multimer gels (section 2,7.12) and 
collagen binding assay (2.7.11) and purity assessed by Coomassie staining (section 
2.6.4). 
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2.6 Analysis of ADAMTS13, VWF and VWF115 
2.6.1 BCA total protein assay 
This total protein assay is performed to assess protein concentration of highly 
purified protein preparations such as VWF115 purified from inclusion bodies. This 
method is based on the reduction of Cu "^" to Cu^ by proteins in an alkaline medium. 
The calorimetric reaction is formed by the chelation of two moleules of BCA with one 
cuprous ion. The intensity of calorimetric reaction is proportional to the protein 
concentration. Serial dilutions of a BSA protein standard, ranging from 2mg/ml to 
25|ig/ml, were prepared and 25^1 of each concentration loaded into microtiter wells. 
Different dilutions of unknown protein samples (25|jl) were loaded for comparison. 
BCA solution B was added at 1:50 dilution of BCA solution A and 200|il of this 
mixture loaded into wells containing the samples. The reactions were incubated at 
37°C for 30 minutes and the absorbance read at 540nm using an automated lEMS 
plate reader (LabSystems.USA). 
2.6.2 ELISA for ADAMTS13 
The ADAMTS13 ELISA was designed, set up and optimised previously in our 
laboratory by Dr James Crawley. MaxiSorp plates (Nunc) were coated overnight at 
4°C with a rabbit polyclonal anti-ADAMTS13 antibody (pAb) (depleted of antibodies 
against the ADAMTS13 TSP2-4 domains) was previously generated in the laboratory 
was diluted to lOpg/ml in 50 mM carbonate buffer (pH9.6). After coating, wells were 
washed 3 times with PBS-T and blocked with PBS-T-2.5%BSA for 1 hr at room 
temperature. After blocking, wells were washed 3 times as before and 100^1 of test 
samples or reference plasma (Technoclone) at dilutions 1:10, 1:20, 1:40, 1:80, 1:160 
and 1:320 were added to the wells and incubated for 2 hrs at room temperature. After 
washing, the wells were incubated for 2 hrs with 0.1|_ig/ml biotinylated anti-
ADAMTS13 TSP2-4 pAb diluted in PBS-T-2.5%BSA. The plate was washed as 
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before and then incubated for 1 hr at room temperature with streptavidin-HRP 
(Amersham Pharmacia, UK) diluted 1:1000 in PBS-T-1%BSA. After a final wash 
step, 180(il chromogenic substrate (Sigma colour fast OPD tablets) was added to the 
wells, the reaction stopped with 70pl 1M H2SO4, and the absorbance measured at 
492nm using an automated iEMS plate reader (LabSystems, USA). A standard curve 
was plotted with Abs492 along the Y-axis and concentration of standards along the X-
axis. Reference plasma was taken to be 100% ADAMTS13 (originally determined by 
Gerritsen et al, 2001^^°), assigned a concentration of Ipg/ml. The highly purified 
ADAMTS13 standard concentration had been confirmed by comparison with 
reference plasma. 
2.6.3 ELISA for VWF 
Rabbit anti-VWF capture pAb (DakoCytomation, Denmark) (1:500 dilution) in 
carbonate buffer was immobilised onto a 96 well Maxisorp plate overnight at 4°C as 
previously described^^\ Samples containing VWF were diluted in PBS-T containing 
2%BSA (w/v) and incubated for 1 hr with shaking at room temperature. Normal 
pooled plasma was used to determine the VWF concentration in the sample. The 
VWF plasma concentration is ~10|ag/mP®^. VWF was detected by incubating with the 
anti-VWF HRP pAb (1:2000 dilution) (DakoCytomation, Denmark) for 1 hr with 
shaking at room temperature. As for the ADAMTS13 ELISA, 200^1 OPD chromogenic 
substrate was added. The reactions were stopped with 100^11.4IV1 sulphuric acid and 
the absorbance read at 492nm using an automated lEMS plate reader (LabSystems, 
USA). A standard curve was plotted with AbS492 along the Y-axis and concentration of 
standards along the X-axis. Reference plasma was taken to be 100% VWF with an 
assigned value of 1 |ig/ml. 
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2.6.4 SDS-PAGE and Coomassie staining 
SDS-PAGE was used to separate proteins based on their molecular weight. SDS is 
an anionic detergent, which unfolds proteins and confers a negative charge 
proportional to their size. Protein samples were diluted in 2X loading buffer (65mM 
Tris-HCI (pH7.8) (pH 8.0), 0.1% SDS w/v, 0.01% bromophenol blue w/v) and heated 
at 95°C for 10 minutes to denature the protein. When necessary, 4% v/v |3-
mercaptoethanol was added to the 2x loading buffer to reduce disulphide bonds. 
Protein samples were added to pre-cast SDS-PAGE gels (BioRad, USA) and 
electrophoresed at 120V for 70 minutes in running buffer (25mM Tris (pHB.S), 192 
mM glycine, 0.1% SDS). The gel was then used for either Western blot analysis or 
stained with SimplyBlue Coomassie stain (Invitrogen, UK). For Coomassie staining, 
the gel was rinsed three times with 100ml ddHgO for 5 minutes before applying 25ml 
SimplyBlue Coomassie stain for 1 hr. The gel was then destained by washing the gel 
for 1 hr with 100ml ddHgO before the gel was dried using Model 583 gel dryer 
(BioRAd, USA). 
2.6.5 Native-PAGE Gel electrophoresis 
Native-PAGE Gel electrophoresis was used to separate proteins in their native 
conformation. Proteins in an aggregated state could also be visualised using a Native 
gel. Samples were mixed with 4 x Native PAGE sample buffer and ddHgO to a final 
volume of 20|j1. The outer chamber was filled with Native PAGE 20 x running buffer, 
while the inner chamber was filled with Native PAGE 20 x cathode buffer (Light blue), 
containing 0.4% Coomassie. Samples were loaded onto 4-16% Native PAGE Novex 
bis-tris gels before filling the inner chamber with Cathode buffer. Gels were run at 
150V constant for 100 minutes, after which gels were fixed and stained. Briefly, gels 
were placed in 100ml Fix solution (40% methanol, 10% acetic acid) and microwaved 
on high power for 45 seconds. Gels were then placed on a shaker for 30 minutes at 
room temperature. This fixing step was repeated, after which 100ml Coomassie 
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solution was added (0.02% Coomassie R-250 in 30% methanol, 10% acetic acid) 
and the gel microwaved on high power for 45 seconds. The gel was then placed on a 
shaker again fro 30 minutes at room temperature, and 100ml destaining solution 
added (8% acetic acid), and microwaved for a further 45 seconds on high power. The 
gel was then shaken at room temperature until the desired band intensity could be 
observed. 
2.6.6 Western blotting 
Following SDS-PAGE analysis, the pre-cast gel, nitrocellulose membrane 
(Amersham Pharmacia, UL) and filter paper were soaked in transfer buffer (25mM 
Tris-base, 192mM glycine, 20% methanol (v/v)) for 10 minutes. These were then 
assembled into a 'sandwich' and transferred at 90V for 60 minutes. Following transfer 
of proteins from an SDS-PAGE gel to a nitrocellulose membrane, the membrane was 
incubated with 5% blocking reagent (Amersham Pharmacia, UK) in PBS-0.1% Tween 
for 1 hour with shaking at room temperature to prevent non-specific binding. The 
primary recognition antibody diluted in PBS-0.1%Tween with 5% blocking reagent 
was then added for 1 hour with shaking at room temperature. The membrane was 
washed 3 times with PBS-0.1% tween for 5 minutes and a secondary detection 
antibody conjugated with HRP (DakoCytomation, Denmark) (1:2000) dilution in 5% 
blocking reagent was added for 1 hour with shaking at room temperature. The 
membrane was washed 5 times with PBS-0.1% Tween for 5 minutes and proteins 
detected using the ECL chemiluminescent kit (Amersham Pharmacia, UK) according 
to the manufacturer's instructions. The membrane was exposed on to 
chemiluminescent film (Amersham Pharmacia, UK). 
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2.7 Activity assays for ADAWITSIS 
2.7.1 Time course for VWF115 
For time-course analysis of proteolysis of VWF115, 20nM purified recombinant 
ADAMTS13 or 1nM of transiently expressed ADAMTS13 in conditioned media, both 
in 20mM Tris-HCl (pH7.8), 150mM NaCI, 5mM CaClg were pre-incubated at 37°C for 
1 hour (unless othenwise stated) without the substrate. The reaction was started by 
addition of the substrate at a concentration of either 700nM or 1.6|iM, (stated in each 
experiment). Samples were taken at various time points over a period of 2 hours, and 
the reaction quenched with 5(il 0.5M EDTA. Samples were then analysed using 
(HPLC) to ascertain the extent of cleavage. 
2.7.2 Cleavage of VWF115 by ADAMTS13 in the presence of varying 
concentrations 
When setting up reactions, preliminary studies were carried out. Typically, 
700nM purified VWF115 was added to 20nM purified ADAMTS13 or InM 
transiently expressed ADAMTS13 in dialysed conditioned media (both 
determined by ELISA), in the presence of 0-8mM CaClg, 150mM NaCI and 
20mM Tris-HCl (pH7.8) and incubated at 37°C. At early time points, samples 
were taken and the reactions stopped with 5)il 0.5M EDTA. Early time points 
were used to ensure that the reaction was still in the linear part of the time 
course curve so that it was proceeding at the fastest rate, and the only 
parameter being altered was the Ca^^ concentration. Concentrations of 
VWF115 were then changed according to the progress and efficiency of the 
reactions and is stated in each case. Quenched samples were analysed using 
HPLC to determine the extent of proteolysis. 
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2.7.3 HPLC analysis and kinetic analysis 
To quantitate cleavage, HPLC analysis was performed. This technique is based on 
the separation of molecules through a chromatography column under high-pressure 
conditions. The stationary phase refers to the immobile packing material in the 
column to which ADAMTS13 becomes bound. The mobile phase refers to the 
solvent, in which the sample has been dissolved, prior to being applied to the 
column. The chemical interactions of the mobile and stationary phases determine the 
degree of migration and separation of components contained in the sample. The 
mobile phase can be altered to manipulate the interactions between the sample and 
the stationary phase, leading to different grades of resolution of the molecules 
contained in the sample. In reverse phase chromatography, the stationary phase is 
hydrophobic, whereas the mobile phase is polar. Biomolecules are then adsorbed to 
the surface of a reverse phase matrix under aqueous conditions. Subsequently, the 
mobile phase composition is modified by adding organic modifiers, such as 
acetonitrile, which is apolar, which favour the desorption of the solute from the 
stationary phase back into the mobile phase. Proteins or protein fragments are eluted 
at different points of the acetonitrile gradient based on their hydrophobic properties. 
Ion-pairing agents such as trifluoroacetic acid (TFA), are also added to the mobile 
phase to maintain a pH <7.5. The AKTA BasidO HPLC machine 
(AmershamPharmacia, UK) with a BioBasic C4 column (Thermo Electron 
Corporation, UK) was used to assess VWF115 cleavage by ADAMTS13. 50pl 
samples were loaded at a flow rate of 2ml/min. VWF115 and its cleavage products 
were then eluted using a 20-48% acetonitrile - 0.1% TFA gradient. Each fragment 
had a specific retention time, based on its hydrophobic properties. Unicorn analysis 
software was used to calculate the areas under the peaks of the full length and 
cleaved fragments (Figure 2.2). Since the peak area of the intact VWF115 was equal 
to the peak areas of the cleavage fragments generated, percentage proteolysis of 
VWF115 was plotted against time enabling the rate kinetics to be determined. 
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Figure 2.2 Example of HPLC trace 
The peak eluted at 8.28 (A) represents the uncleaved VWF115 fragment, and the peak at 6.81 (B) 
represents the N terminal cleavage product after VWF115 is cleaved at Y1605-M1606. The C terminal 
cleavage fragment is not seen in this chromatogram because its peak elutes at the same place as the 
uncleaved peak. Peak A decreases in size during the course of the reaction, since the C terminal 
cleavage peak increases as the larger uncleaved substrate peak decreases. This means that when the 
reaction has gone to completion and all the substrate has been cleaved, the two peaks that will be seen 
will represent the two cleavage products, and will be of the same area. The calculation of percentage 
cleavage to represent the course of the reaction is as follows: area of N terminal cleavage peak / (1/2 
total peak area). 
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2.7.4 Kinetic analysis of VWF115 proteolysis by ADAMTS13 
To derive tlie kinetic constants kcat, Km and kca/Km.tiie initial rates (nMs'^) of VWF115 
proteolysis by ADAMTS13 was plotted against VWF115 concentration and the 
results fitted using the MIchaelis-Menten equation using Prism 4 software 
(GraphPad, USA); 
Equation 2.1 v = Vm v^X [SI 
Km + [S] 
Where V is the initial velocity, Vmax is the maximal velocity reached at high substrate 
concentrations when the enzyme is saturated, [S] is the substrate concentration and 
Km (MIchaelis constant) is the substrate concentration at which the reaction velocity is 
half-maximal. In this way, Km and V^ax were determined and therefore the turnover 
number, kcat (in s'^), calculated from the ratio Vmax/[e], where [e] refers to ADAMTS13 
concentration. The catalytic constant kcat represents the number of reactions that 
each active site catalyses per unit time. The kca/Km could then be calculated. This is 
a second order rate constant which measures the overall catalytic efficiency of free 
enzyme. The kcat/Km was also determined using low substrate concentration using 
the Enzfitter programme by fitting the data to the equation: 
Equation 2.2 kcat/Km = -ln(1-[AP1/rAPf1) 
et 
Where [AP] is the area under the first major cleavage product peak curve that eiuted 
at time t, [APf] is the area under the first major cleavage product peak curve after 
complete cleavage, e Is ADAMTS13 concentration and f is time. 
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2.7.5 Kinetic analysis of Ca^* enhancement of ADAMTS13 
Initial rates of proteolysis of VWF115 by ADAMTS13 can be determined as described 
in section 2.7.3. The effect of Ca^^ was determined by titrating initial rates against 
increasing Ca^* concentration instead of substrate concentration, maintaining a 
constant substrate concentration. The Kd value obtained corresponds to the 
concentration of Ca^ "^  at which the rate was half maximal and this can be thought of 
as the apparent dissociation constant (KD(app)) of Ca^+ for ADAMTS13. It is only an 
'apparent' dissociation constant as no direct measurement of Ca "^" binding was 
made. 
2.7.6 Statistical testing to compare models of Ca^* binding 
The initial rates of VWF115 proteolysis by ADAMTS13 was plotted using both one-
site and two-site binding models using Prism 4 software (GraphPad, USA). This 
program also allows statistical analysis of the models to see which one fits the data 
better, and the principal behind this analysis is now discussed. 
The two-site model is more 'complicated' compared to the one-site binding model. If 
the simpler model is correct, the relative increase in the sum of squares (going from 
more complicated to simpler model) is expected to equal the relative increase in 
degrees of freedom. In other words, if the simpler model is correct it is expected that: 
Equation 2.3 (SS1-SS2)/SS2 = (DF1-DF2)/DF2 
SS1 is the sum-of-squares for the simpler model (which will be higher) and SS2 is 
the sum-of-squares of the more complicated model. 
If the more complicated model is correct, then it is expected that the relative increase 
in sum-of-squares (going from complicated to simple model) to be greater than the 
relative increase in degrees of freedom: 
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Equation 2.4 (SS1 -SS2)/SS2 < (DF1 -DF2)/DF2 
Tlie F ratio quantifies the relationship between the relative increase in sum-of-
squares and the relative increase in degrees of freedom. 
Equation 2.5 F= ((SSI -SS2)/SS2) / ((DF1 -DF2)/DF2) 
F ratios are always associated with a certain number of degrees of freedom for the 
numerator and a certain number of degrees of freedom for the denominator. This F 
ratio has DF1-DF2 degrees of freedom for the numerator, and DF2 degrees of 
freedom for the denominator. If the simpler model is correct it is expected to get an F 
ratio near 1.0. If the ratio is much greater than 1.0, there are two possibilities; 1) The 
more complicated model is correct, 2) the simpler model is correct but random 
scatter led the more complicated model to fit better. The P value tells you how rare 
this coincidence would be. The P value answers this question: 
If the simple model is really correct, what is the chance that you would randomly 
obtain data that fits the complicated model so much better? 
If the P value is low, it can be concluded that the complicated model is significantly 
better than the simple model. Otherwise, it is concluded that there is no compelling 
evidence supporting the complicated model, and the simpler model can be accepted. 
2.7.7 Cleavage of VWF115 by ADAMTS13 in the presence of various metal ions 
In preliminary experiments, purified ADAMTS13 was treated with 15mM EDTA for 30 
minutes, dialysed in 5L 20mM Tris-HCl (pH7.8) for 4 hours, dialysed again in 5L 
20mM Tris-HCl (pH7.8) with 500|JM ZnClg for 4 hours, and finally dialysed in 5L 20mM 
Tris-HCl (pH7.8) alone for 4 hours. The initial rate of VWF115 cleavage using 20nM 
ADAMTS13 (in 20mM Tris-HCl (pH7.8), 150mM NaCI, 5mM CaClg) was 0.23 nMs"^ 
compared to 0.25 nMs"' for ADAMTS13 not subjected to EDTA and cation re-
supplementation. This suggested that re-supplementation of removed divalent 
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cations reversed any induced functional deficit. Since the Vmaxwas also restored to its 
previous level by the above protocol, this also suggested that ADAMTS13 freshly 
expressed into conditioned media already contains Zr f * in the active site. In selected 
experiments where specifically stated the functional response of ADAMTS13 to 
added was studied. The protease had been pre-treated with EDTA and then 
dialysed. In all other assays it can be assumed that the ADAMTS13 used already 
had Zn^^ bound but had no bound Ca^ at the start of the experiment. ADAMTS13 in 
these assays (unless otherwise stated) had been dialysed overnight in 20mM Tris-
HCI (pH7.8) after expression, concentration and/or purification. For these activity 
experiments, 0.15M NaCI was subsequently added to the buffer. 
2.7.8 Monitoring cleavage of VWF115 by SDS-PAGE 
ADAMTS13 activity was assessed via SDS-PAGE and HPLC. A NuPAGE 10% Tris-
Tricine precast polyacrylamide gel (Invitrogen) was used to resolve proteins VWF115 
and its cleavage products using this technique. Samples to be analysed were diluted 
with loading buffer. A pre-stained molecular weight protein marker (invitrogen) was 
run in parallel with all samples. Samples were heated for 5 minutes at 95°C, then 
electrophoresis was carried out in NuPAGE gel tanks (invitrogen) at 100V constant, 
until the gel dye had reached the end of the gel ~ 90 minutes. Non-specific detection 
of proteins was achieved using SimplyBlue™ SafeStain (Invitrogen, UK) that has a 
detection limit of 7ng total protein. After SDS-PAGE, gels were washed 3 times with 
ddHgO for 5 minutes, then incubated with 25ml SimplyBlue™ SafeStain for 1 hour at 
room temperature on a shaker. Gels were then washed with double distilled HgO until 
the gel was destained. 
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2.7.9 Cleavage of VWF by ADAMTS13 in the presence of denaturants 
Purified recombinant VWF was incubated with 1 .SIVI guandine-HCI at 37°C for 1hour. 
The denatured VWF was then added to 20nM ADAMTS13, pre-incubated for 1 hour 
in 150mM NaClg, 20mM Tris-HCI (pH7.8), 5mM CaClg, so the final VWF concentration 
in the reaction was 20ng/mi and the final concentration of guanidine-HCI was 75ml\/1. 
The reaction was incubated at 37°C for 2 hours before quenching with 10ul O.SM 
EDTA. The cleavage products were detected by multimer gel analysis (section 
2.7.12) and collagen binding assay (section 2.7.11). 
2.7.10 Cleavage of VWF by ADAMTS13 using the vortex assay in the presence 
of shear 
50nM ADAMTS13 was pre-incubated for 1 hour with 150mM NaCl, 20mM Tris-HCI 
(pH7.8), 5mM CaClg, and O.Spg/ml BSA in a 0.2ml thin-walled PGR tube with dome 
caps, after which purified recombinant VWF (20(jg/mi final concentration) was added. 
The reaction mixture was subjected to vortexing at 2500rpm for 5 minutes on a mini 
vortexer (MaxiMix II, Barnestead, Thermolyne, UK), with the PGR tube taped 
horizontally to the vortex plate. The cleavage products were detected by multimer gel 
analysis (section 2.7.12) and collagen binding assay section (2.7.11). 
2.7.11 Collagen binding assay 
Collagen binding activity (VWF:GB) is a sensitive measure of high molecular weight 
VWF (HMW-VWF). As mentioned previously (section 1.2.2.2) The highest molecular 
weight VWF multimers bind to collagen with the highest affinity. The VWF:CB of a 
sample can be determined by an ELISA based collagen binding assay. Human type 
III collagen prepared from the placenta by trypsin digestion (Sigma, UK C-4407) was 
dissolved for 16 hours at 4°G in 200mM acetic acid (final concentration of 0.1 mg/ml) 
as it is available in a lyophilised form that is acid-soluble. Dissolved collagen was 
aliquoted and stored at -20°G until use. Aliquots were used only once and never re-
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frozen. Optimal coating concentration was previously determined in our laboratory by 
Dr. Thomas McKinnon (who set up the assay) to be ~ Spg/ml in 50mM carbonate 
buffer, pH 9.6 and 100ul per well, applied to Maxisorp plates (Nunc) and incubated 
for 24 hours up to 49 days at room temperature. After blocking, wells were washed 3 
times with phosphate buffer saline with 0.1% Tween (PBS-T) and blocked with 2% 
BSA-PBS-T for 1 hour at room temperature. Wells were washed 3 times and 
samples diluted to between 1:10 and 1:240. Reference plasma (Technoclone, UK) 
diluted in the same way was used as a standard preparation of VWF. lOOjal of 
sample or standard was applied to each well. After incubation for 2 hours at room 
temperature, wells were washed 3 times with PBS-T and anti-VWF-HRP antibody 
was applied to the wells, (1/1000 in PBS-T) for 1 hour. After a final wash step, 180pl 
substrate solution (Sigma colour fast OPD tablets) was added to the wells, the 
reaction stopped with lOOgl 2M H2SO4 after ~ Sminutes, and the absorbance 
measured at 492nm. Inter and intra experimental coefficients of variation were <5%. 
A standard curve was prepared plotting %CBA along the x-axis (reference plasma 
diluted 1:10 =100% CBA and absorbance along the y-axis. The equation of the line 
was given in the format: 
Equation 2.6 y= mx-t-c 
Where 'y' is the absorbance value, 'm' Is the gradient of the slope, 'x' is the % CBA 
and 'c' is the y intercept. To calculate the %CBA of unknown samples the equation 
was rearranged to: 
Equation 2.7 x = (y-c)/m 
Absorbance values (y) of the unknown samples were substituted into the equation. 
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2.7.12 Multimer gel analysis and Western blotting of VWF 
VWF exists as multimers of varying size and the pattern of multimers may be 
visualised by analysis in agarose gels under non-reducing conditions. 1.4% agarose 
gels were prepared by dissolving 1.4g high gelling temperature agarose (Seakem) in 
100 ml of gel buffer [200mM Tris, lOOmM glycine, 0.1% SDS, pH 9.0] and cast using 
a Bio-Rad mini gel casting system and stored at 4°C for a minimum of 2 hours and a 
maximum of 7 days. Samples were diluted 1:10 with sample buffer (lOmM Tris, ImM 
EDTA, 2%, 8M Urea, 0.01% bromophenol blue, pH 8) and incubated for 30 minutes 
at 60°C. Gels were assembled in a Bio-Rad mini-gel electrophoresis tank and 
running buffer (lOOmM Tris, 150mM glycine, 0.1% SDS, pH 8.4) applied to the tank 
and cooled at 4°C for 30 minutes. A 10|il sample was applied to each well and 
electrophorised at 60V for 20 minutes then 35V until the tracking dye had reached 
the end of the gel. After electrophoresis, transfer of protein to Hybond nitrocellulose 
membranes (AmershamPharmacia, UK) was carried out for 2 hours at 400mA at 4°C. 
The membranes were then rinsed in PBS-T, and blocked for 1 hour with 5% blocking 
reagent/PBS-T (Amersham Pharmacia, UK). Finally, the membranes were incubated 
with anti-VWF-HRP antibody (DAKO) diluted 1/1000 for 1 hour. After washing, bound 
antibody was detected with ECL chemiluminescent kit (Amersham Pharmacia, UK) 
and exposure to Amersham Hyper-Film. 
2.8 Molecular modelling of ADAMTS13 to predict binding sites 
The crystal structure of Adamalysin II has been elucidated and this structure is 
available to view in the Protein Data Bank (www.rcsb.orq/pdb). The accession 
number for this crystal structure is 11 AG. The ADAMTS13 protein sequence was 
modelled on the known crystal structure of Adamalysin II. Swiss-model was used to 
achieve this, whereby the protein sequences of ADAMTS13 and Adamalysin II were 
first aligned to check that the degree of homology was suitable for modelling, and 
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then the ADAMTS13 protein sequence was threaded through the Adamalysin II 
template crystal structure (PDB:1IAG). Using this to model, it was possible to 
elucidate dense areas of negative charge by searching the predicted surface of the 
domain, and setting negatively charged side chains to appear in red. This then gave 
clusters of red-coloured side chains, and the most dense were investigated for 
possible residue coordination and orientation, which may correspond to a binding 
pocket for a positive ion, such as Ca^^. 
2.9 UV absorbance at 280nm of ADAMTSIS 
It has been reported that optical spectroscopic techniques can be used to measure 
Ca^'' binding constants when the Ca^^ bound and free forms of the protein display a 
difference in UV absorbance^^®. Absorbance of a protein at 280nm depends on three 
chromophores: side chains of Trp, Tyr and Phe, and to a lesser extent Cys (in a 
disulphide pair)^ ®"^ . The absorbance of IpM ADAMTS13 in 20mM Tris-HCI (pH7.8) 
(pH7.8) was measured at 280nm using a UV-1601 spectrophotometer (Shimadzu). 
IplVI ADAIVITSIS was then incubated also in a range of Ca "^" concentrations (0-8mM) 
and pre-incubation times (0-60 minutes) to see if the absorbance at 280nm would be 
altered. 
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Chapter 3 
Metal ion activation of ADAIVITS13 
3.1 Introduction 
Currently 13 metals are known to be essential for plants and animals, four of which 
are present as bulk metals; Na \ K"", and Ca^^ The other nine are present as 
trace elements and are Cr^"', Mo^'", Mn "^", Fe^*, Co^, Ni^ '^ , Cu^^ and Zrf*. The 
concentration of metals inside cells must be tightly regulated as too much or too little 
may be lethal to the organism. The amino acids that regularly act as metal ligands in 
proteins are the thioiates of Cys, imidazoles of His, carboxylates of Glu and Asp, and 
phenolates of Tyr^ ®®. Each metal favors a different set of protein ligands, and the 
coordination number and specific geometry of a site is determined by the metal's 
oxidation state. Each metal also serves to carry out a specific biological function 
based on their individual chemical properties. Among all naturally occurring 
metalioproteins, those containing IVIg^ ,^ Zn^^ and Ca^^ are the most abundant^^®. A 
previous study of ADAMTS13 demonstrated that out of eight divalent cations, 
increasing concentrations of Ba^, Mg^^, and Cu^^ had little effect on activity. 
Increasing concentrations of Co^^, and NF+ inhibited ADAIVITS13 activity, while 
Ca^^ and enhanced ADAMTS13 activity^®®. An even earlier study by Furlan et a! 
(1996), however, showed that excess Zn^"", Cu^*, Cd^"', Co^^, or Mn^ did not 
activate plasma purified ADAMTS13, while Mg^ produced partial activation^®®. In this 
same study and Sr^ "" produced significant activation but Ba "^" gave the most 
substantial activation of all divalent cations. In order to get a working perspective on 
the possible roles of metal ions in ADAMTS13, I investigated their effects on the 
activity of the protease. In what follows, I describe experiments with purified 
ADAMTS13 and with ADAMTS13 in dialysed conditioned media. 
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3.2 Purification of Recombinant ADAIVITS13 
ADAMTS13 is continuously generated in the lab by expression of recombinant 
myc/6xHis-tagged ADAMTS13 which was stably transfected into HEK293 cells with 
the pcDNA3.1 + ADAIVITS13/myc/His vector (section 2.2). Briefly, cells were grown to 
80% confluence, after which expression media was added. Conditioned media was 
collected after three days and concentrated and desalted, by thorough dialysis in 
20mM Tris overnight, ADAMTS13 was purified and further concentrated on a Ni^^-
chelating column by FPLC (Fig. 3.1). SDS-PAGE (section 2.6.4) was used to confirm 
the presence and purity of ADAMTS13 with Coomassie staining and Western blotting 
(section 2.6.6) using an anti-ADAMTS13 protease domain antibody (Fig. 3.2). A 
typical preparation of purified ADAMTS13 had a concentration of -Sj iM calculated by 
ADAMTS13 ELISA (section 2.6.2). 
ADAMTS13 was also transiently expressed by transfection of pcDNA3.1 
ADAMTS13/myc/His into HEK293T cells using PEI. Expression was induced by 
removal of growth media and addition of conditioned media, and the cells were 
allowed to express for 3 days, after which, conditioned media was collected and 
concentrated as described above. The media was thoroughly dialysed but not 
purified as the concentration was too low. ADAMTSIS in conditioned media was also 
analysed by Western blotting and is shown in Fig. 3.2. A typical preparation of 
transiently expressed ADAMTS13 in concentrated dialysed conditioned media had a 
concentration of ~50nM. 
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Figure 3.1 Purification of recombinant ADAIVITS13 
ADAMTS13 was expressed by HEK293 cells stably transfected with the pcDNA3.1+ADAMTS13/myc-
His expression vector. ADAMTS13 was purified from concentrated and desalted conditioned media 
using a Ni^^ Hi-Trap column. Conditioned media was injected onto the column (A) at 1 ml/min to allow 
gradual binding of the ADAMTS13 His tag to the Ni^ "^  filled column, and all the other proteins to pass 
through the column unattached. The column was washed in Buffer A (20mM Tris-HCI (pH7.8), 500mM 
NaCI and 20mM Imidazole), and then the buffer was switched to Buffer B (B) (20mM Tris-HCI (pH7.8), 
500mM NaCI and 500mM Imidazole). ADAMTS13 eluted as a large peak (C), after which the column 
was stripped of all remaining bound protein using EDTA to chelate (D). 
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Figure 3.2 SOS-PAGE with Coomassie staining and Western Blot of purified ADAMTS13 
ADAMTS13, purified and electrophioresed in 4-12% poiyacryiamide gels in the presence of SDS. Lane1; 
Novex-Sharp Pre-stained gel. Lane 2: Coomassie stain under non-reducing conditions, demonstrating a 
single~190kDa band. Lane 3: Western Blot analysis of purified ADAMTS13 (lane 2) with the anti-
ADAMTS13 antibody (pAb) (depleted of antibodies against the ADAMTS13 TSP2-4 domains). The 
same 190kDa band is seen demonstrating the presence of ADAMTS13. Lane 4: Western blot analysis 
of ADAMTS13 in conditioned media, dialysed overnight in 20mM Tris-HCI (pH7.8). pH 7.8. 
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3.3 Expression and Purification of VWF115 
ADAMTS13 activity may be assessed by using a short VWFA2 domain fragment, 
VWF115, which contains the Y1605-M1606 cleavage site. The advantage of using 
this substrate, as opposed to full length VWF is that the cleavage site is exposed and 
not masked by other VWF domains. There is no requirement for denaturants to 
unravel the substrate before cleavage can occur. VWF115 was expressed in Rosetta 
DE3 E. Co//cells (section 2.4.1 and 2.4.2), and then purified on Np+ chelating column 
(section 2.4.3), and a high purity fraction was eluted (Fig. 3.3a). This fraction was 
then examined by HPLC to check the peak size and purity (Fig. 3.3b), and run on 
SDS-PAGE (section 2.6.4) using a 10% Tris-tricine gel to check the size and purity 
visually, and also to give a rough estimate of what the concentration may be. After 
purification, VWF115 eluted fraction was dialyzed in 20mM Tris-HCI (pH7.8) three 
times, and then a BCA assay performed to determine protein concentration (section 
2.6.1), giving a final concentration of VWF115 of SSjiM. 
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Figure 3.3: Purification of VWF115 
a) FPLC chromatogram showing purification and refolding of VWF115 using a Ni^^ chelating column. A -
Inclusion bodies were solubilised in a buffer containing 8M urea, 20mM Tris-HCI (pH7.8), 500mM NaCI 
and 20mM Imidazole and refolded using an 8M-0M urea linear gradient (B). The elution was performed 
using 20mM Tris-HCI (pH7.8), 500mM NaCI and 500mM Imidazole (C). D - EDTA containing solution 
passed over the column, resulting in a small peak of remaining column-bound protein, b) HPLC 
chromatogram showing pure sample of eluted fraction from a) exhibited a peak at -8.5, which is in 
accordance with previous studies^", c) Coomassie staining analysis on a 10% Tris-Tricine gel is 
depicted showing a single band of 16.9kDa (lane 2). Lane 1 shows a ladder of protein molecular weight 
markers with the actual markers and relevant molecular weights (Novex) shown for clarity. 
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3.4 Purification of full length V W F from Haemate P 
3.4.1 Gel Filtration 
In order to check that the quantifiable results obtained with the short VWF substrate, 
VWF115, could be generalised, some experiments were repeated using full length 
VWF. To obtain this, VWF was purified from Haemate P, which is a commercial 
VWF-Factor VIII concentrate. This concentrate is useful as a physiological substrate 
as it has been shown to have a multimer pattern resembling that of VWF in normal 
human plasma^®®. Lyophiiised Haemate P was resuspended in 10mls of ddHgO, then 
gel filtered through a Sephacryl 400 gel filtration column (section 2.5.1). The column 
was eluted at a flow rate of Iml/min and 5ml fractions were collected. Protein began 
to elute from the column typically at fraction B6 (Fig. 3.4a). Early eluted fractions and 
selected later fractions were analysed by SDS-PAGE under reducing conditions 
using SDS-PAGE on 4-12% gels and protein bands were visualised by Coomassie 
staining. Fractions A10-B3 demonstrated a major 250kDa band, consistent with 
monomeric VWF (Fig. 3.4b) To remove contaminating proteins (mainly albumin) and 
to concentrate the VWF samples, fractions A10-B3 were pooled and further purified 
using Heparin-Sepharose affinity chromatography. 
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Figure 3.4 Gel filtration of Haemate P 
a)Haemate P was gel filtered througfi a Sepfiacryl 400 gel filtration column (section 2.5.1) and 5ml 
fractions were collected. Protein began to elute from the column typically at fraction A10. b) Early eluted 
fractions and selected later fractions were analysed using reducing SDS-PAGE in 4-12% gels followed 
by Coomassie staining (Bottom frame). Fractions A10-B3, demonstrating a major 250kDa band 
consistent with monomeric VWF, were pooled and VWF was further purified by Heparin-Sepharose 
chromatography (section 2.5.2). 
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3.4.2 Heparin-Sepharose Chromatography 
Gel-filtered Haemate P was passed over a Heparin-Sepharose column to further 
purify and concentrate VWF (section 2.5.2). Five fractions of ~10ml were collected 
with the first three fractions containing the majority of the VWF (Fig3.5a). The 
multimer pattern of purified VWF was assessed using multimer gel analysis (section 
2.7.12) (Fig. 3.5b). Fractions B11- A4 showed a normal multimer pattern. Fractions 
B11 and B12 were pooled together, as were fractions A1 and A2, and A3 and A4, 
and the concentrations of these pooled fractions determined by VWF ELISA (section 
2.6.3). The concentration of the pooled fractions were ~200|ig/ml for B11-B12, 
~350iag/ml for A1-A2 and ~60iig/ml for A3-A4. 
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Figure 3.5 Heparin-Sepharose purification of gel filtered Haemate P 
a) Pooled fractions A10-B5 of gel filtered Haemate P were passed over a 30ml Heparin-Sepharose 
column (section 2.5.2) and the column eluted with 300mM NaCI. b) Fractions 811-A4 were analysed for 
multimer pattern by multimer gel analysis. 
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3.5 Effect of different divalent cations on ADAMTS13 activity 
The effect of different metal ions on ADAMTS13 activity has been previously been 
investigated^®". In these experiments, however, results may have been affected by 
the residual levels of Ca^^ and Zn^^ that were present in the reaction buffer due to the 
plasma assay conditions under which the experiments were run. The authors report 
that in complete reactions containing buffer, substrate and plasma, Zn^^ was <2iiM 
and was <250|iM. Most striking was the finding of no increase in activity of 
ADAMTS13 in the presence of increasing concentrations of Ba^"'. The preliminary 
results above (Fig. 1.11) appear to contradict that finding. To clarify further, I have 
conducted experiments under similar conditions reported by Anderson et al (2006)^®°. 
1M metal ion stock solutions were made in 20mM Tris-HCI (pH7.8), from which fresh 
50mM stock solutions were made by diluting 1 in 20 into 20mM Tris-HCI (pH7.8). To 
determine the effect of different divalent cations on ADAMTS13 activity, InM 
transiently expressed ADAMTS13 in dialysed conditioned media (see section 4.4) 
was pre-incubated for 1 hour (see section 4.3) with 150mM NaCI, 20mM Tris-HCI 
(pH7.8) and 5mM of CaCl2, BaCIa, MgS04, MnCIa, NiS04 or CUSO4, or no added 
metal ions, before addition of 1.6|aM VWF115 in the same buffer. Time points were 
taken at regular intervals and samples quenched with EDTA to remove all activating 
metal ions including the catalytic Zn^. Percentage cleavage of VWF115 was 
determined using HPLC analysis and plotted using GraphPad Prism. From 
preliminary work (Fig. 1.11), ADAMTS13 activity appears to be minimal in the 
absence of added Ca^VBa^"" which suggests that a minimal amount of Ca "^", if any, is 
present in the reaction buffer. The subsequent significant activation of ADAMTS13 
with excess Ca^VBa^* (Fig. 1.11) suggests that ADAMTS13 in these preparations is 
already activated by the catalytic Zn®^ ion. This was confirmed by treating 
ADAMTS13 with EDTA, and adding back the Zn^"", as described in section 2.7.4, with 
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the EDTA-treated and non-treated ADAMTS13 having comparable activity 
determined by rates of substrate proteolysis. In the following experiments, it is 
therefore assumed that the preparation of ADAMTS13 used already has Zn "^" bound 
in the active site, but does not contain Ca^"'. Out of all the divalent cations tested, 
Ca^* was the most activating, reaching total substrate cleavage in the fastest time, 
followed by Ba "^". Mg^^, Mn^^, and Cu^^ produced no significant activation of 
ADAMTS13 as did no addition of metal ions (Fig 3.6a). The same experiment was 
performed in the presence of 200|iM CaClg (Fig. 3.6b). Here, both Ca^^ and Ba "^" 
were weakly activating, but Mg "^^ , Mn^ and gave no added activity to 
ADAMTS13 compared to no added metal ions. Interestingly, inhibited 
ADAMTS13 at a concentration of 5mlVl, which was not apparent in the previous 
experiment shown in Fig. 3.6a. 
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Figure 3.6 Modulation of ADAMTS13 activity by divalent cations 
a)1nM ADAIVITS13 in dialysed conditioned media was pre-incubated for 1 hour with 150mM NaCI, 
20mM Tris-HCI (pH7.8) and one of 5mM CaCIa, BaCIa, MgS04, MnCh, NISO4, CUSO4 or no added metal 
ions. 1.6|iM VWF115 was then added to start the reaction. Time points were taken every 30 minutes 
and samples quenched with EDTA, Percentage cleavage of VWF115 was determined using HPLC 
analysis and plotted using GraphPad Prism, b) as for a) but all reactions contained 200|_iM CaCh in 
addition to 5mM metal ion. The data in both a) and b) are representative of 3 experiments with similar 
results. 
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3.6 Activity of ADAIVITS13 at varying metal ion concentrations 
To determine tlie optimal concentrations of metal ions for activation or inhibition, 1nM 
ADAMTS13 in dialysed conditioned media was pre-incubated with ISOmM NaCI, 
20mM Tris-HCI (pH7.8) and varying concentrations one of CaCl2, BaClg, MgS04, 
MnCIa, NiS04, CUSO4 between 0 and 5mM for 1 hour before the addition of 1.6[iM 
VWF115. Time points were taken at 20 minutes and reactions were quenched with 
EDTA. The percentage cleavage of VWF115 was determined by HPLC analysis and 
the initial rate determined as described in Methods. With no added metal ions there 
was no activity detectable (Fig. 3.7a). This inactivity remained for increasing 
concentrations of Mg^^, Mn^^, and Cu^*. In contrast, increasing concentrations of 
Ba^"" and Ca^* resulted in increase ADAMTS13 activity, with fully activating the 
enzyme at a concentration of 1mM. ADAMTS13 requires a higher concentration of 
Ba^"" to be 80% as active. As in section 3.5, the above experiment was repeated 
using 200nM CaClg in the reaction buffer in addition to increasing metal ion 
concentrations (Fig. 3.7b). Here, ADAMTS13 was demonstrated to have a baseline 
rate of ~0.35nMs'^ with no additional metal ions. The initial rate in the presence of 
increasing Mg "^^ , M n ^ or Cu^"" concentrations was unchanged compared to the 
baseline (fig. 3.7b), confirming the result in Fig. 3.7a that these ions have no effect on 
activity. Ba^^ ions do not appear to produce a significant increase in activity in the 
presence of 200|JM CaClg, whereas they do produce a significant increase in the 
absence of Ca '^^  (Fig. 3.7a). Increasing concentrations of produce an increase in 
activity even In the presence of 200nM CaClg, but the increased activity is not as 
pronounced as in the absence of 200|jM CaClg. Increasing concentrations of N f * 
inhibited ADAMTS13 with maximum inhibition taking place between 3 and 4mM. 
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Figure 3.7 ADAIV1TS13 activity with increasing metal ion concentrations 
a) 1nM ADAMTS13 in dialysed conditioned media was pre-incubated with 150mM NaCI, 20mM Tris-HCl 
(pH7.8) and varying concentrations one of CaClg, BaClg, MgSCk, MnCl2, NiS04, CuSO* between 0 and 
5mM for 1 hour before the addition of I .epM VWF115. Time points were tat<en at 20 minutes and 
reactions were quenched with EDTA. The percentage cleavage of VWF115 was determined by HPLC 
analysis and the initial rate of cleavage (section 2.7.3). b) as for a) but all reactions buffers contained 
200iiM CaClg. The data in both a) and b) are representative of 3 experiments with similar results. 
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3.7 Modulation of ADAMTS13 activity by Ba^* 
has previously been demonstrated to activate ADAMTS13 in in vitro assays with 
plasma derived full-length 129 ,158 ,257 j hese assays used excessive BaClg (8-
10mM) and 5 minute pre-incubation with the ion before addition of VWF. In view of 
the obvious activating capacity of Ba^^, the activity of ADAMTS13 was titrated as a 
function of increasing Ba^^ concentration. 1nM ADAMTS13 in dialysed conditioned 
media was pre-incubated for 1 hour with 150mM NaCI, 20mM Tris-HCI (pH7.8) and 
varying concentrations of BaCl2 between 0 and BmM, before the addition of 1.6|aM 
VWF115. Time points were taken at 30 minutes and the reaction was quenched with 
EDTA. Percentage of VWF115 proteolysis was determined by HPLC analysis as 
described in Methods. ADAMTS13 is activated by Ba^^ with a Kd(app) of 1.4mM ±0.2 
(Fig. 3.8a). This is well below the BaCIa concentrations used in the experiments 
carried out in previous investigations, suggesting that the ADAMTS13 in those 
experiments would have been maximally activated by Ba^^. In order to ascertain 
whether Ca^* or Ba "^" is more able to activate ADAMTS13 in reaction with full length 
VWF, 1 nM ADAMTS13 in dialysed conditioned media was again pre-incubated in the 
reaction buffer for 1 hour with either 5mM CaCl2 or 5mM BaCl2 before the addition of 
VWF which had been pre-treated with 1.5M Gdn-HCl, at a final concentration of VWF 
In the reaction of lOpg/ml. Time points were taken at regular intervals and the 
reaction quenched with EDTA as above. Cleavage of VWF was analysed by multimer 
gel analysis (section 2.7.12). With full-length VWF, ADAMTS13 was rapidly activated 
by Ca "^" while Ba "^" induced a slower rate of cleavage (Fig. 3.8b). 
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Figure 3.8 Ba * modulation of ADAIVITS13 
a) InM ADAMTS13 in dialysed conditioned media was pre-incubated with 150mM NaCI, 20mM Tris-HCI 
(pH7.8) and varying concentrations of BaCb between 0 and 8mM for 1 hour before the addition of 1.6|iM 
VWF115. Samples were taken at 30 minutes and reactions were quenched with EDTA. The percentage 
cleavage of VWF115 was determined by HPLC analysis and the initial rate determined as descried in 
Methods. (n=3) b) 1nM ADAMTS13 was again pre-incubated in the reaction buffer for 1 hour with either 
5mM CaClg or 5mM BaCl2 before the addition of VWF which had been pre-treated with 1.5M Gdn-HCI. 
The final concentration of VWF in the reaction was 10|ig/ml. Time points were taken at regular intervals 
and the reaction quenched with EDTA. Cleavage of VWF was analysed by multimer gel analysis 
(section 2.7.12). The multimer gel results are representative of three experiments with similar results. 
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3.7 Modulation of ADAMTS13 activity by 
The experiments outlined in sections 3.5 and 3.6 did not include Zr\^* as excessive 
amounts in reaction buffers have been reported to be inhibitory, even though the ion 
is absolutely required to be present in the active site®®°. in order to determine the 
amount of Zn^^ required by ADAMTS13 in the active site, ADAMTS13 activity was 
titrated against increasing Zn^^ concentration. Since the Kdopp) of ADAMTS13 for Zn^^ 
was previously reported to be ~0.5|iM^®° and high concentrations reported to be 
inhibitory, 1nM ADAMTS13 in dilaysed conditioned media (treated with EDTA to 
remove the active site Zn "^^ , then dialysed in 20mM Tris-HCI (pH7.8) twice for four 
hours each to remove the EDTA) was pre-incubated for 1 hour with reaction buffer 
containing 20mM Tris-HCI (pH7.8), 150mM NaCI, 5mM CaClg and varying 
concentrations of ZnClg between 0 and 100|aM, before the addition of 1.6nM 
VWF115. ADAMTS13 was activated by Zn^^ with a Kd(app) of 1.5(iM ± 0.6 (Fig. 3.9a) 
in the presence of saturating level of Ca "^". To determine at what concentration Zn^'" 
ions become inhibitory, the above experiment was repeated but with ADAMTS13 that 
had not been EDTA treated so it was assumed that it was already Zn^ "^  activated. The 
reaction buffer already contained 5mM CaCl2, so the enzyme was maximally active 
before the addition of Zn^ "^  at varying concentrations between 0 and 5mM. 
Concentrations of Zn^^ above 1mM were found to be markedly inhibitory to 
ADAMTS13 activity (Fig. 3.9b). 
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Figure 3.9 IVIodulation of ADAIVITS13 activity by Zn * 
a) 1nM ADAMTS13 in dialysed conditioned media was treated with EDTA to remove the active site 
Zn® ,^ then dialysed in 20mM Tris-HCI (pH7.8) twice for four hours each to remove the EDTA. The 
enzyme was pre-incubated for 1 hour with reaction buffer containing 20mM Tris-HCI (pH7.8), 150mM 
NaCI and SmIVl CaClg and varying concentrations of ZnCb between 0 and 100|iM, before the addition of 
1.6|iM VWF115. The percentage cleavage of VWF115 was determined by HPLC analysis and the initial 
rate determined (section 2.7.2 and 2.7.3)(n=3) b) 1nM Zn^* activated ADAMTS13 was pre-incubated for 
1 hour in reaction buffer with 5mM caCb and varying concentrations of ZnClz between 0 and 5mM. The 
percentage cleavage of VWF115 was determined by HPLC analysis and the initial rate determined 
(section 2.7.2 and 2.7.3). This data is representative of 3 experiments with similar results. 
106 
3.8 Modulation of ADAMTS13 activity by Ca^^ and 
It was previously reported that Zn^"" and Ca "^" act synergistically to activate 
ADAMTS13^^°. The results presented so far in this study show that Zn^'^-activated 
recombinant ADAMTS13 is inactive without added metal ions (Fig. 3.9a), but also 
that non-Zn^^-activated ADAMTS13 in the presence of saturating Ca^^ is inactive 
without added Zn^^. To confirm that Ca^* and Zn^^ do not act synergistically but 
independently to activate ADAMTS13, reactions were set up as previously described 
to determine the initial rate of reaction, using three sets of reaction conditions. Under 
conditions described by Anderson et al (2006), with 200iaM CaCl2 already present in 
the reaction buffer, the activity of ADAMTS13 with no added metal ions was 
~0.35nMs"^ (Fig. 3.10a). With added 250|aM ZnCIa, the rate was unchanged. 
However, with 5mM CaClg the rate increased to ~0.45nMs"\ which was not 
significantly increased further by the addition of 250|iM ZnClg Under conditions 
where ADAMTS13 is already Zn^^-activated, but no Ca^^ is present in the starting 
reaction buffer, with no added metal ions the rate of VWF proteolysis is minimal (~ 
0.02nMs"') (Fig. 3.10b). Addition of 250|iM ZnCl2 does not increase this rate. Activity 
(~ 0.45nMs"^) is restored by addition of 5mM CaClg, and remains unchanged by 
addition of 250|iM ZnCIa as well as 5mM CaClg. Finally, under conditions where 
ADAMTS13 is not Zn^^-activated (i.e. has undergone EDTA treatment and 
subsequent dialysis), the enzyme is completely inactive without added metal ions 
(Fig. 3.10c). Here, addition of 250|aM ZnCl2 induces mild activation of ADAMTS13, 
but not as significant as both 250iaM ZnClg and 5mM CaClg, which completely 
restores ADAMTS13 maximal activity. The addition of 5mM CaClg alone cannot 
induce activity as Zn^^ is not present in the active site. 
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Figure 3.10 Modulation of ADAMTS13 activity by Ca^* and Zn^* 
a) 1nM Zn^*-activated ADAMTS13 was pre-incubated with 150mM NaCI, 20mlVI Tris-HCI (pH7.8), 
200nM CaCIa and either no metal ions (clear), 250ijM ZnCIa (chequered), 5mM CaCb (striped) or both 
250nM ZnCb and 5mM CaClg for 1 hour before the addition of 1.6iiM VWF115. The percentage 
cleavage of VWF115 was determined by HPLC analysis and the initial rate determined as descried in 
Methods, b) as for a) but the reaction buffer did not already contain 200|iM CaCb. c) as for b) but the 
ADAMTS13 was not Zn^^-activated. (n=3 for all experiments). 
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3.6 Discussion 
ADAMTS13 has historically been shown to be dependent on Zn "^" and Ca^7 for 
activity^ 28,129,155,1 sa.183,258 some metalloproteases, divalent cations other than Zn '^^  
and Ca^^ can support activity. MMP 3, for example, can be activated by Co "^" ions to 
80% activity of that induced by Zn^ ^^ ®®. In this study, the dependence of ADAMTS13 
activity upon a variety of divalent cations was investigated. Fig. 3.6a shows that the 
presence of excess Ca^^ was able to activate ADAMTS13 to proteolyse the short 
VWF substrate, VWF115. Ba^* was able to induce activity, but less so than Ca^\ All 
other ions appear to have no activating effect on ADAMTS13. is shown to have 
an inhibiting effect on the enzyme's activity (Fig. 3.7b). To understand why Ca^* and 
Ba^ "^  are the most activating divalent cations compared to the others tested, we must 
look at their specific coordination geometries. Ba^^ and Ca^^ are similarly coordinated 
with the usual donor atoms being an oxygen atom of Asp or Glu or a main chain 
oxygen. Water can also provide additional oxygen atoms to take the coordination 
number up to the normal six, providing octahedral coordination (see section 1.4.1)^®°. 
It is widely reported in many biological scenarios that Ba^ "^  (and Sr^^) can substitute 
for Ca^^. For example, Ba '^" can pass through the voltage-dependent Ca^"' channel in 
the plasma membrane of smooth muscle^®\' Ba^^ can replace Ca^* in calmodulin in 
the activation of protein phosphatases^®^; Ba^^ was found to substitute fully for Ca^^ in 
supporting the KCI-evoked release of glutamate from guinea-pig cerebrocortical 
synaptosomes^®®; Ca^VBa^VSr^^ can all equally induce conformational changes in 
ciliary axonemes^®"^. These examples clearly demonstrate the exchangeability of 
these ions, especially Ca^ "^  and Ba "^", however it is not always possible to substitute in 
this way. One investigation into Ca^^- sensitive adenylyl cyclases revealed an EF-
hand like Ca^^-binding site involved in inhibition of a sub-type of this enzyme, but 
Ca^^, Sr^^ and Ba^^ did not induce this inhibition equally, and EF-hand Ca^^-binding 
sites are known to display characteristic preferences for these ions^ ®®. This suggests 
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that the exchangeability of Ca^VBa^VSi^'^ depends on the type of Ca^^-binding site 
involved. EF-hand sites, as explained in section 1.4.1, provide all the ligands for Ca "^" 
coordination from a single sequence, in which seven oxygen atoms bind to the Ca^^ 
ion in pentagonal bipyramidal geometry, and allow rapid substitution of inner sphere 
water molecules to accommodate the ion. The specificity of EF-hand type sites is 
necessary for some proteins to be specifically regulated by Ca^^ in the face of a great 
excess of Mg^"", which coordinates only 6 nitrogen or oxygen atoms and substitutes 
water much more slowly. This specificity for Ca^^ over Mg^ also means that these 
sites are more selective for than Sr^'' or Ba^^, which, despite having the same 
high coordination number and rapid water substitution, have much larger crystal ionic 
radii (1.4A for Sr^ "^  and 1.56A for Ba^^) making them less effective at substituting for 
Ca^+ in highly specific Ca^^ binding sites. However, the fact that Ba^"' and Sr^^ are 
both non-physiological ions, the ability of ADAMTS13 to be partially activated by Ba^^ 
can be attributed to the similar coordination properties of the two ions, rather than a 
natural exchangeability between the two. These findings and previous reports on the 
ability of Ba "^" to activate ADAMTSI 3129,158,257,258^  suggest that this enzyme is 
activated by Ca^* in vivo, and that the Ca^'' binding site involved is not of an EF-hand 
type. However, since Ba^^ can activate ADAMTS13, and is assumed to do so by 
interacting with a Ca^^ binding site, it is interesting to investigate the specifics of Ba^^ 
binding. Ba^'" was found to activate ADAMTS13 with a K^ a^pp) of ~1.4mM (Fig. 3.8a), 
similar to the value obtained by Anderson et al (2006) of ~1.7mM. It is possible that 
Ba^^ uses a Ca '^^  binding site to activate ADAMTS13, as this is a very low affinity for 
an ion to bind with. In reaction with full-length VWF, results from sections 3.5 and 3.6 
are confirmed, with ADAMTS13 being maximally activated by Ca^^ and activated to a 
lesser degree by Ba^^, indicated by a slower drop in high molecular weight multimers. 
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In this study, no significant activation by Mg^ was observed (Fig, 3.6), although 
some activation had been previously reported^^®'^ ®®. Mg "^" and Ca "^" are 'hard' ions, 
which means they are hard to polarize and small, and as such prefers 'hard' ligands 
of low polarisability Oxygen is the preferred coordinating atom of Mg^'", followed 
by nitrogen. The amino acids most commonly contributing to Mg^ binding sites are 
those with carboxylate side chains, namely Asp and Glu which specifically coordinate 
the ion in a monodentate fashion. Non-charged residues commonly involved are 
Asn/Gln, followed by Ser/Thr, His, and Tyr side chains. Mg^ ions are most commonly 
coordinated in proteins in an octahedral manner, in which water is a common feature. 
The Mg-oxygen internuclear separation ranges from 2 to 2.2 A. Ca^^ also prefers 
'hard' ligands, however unlike Mg^ which usually occupies the centre of an 
octahedron, the coordination number of Ca^* is between 6 and 8^^. Also the ionic 
radius of a Ca^^ ion with a given coordination number is always higher than that of 
Mg^^ with the same coordination number due to the fact that the atomic number of 
Ca^^ is 20 while that of Mg^ is 12, so the ionic radii of 6- and 8- coordinated Ca^^ are 
1.00 and 1.12 A respectively, whereas the corresponding values for Mg^ are 0.72 
and 0.89 A ^ . The internuclear separations for Ca^^ range from 2.1 A (monodentate 
whereby the coordinating amino acid provides one oxygen atom) to 2.8A (bidentate 
whereby the coordinating amino acid provides two oxygen atoms) for carboxyl and 
carbonyl ligands, whereas the Ca-oxygen separation with coordinating water 
molecules is between 2.3-2.9A^^®. Compared to Mg "^^ , Ca^ "^  shows a greater tendency 
towards bidentate carboxylate binding but a lower affinity for water. It is therefore rare 
for Mg^ "^  ions to bind to Ca "^" binding sites. This is physiologically significant as the 
concentration of Mg^ in the blood is comparable to Ca^^ (0.8-1.1mM Mg^ compared 
to 1.2-1.8mM Ca^""), and Ga^^ binding sites must therefore be selective against Mg^^. 
Mn^ has a similar size to Ca^* (atomic number 25) but its coordination is classically 
different with its usual donor atoms including the nitrogen atom of His, and a 
coordination number of 5 or 6^ ®°. Cu^ is larger than Ca^^ (atomic number 29), and 
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has an entirely different coordination geometry. Its usual donor atoms are the 
nitrogen and sulphur atoms of Cys, although it can bind to the oxygen atoms of Asp, 
Glu, Asn and Gln^®°. Its coordination number is usually 3 or 4, and it would be 
virtually impossible for it to bind to a binding site as it could not be coordinated 
correctly. This would explain why it has no effect on ADAMTS13 activity. 
however appears to have an inhibitory effect on ADAMTS13 which only becomes 
clear when ADAMTS13 is already significantly activated by 200iiM CaClg (Fig. 3.7b). 
This inhibition takes place partially at concentrations up to 3mM NiS04, with complete 
inhibition by 4mM (Fig. 3.7b). Inhibition of ADAMTS13 by has been previously 
reported^®", although an explanation was not provided. Looking at the features of 
Ni^^, we can see that it has a similar size to Zn^^ (Ni^'' atomic number 28, Zn^^ atomic 
number 30)^®°. The size is similar to Cu "^^ . However, an important difference between 
these two ions is that the usual donor atoms for coordination are the nitrogen 
atom of His and less frequently the oxygen of Asp or Glu. This is important as the 
Zn^'" ion in the active site of ADAMTS13 is coordinated by three His residues and so 
the ion may be competing for the Zn^^ binding site at high concentrations. The 
usual coordination number of Nf* is 6 but it is sometimes found in tetrahedral (4) 
coordination like Zn "^"^ ®". is the only ion tested here that preferentially binds His 
residues, whereas all the others preferentially bind Asp, Glu or Cys, which, again, 
may suggest that N f * is substituting for Zn^^ in the active site and subsequently 
inactivating the enzyme, although this would require further investigation to confirm if 
this is actually taking place. 
Unlike Mg^^, Ca "^" and Ba "^^ , Zn^^ prefers 'soft' ligands like Cys and His as mentioned 
above^^®. In aqueous solution Zn^^ is octahedrally bound to water, but in enzymes it 
is usually found in a tetrahedral coordination. It can be assumed that the Zn^^ and 
Ca '^^  binding sites in ADAMTS13 are mutually exclusive because of this difference in 
coordination geometry, but also the relative Zn-oxygen/Ca-oxygen distances 
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commonly adopted; For Ca-oxygen where the oxygen is donated from the main chain 
or Asp/Glu residues, the distance if 2.35-2.45, while for the equivalent distance 
is 2.00-2.10^®°. Also the relative sizes of these ions (atomic number 20 for Ca^^ and 
30 for Zn^) would make it difficult for one to bind to the others site, as well as the 
particular ligand preference as ions do not usually bind to His residues. It has, 
however been suggested that the effects of Ca^* and Zn^^ on ADAMTS13 may be 
synergistic, which would suggest some cooperativity between Ca^^ and Zn '^^  binding 
sites, either directly or through conformational changes in the enzyme^®°. The Zn^* 
dependence of ADAMTS13 was found to be similar to that reported by Anderson et 
a! (2006) where a Kd(app) 0.5iiM was reported, and this study showed a Kd(app) of 
~1.5nM (Fig. 3.9a) for Zn^^. Zn^^ has also been reported to be inhibitory to 
ADAMTS13 at high concentrations^^". I, therefore titrated ADAMTS13 with higher 
Zn '^^  concentrations and this was indeed found to be the case (Fig. 3.9b). Anderson 
et al suggested that this may be due to the formation of a hydroxy! ion Zn(OH)^ which 
binds to the catalytic Glu residue in the active site, or perhaps other acidic residues in 
the active site and so interfere with the proper binding of the Zn^^ ion to its three 
coordinating His residues in the active site. It is also possible, in light of this finding, 
that N f * is inhibiting the enzyme through a similar mechanism at high concentrations 
with the formation of a Ni(OH)^^ interfering with Zn^^ in the active site. 
In terms of synergy between Ca^ and Zn '^^  in activating ADAMTS13, the results 
presented here do not support those reported by Anderson et al. With present in 
the reaction buffer, ADAMTS13 activity was not enhanced by the presence of excess 
but not inhibiting ZnClg, although was slightly enhanced by the addition of excess 
CaCl2 (Fig. 3.10a). No further enhancement was seen with both CaClg and ZnClg 
compared to CaCl2 added alone. With no present in the reaction buffer 
(ADAMTS13 assumed to be Zn^^ activated) there was no enhanced activity in the 
presence of added ZnClg, but a significant enhancement in the presence of added 
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CaClg (Fig.3.10b). No further enliancement was seen with both CaCIa and ZnClg 
compared to CaClg added alone. The only evidence for some degree of synergy can 
be seen when recombinant ADAMTS13 is pre-treated with EDTA to remove the Zr?* 
from the active site. The EDTA is then thoroughly dialysed out. Without any added 
metal ions, ADAMTS13 treated in this way is completely inactive (Fig. 3.10c). 
Addition of ZnCla activates the enzyme partially but to only a fraction of the maximum 
rate. Addition of CaCl2 alone cannot activate the enzyme if is not present in the 
active site, which is a key finding, and which is not in support of previously reported 
data^^°, which suggested that Ca^^ alone can activate ADAMTS13 to a degree. 
Maximum activity is restored with the addition of both excess CaCla and ZnClg 
These results suggest that, while is vital to full activation of ADAMTS13, the 
enzyme cannot function without Zn^^ in the active site, which would suggest that Ca^* 
and Zn^^ do not act synergistically, but are instead required independently for full 
activation of ADAMTS13. 
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Chapter 4 
dependence of ADAMTS13 
4.1 Introduction 
It has been previously reported that ADAMTS13 is dependent on Ca^+ ions for 
efficient proteolysis of Anderson et al (2006) reported that 
ADAMTS13 was activated by Ca^^ with a KD(app) of ~60|iM in reactions containing the 
short fluorescent VWF substrate, FRET-VWF73, and with a Ko^pp) of ~5iiM in 
reaction with full length VWF. Prior to that study, however, reports of the Ca^* 
dependence of ADAMTS13 had suggested somewhat variable results (see section 
1.4.3). In Chapter 3, I showed that the most important activating divalent cation 
required by ADAMTS13 is Ca^^. Although Ba^^ exhibited some ability to enhance 
ADAMTS13 function, it is not present physiologically. Moreover, I also showed that 
Ca "^" and Zr f * act independently to activate the protease. Free is present in 
plasma at physiological concentrations of ~1.25mM^®® and is the most abundant 
metal ion in the human body. In this chapter, I aimed to quantify the dependency of 
ADAMTS13 for Ca^* using kinetic analysis under different Ca^^ concentrations. 
4.2 The concentration of significantly influences the rate of 
proteolysis of VWF115 by ADAMTS13 
To assay the effect of Ca^^ on ADAMTS13 activity, 50nM purified ADAMTS13 was 
pre-incubated with varying concentrations of CaCl2 (0 and 5mM), contained in 
150mM NaCl, 20mM Tris-HCI (pH7.8) at 37°C for 30 minutes. After this 30 minute 
pre-incubation, 700nM VWF115 was added to start the reaction, and 50|al aliquots 
were removed at progressive time points from 0 to 180 minutes. The reaction was 
then quenched with 5^1 0.5M EDTA. These samples were then analysed using HPLC 
to assess the percentage cleavage of VWF115 that had taken place (Fig. 3.6 shows 
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how the percentage cleavage of VWF115 was calculated). After analysis of all the 
time points at different concentrations it was demonstrated that increasing 
concentrations of increase the rate of proteolysis of VWF115 (Fig. 4.1a). Lower 
concentrations of Ca^* were then used to assess its influence more accurately. The 
reaction was carried out as described above, but using 20nM purified ADAMTS13 to 
decrease the rate of proteolysis. It was again shown that increasing concentrations of 
between 0 and 1.2mM progressively increased the rate of proteolysis of 
VWF115 by ADAMTS13 (Fig. 4.1b). 
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Figure 4.1: Proteolysis of VWF115 by ADAIWTSI3 at different concentrations 
a) 50nM purified ADAMTS13 was pre-incubated with 20mM Tris-HCI (pH7.8), 150mM NaCI and various 
concentrations of CaCIa between 0 and 5mM for 30 minutes at 37°C. 700nM VWF115 was then added. 
Percentage cleavage of VWF115 was calculated for the different concentrations at various time 
points, b) 20nM purified ADAMTS13 was used in the same procedure as in a) but Ca^* concentrations 
were reduced to between 0 and 1200iiM. The influence of in the rate of cleavage of VWF115 is 
shown clearly, especially in b). 
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4.3 The rate of cleavage of VWF115 is significantly altered by pre-
incubation time of ADAMTS13 with Ca^^ 
In an attempt to determine the Kp^pp) of ADAMTS13 for activity assays were 
repeated with varying Ca^+ concentrations between 0 and SmIVI to assess the initial 
rate of proteolysis of VWF115. To ensure that incubation mixtures with 10 different 
Ca^^ concentrations could be accurately sampled every 30 seconds at 5 minute and 
10 minute time points, the reactions were set up as follows: 
1) 20nM purified ADAMTS13 was set to pre-incubate at 37°C with 20mM Tris-
HCI (pH7.8), 150mM NaCl, and 10 different CaCl2 concentrations: 0, 0.05, 
0.15, 0.3, 0.5, 0.8, 1.2, 2, 4 and BmM. 
2) After 20 minutes of pre-incubation, 700nM VWF115 was added to the 
reaction mixtures containing 0, 0.15, 0.5, 1.2 and 4mM CaClg. Samples were 
taken every 30 seconds at 5 and 10 minute time points and quenched with 
5|al 0.5M EDTA. 
3) 700nM VWF115 was then added to the remaining reactions containing 0.05, 
0.3, 0.8, 2 and 8mM CaCtg, which, by this time, had been pre-incubating for 
40 minutes. Samples were taken every 30 seconds at 5 and 10 minute time 
points and quenched with 5pl 0.5M EDTA. 
4) All samples were analysed together using HPLC (section 2.7.3) and initial 
rates determined (section 2.7.5) and plotted using Prism 4 software 
(GraphPad, USA) 
Fig. 4.2 shows the curves for the influence of Ca^^ concentration on ADAMTS13 
activity. When these initial rate results were plotted according to pre-incubation time 
with Ca^^ (20 minutes or 40 minutes) it is apparent that longer pre-incubation with 
causes an increase in the rate of proteolysis (Fig. 4.2), with a maximum of 
-13% cleavage after 10 minutes (V^ax ~ 0.13nMs"') with 20 minutes pre-incubation. 
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but a maximum of -20% cleavage (Vmax ~ 0.2nMs"') after 10 minutes witin 40 minutes 
pre-incubation. 
0.20n 
m 0.15-
(0 0.10-
P 0.05 
• 20 minutes 
• 40 minutes 
Ca concentration (mlUl) 
Figure 4.2 Trial experiment to determine KD(app) of ADAMTS13 for Ca^* using initial rates of 
VWF115 proteolysis 
20nM purified ADAMTS13 was set to pre-incubate at 37°C witii 20mM Tris-HCI (pH7.8), 150mM NaCI, 
and varying CaCIa between 0 and 8mlVI. After 20 minutes, 700nM VWF115 was added to half of the 
samples and time points tal<en after 10 minutes. 10 minutes later, 700nlVl WVF115 was added to the 
remaining reactions that were still incubating. Initial rates of proteolysis of both sets of samples were 
calculated from percentage cleavage of VWF115 determined with HPLC, and plotted as a function of 
increasing Ca^* concentration. Initial rates of the two sets of samples are plotted separately (one with 20 
minute pre-incubation and one with 40 minute pre-incubation). 
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To further examine the time dependence of Ca^+ activation of ADAMTS13 activity, 
the cleavage assay was repeated, but with 5mM CaCl2 and the variable measured 
was the pre-incubation time from 0-90 minutes. Fig. 4.3a demonstrates that the rate 
of VWF115 proteolysis increases with increasing pre-incubation time with Ca^\ and 
that for maximum activation, a pre-incubation time of -60 minutes was required. To 
investigate this effect further, a time course study of proteolysis of VWF115 was 
carried out with and without prior incubation of ADAMTS13 with Ca^. Without pre-
incubation, there was a lag phase at the start of the reaction up until - 40 minutes 
compared to the curve 'with pre-incubation' (Fig. 4.3b). 
a) b) 
W C 
5-- p dj 
0 20 40 60 80 100 
pre-incubation time (rnins) 
with ptB-inatelicn 
KIT 1^1 I I — I 1 1 
0 30 60 90 120 150 180 
vvithout pre-inaiHticn 
without 
timB(rrins) 
Figure 4.3 Effect of pre-incubation time on the rate of proteolysis of VWF115 by ADAIVITS13 
a) 20nM purified ADAIV1TS13 was pre-incubated with 20mM Tris-HCi (pH7.8), 150mM NaCI, and 5mlVl 
CaCl2 for varying lengths of time before addition of 700nM VWF115. Samples were taken after 10 
minutes and quenched with Sjil 0.5M EDTA, and then analysed on HPLC to assess the percentage 
cleavage of VWF115, b) 20nM purified ADAMTS13 was added to a mixture containing 700nM VWF115, 
20mM Tris-HCI (pH7.8), 150mM NaCI, and 5mM CaCb, either with pre-incubation for 1 hour, no pre-
incubation or no Ca^, as indicated. Samples were taken at various time points and quenched with 5|il 
0.5M EDTA, and then analysed using HPLC to assess the percentage cleavage of VWF115. 
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4.4 Determination of the KD(app) of ADAMTS13 for 
Between the experiments in section 4.3 and those I will present here, several months 
of optimisation of the range of Ca^^ concentrations were necessary to achieve an 
accurate method of determination of Kofapp) of ADAMTS13 for Ca^\ During this time, 
problems of reproducibility were encountered, but subsequently overcome, and the 
results I present in this section are more quantitatively accurate. To make both low 
and high concentrations of Ca^^ as accurate as possible, a 1M stock solution of 
CaClg was made (7.35g CaCl2 in 50 ml 20mM Tris-HCl (pH7.8)). From this 1M stock, 
50mM, 5mM and 1mM stock solutions were made by dilution, so that pipetting of 
small volumes could be avoided. Previously, in section 4.3, only 10-12 Ca^* 
concentrations were tested between 0-8mM. To get a more accurate KD(app), 22 
different Ca^^ concentrations were used over the same concentration range. Also, to 
ensure a more accurate measurement of cleavage peaks using HPLC, the substrate 
concentration was increased from 700nM to 1.6|JM. These new assay conditions 
gave a KD(app) of purified ADAMTS13 -80 pM using a 1 hour pre-incubation time (Fig. 
4.4a). 
Using ADAI\/ITS13 that had been expressed in conditioned media, concentrated and 
thoroughly dialysed (see section 3.2), a very similar value of - 70 ± 20|aM was 
obtained (Fig. 4.4b). It was noted, however, that despite the similarity in these KD(app) 
values, the V^ax of purified ADAMTS13 was appreciably lower than that of 
ADAMTS13 in dialysed conditioned media. Moreover, lower ADAMTS13 antigenic 
concentrations in conditioned media (1nM compared to 20nl\/l) were needed to 
proteolyse the substrate at a similar rate. This reduced Vmax was attributed to loss of 
activity during purification, as previously suggested®". This reduction in Vmax was a 
potential obstacle for the comparison of responses of fully purified mutants to Ca^^. 
Consequently, the Ca^* induced functional responses of wild-type and mutant 
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ADAMTS13 against substrate proteolysis in following cfiapters were compared using 
extensively dialysed conditioned media samples rather than purified material, except 
where specifically stated otherwise. In order to further establish that transiently 
expressed ADAMTS13 in conditioned media behaved the same as stably expressed 
purified material, experiments from section 4.3 were repeated with ADAMTS13 in 
dialysed conditioned media. Similar results (Fig. 4.5) demonstrated that ADAMTS13 
in dialysed conditioned media has a comparable requirement for pre-incubation with 
Ca^\ 
a) Purified b) Conditioned media 
0.15i 
a 0.10 
1 1 
0 . (» 
^^app)=S0±15)jM (n=3) 
0.0 25 5.0 7.5 mo 
CaP^concenbation (rrM) 
KD(app) = 70±2QjM (n=3) 
0.0 2.5 5.0 7.5 10.0 
concentration (rrM) 
Figure 4.4 KD(app) of A D A M T S 1 3 for Ca^* using initial rates of proteolysis of V W F 1 1 5 
a) A representative experiment of 3, demonstrating how the KD{app) was determined. 20nM purified 
A D A M T S 1 3 was pre-incubated for 1 hour with 20mM Tris-HCI (pH7.8), 150mM NaCI, and 1 of 22 
different concentrations of Cs?* between 0 and 8mM at 37°C, after which 1.6pM VWF115 was added to 
start the reaction. Initial rate of proteolysis was assessed by sampling at 20 minutes and analysing on 
HPLC to determine percentage cleavage of VWF115, from which the initial rate of proteolysis was 
calculated, b) as a) but 1nM A D A M T S 1 3 in dialysed conditioned media was used. 
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Figure 4.5 Effect of pre- incubat ion t ime on activity of ADAIVITS13 in dialysed condit ioned media 
a)1ni\/l A D A M T S 1 3 in dialysed conditioned media was pre-incubated with 20mM Tris-HCl (pH7.8), 
150mM NaCI, and 5 m M CaClg for varying lengths of time before addition of 1.6pM VWF115 . Samples 
were taken after 10 minutes and quenched with 5|il 0.5M EDTA, and then analysed on HPLC to assess 
the percentage cleavage of VWF115 . b) I n M ADAMTS13 in dialysed conditioned media was added to a 
mixture containing 1.6i iM VWF115 , 20mM Tris-HCl (pH7.8), 150mM NaCI, and 5mM CaClg, either with 
pre-incubation for 1 hour, no pre-incubation or no C a ^ , as indicated. Samples were taken at various 
time points and quenched with 5pl 0.5M EDTA, and then analysed on HPLC to assess the percentage 
cleavage of VWF115 . 
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4.5 significantly changes the absorbance of ADAMTS13 at 280nm 
Abs280nm of 3 protein is influenced by amino acids with aromatic rings that are present 
in the protein sequence, and their interactions with neighbouring residues in the 
folded structure. Such aromatic residues include Trp, Tyr and, to a lesser extent, 
Phe^®'^ . Bisulphide bonds between Cys residues also influence the specific 
absorbance. The above residues can be on the inside or the outside of a particular 
domain, and their exact position will also influence the absorbance. Spectral changes 
have often been used to observe conformational changes in proteins, since, when 
the conformation changes, the position of these aromatic amino acids or disulphide 
bonds will also change. 1[iM purified ADAMTS13 was pre-incubated with 10mM 
CaCl2, or 20mM Tris-HCI (pH7.8), for 1 hour to see if its absorbance at 280nm would 
change (note: these buffer conditions excluded NaCI). Purified ADAMTS13 was used 
in these experiments to ensure that any absorbance changes after addition of Ca^^ 
were due to changes in ADAMTS13 and not contaminating proteins. The results are 
shown in Fig. 4.6, and clearly demonstrate that the absorbance increases by -40% 
when ADAMTS13 is pre-incubated with Ca "^" for 60 minutes. The absorbance without 
or without pre-incubation was -0.1. For the sample without Ca^^, this value did 
not change with incubation at 37°C for 60 minutes, or with added just before the 
absorbance is tested. 
Since there was such a difference in absorbance of ADAMTS13 with pre-incubation 
with Ca^^, the Ca^ "^  was then titrated to determine at what concentration this change 
occurred. 1[iM ADAMTS13 was pre-incubated with various Ca^"' concentrations 
between 0 and 6mM CaClg for 1 hour at 37°C, and then the absorbance at 280nm 
was checked. There was an increase in absorbance between 0.5mM and 1.5mM 
CaCIa, of -30%, with an EC50 value of -SBOuM (Fig. 4.7a). To test the time 
dependence of the changes in AbSasonm with Ca^^ , 1|iM ADAMTS13 was incubated 
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with 10mM Ca^'^and its absorbance tested every minute over a time course of 1 hour. 
The change in Abszaonm took place over -20 minutes, between 20 and 40 minutes 
incubation of the enzyme with an excess of Ca "^" (Fig. 4.7b) 
E 0.10-
< 0.05-
no pre-incubation 1 hr pre-mcubation 
Figure 4.6: A D A M T S 1 3 absorbance at 280 nm with and without Ca^* pre-incubation 
The AbS280nm of a 1i iM A D A M T S 1 3 solution was measured at 280nm with no Ca^* present in a buffer 
containing 2 0 m M Tris-HCI (pH7.8). At the same time 10mM CaCb was added to a l i i M ADAMTS13 
solution in buffer containing 20ml\/l Tris-HCI (pH7.8), and the absorbance immediately measured so 
there was no pre-incubation with Ca^ "^  (shown in the 'no pre-incubation' column). 1|iM ADAMTS13 was 
then pre-incubated with lOmM CaClg for 1 hour at 37°C in buffer containing 20mlVI Tris-HCI (pH7.8). At 
the same time 1nM A D A M T S 1 3 was pre-incubated with 20mM Tris-HCI (pH7.8), for 1 hour at 37°C to 
see if the absorbance would remain the same after pre-incubation with no Ca^* (shown in the '1 hr pre-
incubation' column). n=5. 
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Figure 4.7 Ca^* and t ime dependent change in Absaaonm of A D A M T S 1 3 
a) I j j M A D A M T S 1 3 was pre-incubated with various concentrations of CaClg, in buffer containing 2 0 m M 
Tris-HCI (pH7.8), for 1 hour at 37°C. Absorbance was measured at 280nm. A typical experiment 
showing change in absorbance with Ca^* concentration. (n=3). b) I p M ADAIVITSIS was incubated with 
l O m M in buffer containing 20ml\/l Tris-HCI (pH7.8), over 1 hour and the absorbance at 280nm 
recorded at 1 minute intervals. 
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4.6 The Ca^ + dependent change in Absggonm of ADAMTS13 is abolished in 
ISOmlVI NaCI 
The change in Absggonm observed in section 4.5 was next investigated under more 
physiological conditions using 150mM NaCI in the reaction buffer. Fig. 4.8a shows 
the absorbance values of 1|aM ADAMTS13 pre-incubated under various conditions 
for 1 hour before the absorbance readings were taken. In the absence of Ca^* there 
was no change in absorbance either in the presence or absence of NaCI. In the 
presence of 10mM CaClg there was an increase in absorbance in the absence of 
150mM NaCI, but not in the presence of NaCI, suggesting that physiological ionic 
conditions inhibit the conformational change. The observation that the presence of 
NaCI inhibited the increase in absorbance also raised the possibility that this change 
in absorbance could be due to aggregation of ADAMTS13, rather than a 
conformational change. Native-PAGE gel electrophoresis was used to separate 
proteins without denaturation. If proteins aggregate, this would be detected on a 
Native gel (section 2.6.5). The Native gel clearly showed that ADAMTS13 ran as a 
single band regardless of the presence of Ca^^ or NaCI (Fig. 4.8b). In light of this, 
initial rates experiments were repeated exactly as in section 4.4, except they were 
carried out in the absence of NaCI. Both KD(app) of ADAMTS13 for Ca^^ (~75|iM) and 
Vmax (0.3nMs"^) were unaltered in reaction with VWF115, compared to experiments 
with 150mM NaCI (Fig. 4.8c). To investigate if this was also the case for ADAMTS13 
in reaction with full-length VWF, 5nM ADAMTS13 in dialysed conditioned media was 
pre-incubated with the reaction mixture either with or without 150mM NaCI, before 
the addition of denatured VWF to a final concentration of 20pg/ml. ADAMTS13 
clearly proteolyses VWF faster in the absence of NaCI (Fig. 4.8d), although this is 
probably an effect on VWF rather than ADAMTS13^®^. 
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Figure 4.8 Absorbance of A D A M T S 1 3 at 280nm in t l ie presence of physiological NaCI 
a)1 | iM A D A M T S 1 3 was pre-incubated under various conditions: without or Na^ in 20mM Tris-HCi 
(pH7.8); with SmIVi CaClg in buffer containing 20mM Tris-HCI (pH7.8), but without Na"^ ; without but 
with 150mM NaCI in buffer containing 20mM Tris-HCI (pH7.8); with both SmIVl CaCb and 150mlVI NaCI 
in buffer containing 2 0 m M Tris-HCI (pH7.8), for 60 minutes at 37°C (n=5), b) Native-PAGE gel showing 
A D A M T S 1 3 conformation with: lane 1- no added ions, lane 2-1 OmM CaClg, lane 3 - ISOmM NaCI, lane 
4 - 10mM C a C b a n d 150mM NaCI, LAD - ladder, c) 1nM ADAMTS13 in dialysed conditioned media was 
pre-incubated for 1 hour with 20mM Tris-HCI (pH7.8), and 1 of 22 different concentrations of Ca "^" 
between 0 and BmM at 37°C, after which I . e p M V W F 1 1 5 was added to start the reaction. Initial rate of 
proteolysis was assessed by sampling at 20 minutes and analysing on HPLC to determine percentage 
cleavage of VWF115 , (n=3) d) 5nM ADAMTS13 in dialysed conditioned media was pre-incubated in the 
reaction buffer for 1 hour either with 150mM NaCI or without, before the addition of V W F which had been 
pre-treated with 1.5M Gdn-HCI, at a final concentration of V W F In the reaction of 20pg/ml. Time points 
were tal<en at regular intervals and the reaction quenched with EDTA. Cleavage of V W F was analysed 
by multimer analysis (see Methods). The multimer gel is representative of two experiments with similar 
results. 
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4.7 ADAMTS13 may have two appreciably different KD(app) values: initial 
rates analysed using a 2-site binding model 
The results obtained in section 4.4 are in agreement with those obtained by 
Anderson et al. Even though ADAMTS13 in their reactions was pre-incubated for 
only ten minutes, their time points for testing initial rates were over 40 minutes, so 
ADAMTS13 would have had ample time for long incubation with during the 
reaction. Looking at Fig. 4.4a and b, another feature of both curves became apparent 
as a result of using many more Ca^^ concentrations in the same range. Initial rates 
appeared to stop increasing between ~200-600iiM. This was noted in all experiments 
conducted. When the curves in Fig. 4.4 were enlarged between 0 and 2mM Ca^^, this 
characteristic could be seen more clearly (Fig. 4.9a and b), suggesting complexity of 
Ca^^ interaction of ADAMTS13 with VWF115, with a possible 2 stage activation of 
ADAMTS13, one at lower concentration and a further activation at higher Ca^"" 
concentration. In light of this observation and the change in AbSggonm observed at 
high Ca^* concentrations (EC50 ~880|iM), the same 6 experiments in section 4.4 were 
therefore re-analysed using a 2-site binding model. Two distinct KD(app) values were 
obtained, one with a higher affinity of ~ 60IJM and one with an 8 -10 fold lower affinity 
(~ 500|JM). Fig. 4.10 shows the same curves as in Fig. 4.4, fitted to a 2-site binding 
curve with the relevant KD(app) values , This raises the issue of whether two functional 
binding sites are present on the metalloprotease domain controlling cleavage. This is 
an idea to which I will return later. 
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Figure 4.9 Initial rates of A D A M T S 1 3 proteolysis of VWF115 at Ca^* concentrat ions up to 2 m M 
a) Ttie curve in Fig. 4 .10a is depicted within a narrower range of concentrations, b) The curve in 
Fig. 4.10b is depicted within a narrower range of Ca^* concentrations. The red box frame in both curves 
indicates a range of Ca^' concentrations during which there is no apparent increase in initial rate. 
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Figure 4.10: Ko^pp) of A D A M T S 1 3 for Ca^* using a 2-site binding model 
a) 20nlVI purified A D A M T S 1 3 was pre-incubated for 1 hour with 20mM Tris-HCI (pH7.8), 150mM NaCl, 
and 1 of 22 different concentrations of Ca^* between 0 and 8mM at 37°C, after which 1 V W F 1 1 5 
was added to start the reaction. Initial rate of proteolysis was assessed by sampling at 20 minutes and 
analysing on HPLC to determine percentage cleavage of VWF115. A 2-site binding model (Prism 4 
software, GraphPad, USA) was then used to determine 2 KD(app) values, b) as a) but 1nM A D A M T S 1 3 in 
dialysed conditioned media was used. 
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Of note is that the two KD(app) values have their own distinct corresponding Vmax 
values (Table 4.1). These imply that the lower KD(app) values correspond to an 
activation of the enzyme up to ~ 80%, and the higher KD(app) values correspond to a 
further activation of the enzyme up to 100% of the total Vmax-
Kdi(|jM) Vmax 1 ( n M s ' ) KD2(M'^) Vmax2(nMs') 
Purified - 7 0 0.1 -650 0.02 
CM - 6 0 0.28 -540 0.039 
label 4.1: 2-stage activation of purified ADAMTS13 or ADAMTS13 in conditioned 
media (CIVI) by 
4.8 dependence of ADAMTS13 proteolysis of full length VWF 
Although the results presented in section 4.4 were in agreement with those 
previously published using a short VWF substrate^®", that study suggested that the 
Ca^"" dependence of ADAMTS13 is different using multimeric VWF. The reported 
KD(app) of ADAMTS13 for in reaction with full-length VWF was ~5|aM, as opposed 
to ~60nM with FRET-VWF73. The Ca^+ dependence of ADAMTS13 in reaction with 
the full-length substrate was therefore investigated. Purified plasma-derived VWF 
was incubated with 1.5M Gdn-HCI at 3 7 ° C for 1 hour to denature the protein. The 
denatured VWF was then added to 5nM ADAMTS13 in dialysed conditioned media, 
pre-incubated for 1 hour with 150mM NaCIa, 20mM Tris-HCI (pH7.8), 5mM CaClg, and 
0.5|ig/ml BSA, so the final VWF concentration in the reaction was 20iag/ml. The 
reaction was incubated at 37°C for 2 hours before quenching with 25mM EDTA. 
Proteolysis was monitored by multimer gel analysis (section 2.7.12) and change in 
collagen binding (section 2.7.11), as described in Methods. 
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Muitimer gel analysis revealed an appreciable drop in high molecular weight VWF 
multimers at a concentration above -SOjiM CaClg. This was accompanied by an 
increase in lower molecular weight bands, arising when the large multimers are 
cleaved (Fig. 4.11a). Residual collagen binding function of VWF after two hours 
incubation with ADAMTS13 was greatly reduced with increasing concentrations of 
Ca^^, with maximum reduction after 50iiM CaClg (Fig. 4.11b). Here, ADAMTS13 had 
no detectable activity in the absence of added Ca^^, with VWF showing full collagen 
binding ability, highlighting the importance of in ADAMTS13 cleavage of full-
length VWF. 
Based on a recently published study^®®, a new method was used to study the 
interaction between ADAMTS13 and full-length VWF under flow-induced shear 
stress. Briefly, 50nM concentrated ADAMTS13 in dialysed conditioned media was 
pre-incubated for 1 hour with 150mM NaCI,20mM Tris-HCl (pH7.8), 5mM CaClg, and 
O.Sng/ml BSA in a 0.2ml thin-walled PCR tube with dome caps, after which purified 
recombinant VWF (20(ig/ml final concentration) was added. The reaction mixture 
was subjected to vortexing at 3000rpm for 5 minutes on a mini vortexer. The 
cleavage products were, again, detected by muitimer gel analysis (section 2.7.12) 
and collagen binding assay (section 2.7.11). In the vortex assay, muitimer gel 
analysis of the cleavage products showed a similar pattern of the appearance of low 
molecular weight multimers at ~50iiM, but the disappearance of high molecular 
weight multimers was less clear (Fig. 4.12a). This was illustrated also by analysing 
the results on a collagen binding assay (Fig. 4.12b), which showed less of a 
decrease in collagen binding activity with increasing Ca^^ concentration than was 
observed for the static assay. 
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Figure 4.11 Ca^* dependence of ADAIVITS13 in reaction with denatured full length V W F 
A representative experiment of 3, where 5nlVI ADAMTS13 in diaiysed conditioned media was pre-
incubated for 1 hour with 150mM NaCig, 2 0 m M Tris-HCI (pH7.8), 5mM CaCIa after which purified 
plasma-derived W V F (pre-treated with denaturant) was added at a final concentration of 20iig/ml. The 
reaction was incubated for 2 hours at 37°C after which samples were taken and quenched with 15mM 
EDTA. Samples were analysed using multimer gel analysis (a) and collagen binding assay (same 
representative experiment of 3) (b). 'RP' denotes the multimer pattern of reference plasma, while 
' -AD13' denotes the multimer pattern of V W F in the reaction mixture with no ADAMTS13 added and in 
the presence of SmIVl CaCla. 
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Figure 4.12 dependence of ADAI\/ITS13 in reaction with full length V W F under flow 
condit ions 
A representative experiment of 2, where 50nM concentrated ADAMTS13 in dialysed conditioned media 
was pre-incubated for 1 hour with 150mM NaCI, 20mM Tris-HCI (pH7.8), 5mM CaCIa, and 0.5pg/ml BSA 
in a 0.2ml thin-walled PGR tube with dome caps, after which purified recombinant V W F (20|ig/ml final 
concentration) was added. The reaction mixture was subjected to vortexing at 2500rpm for 5 minutes 
on a mini vortexer. The cleavage products were detected by multimer gel analysis (a) and collagen 
binding assay (b). 
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4.9 Discussion 
The results presented in this chapter clearly demonstrate an appeciable influence of 
Ca^* on ADAMTS13 function. In simple time course assays, efficiency of proteolysis 
of VWF115 by ADAMTS13 is appreciably increased by increasing 
concentrations up to ~1mM, after which no further increase in activity is observed 
(Fig. 4.1). The results in Fig. 4.1 would suggest ADAMTS13 is maximally active at 
physiological Ca^^ concentrations (~1.25mM). This is not in agreement with results of 
Anderson et a! (2005), who suggested that O.ImM CaClg would provide a saturating 
level of Ca^ ADAMTS13 proteolysis of VWF115 exhibited a lag phase unless 
pre-incubated for at least 20 minutes with Ca^^ (Fig. 4.2 and 4.3). The trial 
experiment to determine initial rates of VWF115 proteolysis by ADAMTS13 illustrates 
the difference in rates between reactions incubated for 20 minutes or 40 minutes, the 
latter proceeding 50% faster than the former (Fig. 4.2). To quantify the optimal pre-
incubation time required for ADAMTS13 maximal activity, initial rates of reaction with 
excess Ca^"' (5mM) were measured with varying pre-incubation times, clearly 
showing an optimal pre-incubation time of 40-60 minutes. This is important as 
previous studies have not used a long pre-incubation time with Ca "^^ , and therefore 
may have been conducted under suboptimal conditions^®". 
The overall KD(app) of ADAMTS13 for was found to be ~80iiM for purified 
ADAMTS13 and ~70iiM for ADAMTS13 in dialysed conditioned media (example 
curves shown in Fig. 4.4), using standard reaction conditions and pre-incubation of 
the reaction mixture with Ca "^" for 1 hour. The difference in rates between purified, 
stably-expressed ADAMTS13 and transiently-expressed ADAMTS13 in 
concentrated, dialysed conditioned media was not fully investigated during this study, 
although it has been previously reported®". 
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With many more concentrations of Ca^"" in the same range, initial rates were 
observed to level off at middling concentrations (Fig. 4.9). This was suggestive 
of a 2-stage activation of ADAMTS13 by Ca^ , with the enzyme being significantly 
activated by increasing Ca^* concentrations up to ~200|iM. No further activation of 
the enzyme was observed until the concentration of Ca^^ reached ~800nM, above 
which there was a definite further, but less dramatic activation. As well as changing 
the rate of ADAMTS13 proteolysis of VWF115, a long pre-incubation with Ca^^ also 
significantly altered the absorbance of ADAMTS13 under low ionic strength (Fig. 4.6, 
4.8a), and this absorbance change was not caused by aggregation of the sample 
with added Ca^^(Fig. 4.8b). This was highly suggestive of a conformational change in 
the protein on Ca^* binding. When this absorbance change was titrated as a function 
of Ca^"" concentration, a surprisingly high concentration (1.5-2mM) was required, with 
an ECSO value of ~880|JM (Fig. 4.7a). This conformational change was also shown to 
be time dependent requiring between 40 and 60 minutes to occur fully (Fig. 4.7b). 
However, the absorbance results presented were only apparent in the absence of 
NaCI: this may be due higher ionic strength changing the surrounding environment 
of Trp residues involved in the absorbance change. Nevertheless, it is a 
conformational change that the enzyme undergoes as a direct result of interaction 
with Ca^^. 
Despite the evidence for the conformational change at high Ca^^ concentrations, the 
importance of the site involved remains elusive, especially given the overall KD(app) 
value of ~70-80|iM, suggesting that a -10 fold higher Ca^+ concentration is needed to 
cause a conformational change than is needed to fully activate the enzyme for 
proteolysis of VWF115. In light of these findings, and the early plateau in initial rates 
observed in Fig. 4.4 and 4.9, the data in section 4.4 was re-analysed using a 2-site 
binding model in Prism 4 software (GraphPad, USA). A curve was generated using 
the equation 
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Equation 4.1 y=Vmaxi*x/(KDi+x) + VMax2*x/(KD2+x) 
Where y is the initial rate, V^axi is the maximum initial rate induced as a result of Ca '^" 
binding to a first site, Kdi is the concentration required to produce half Vmaxi, 
Vmax2 is the maximum initial rate induced as a result of Ca '^" binding to a second site, 
Kd2 is the Ca^* concentration required to produce half Vmax2 and x is 
concentration. Using this equation, two distinct Kofappj values could be derived for 
ADAMTS13 binding to Ca^^, one of ~60iiM and the other of ~500nM (Fig. 4.10), 
suggesting the presence of two Ca^^ binding sites. This might be compatible with the 
absorbance data at low ionic strength (Fig. 4.7a). If we look at the curves in Fig. 4.9, 
a 2-stage activation is apparent, with the first stage being more pronounced than the 
second. Table 4.1 illustrates the Kd and V^ax values generated using the 2-site 
binding model. What is immediately obvious is that the lower Kd values (Kdi) 
correspond to the higher V^ax values (Vmaxi). and the higher Kd values (Kog) 
correspond to the lower V^ax values (Vmax2)- This suggests that the binding site with 
the lower Kd is responsible for activating the enzyme to -80% of the V^ax, while the 
binding site with the higher Kd values can further activate the enzyme by -20% to the 
final Vmax. 
The 2-site binding scenario, although potentially interesting, is not supported by 
statistical analyses (section 2.7.6), which would reject a two-site binding model in 
favour of a one-site model since the F value is lower than 1. However, the limitation 
of computerised statistical tests to distinguish between two binding sites is that a 2-
site model is only favoured when one Kd value is at least 10-fold higher than the 
other^ ®®. Judging from my 2-site KD(app) values, which are less than 10-fold different, it 
is likely that a 2-site model will not be favoured over a 1 -site model for this reason. In 
light of this limitation and the other data presented here, I still favour a 2-binding site 
activation of ADAMTS13 by Ca^\ However this is a personal preference and I 
137 
acknowledge that further work is necessary to strengthen the experimental basis for 
this conclusion. 
In reaction with full-length VWF a similar KD(app) of ADAMTS13 for compared to 
VWF115 was predicted, although the results are qualitative and not quantitative due 
to the nature of the assay. The largest change in appearance of low molecular weight 
multimers and disappearance of high molecular weight multimers occurs between 50 
and 2 0 0 | j M , which is in agreement with the Ko^pp) found using VWF115. These 
results were not, however, in agreement with those published by Anderson et al, who 
reported a Koopp) of ADAMTS13 for Ca "^" of -5pM against full-length VWF. The 
reason for this difference remains unclear. The vortex assay was employed to 
confirm the results of the static assay using shear stress to unravel VWF instead of 
denaturants. However, this method gave inconsistent results and presented 
problems in its design. From Fig. 4.12 it is clear that the pattern of VWF multimers 
does not change in a stepwise fashion like it does in the static assay, and also the 
protein content of each lane appears different (Fig. 4 . 1 1 ) . In the study that first used 
this assay, Zhang et al^ ®® reported a smeared multimer pattern for reactions vortexed 
for longer than 10 minutes. This may have been a problem in the assay presented 
here, even though I only vortexed samples for 5 minutes, as smearing can be seen 
on the multimer gel. Also, in the process of vortexing, VWF may have adhered to the 
side of the tube and so lowered the overall VWF signal in the collagen binding assay 
and multimer gel analysis, possibly explaining the different protein levels in each 
lane. In light of the problems encountered using this method, further vortex assays 
were not performed. 
This chapter has highlighted the importance of Cs?* in ADAMTS13 activity, and 
provided a KD(app) value for Ca '^^  binding to a site or various sites in ADAMTS13. Next, 
potential sites involved in Ca^^ binding were investigated. 
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Chapter 5 
Investigation of the putative binding site in ADAMTS13 
5.1 Introduction 
Investigation of the known crystal structures of various Adamalysin family members, 
reveals common structural features (Fig.5,1). Adamalysin II, Atrolysin C and 
Acutolysin A all share a common Zn^^ dependent active site and all bind a Ca^^ ion in 
a region directly opposite the active site, across the metalloprotease domain. This 
Ca "^" ion is similarly coordinated in all three of these proteins. When the Adamalysin II 
crystal structure was published^^°, the Ca^^-binding site was defined as an isolate 
lobe of high electron density. It showed a high hydrophobicity contrast and short 
distances to surrounding oxygen atoms, of which there were seven placed at the 
corners of a pentagonal bipyramid (section 1.3). The specific coordination was 
provided by both carboxylate oxygens of Glu9, both carboxylate oxygens of Asp93, 
the carbonyl oxygen of Cys197 and the carboxamide oxygen of Asn200. The Ca-
oxygen distances were all -2.4A which is a characteristic value for Ca^* binding 
sites^^°'^^\ Acutolysin A and Atrolysin C also bind a Ca^^ in a similar position and 
coordinating fashion^^\ A homologous region exists in most ADAMTS family 
members when sequences are aligned and in ADAMTS13 comprises residues 
Glu83, Asp 173, Cys281 and Asp284^®®. I investigated the possible existence of a 
Ca^* ion in this position by modelling the ADAMTS13 metalloprotease domain on 
various closely related known crystal structures and targeting putative coordinating 
residues by site directed mutagenesis. ADAMTS13 mutants were then assayed for 
dependence. 
139 
a) 
b ) 
c) 
AsnZOO 
Cys19 .^^ <4- Gl 
Zn2+ in the 
active site 
Asn20i 
Glu9 
Cys197, 
Zn2+ in the 
active site 
n200 
.Glu9 
•Asp93 
Z n " in 
active site 
Figure 5.1 Models of M12B family members from published crystal structures 
a) Adamalysin II, PDB code: 1IAG, b) Acutolysin A, PDB code: Ibsw, c) Atrolysin C, PDB code;1dth. a)-
c) viewed using Pymol doftware (deLano scientific, USA). Shown are the Zn^* ions in the active sites 
(grey), and Cd^* ions (pink) with coordinating ligands. 
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5.2 Molecular modelling of ADAMTS13 metalloprotease domain based 
on the crystal structure of Adamalysin II 
The ADAMTS13 protein sequence was modelled on the known crystal structure of 
Adamalysin II. The Swiss-modeP^ online service was used to achieve this. The 
protein sequences of ADAMTS13 and Adamalysin II were first aligned using AliBee 
multiple alignment (Moscow)^^® (Fig. 5.3), to check that the degree of homology was 
suitable for modelling, and then the ADAMTS13 protein sequence was threaded 
through the Adamalysin II template crystal structure (PDB:1IAG). This revealed the 
presence of a putative Ca^^ binding site as previously predicted using sequence 
alignment, involving residues Glu83, Asp173, Cys281 and Asp284 in ADAMTS13 
(Fig. 5.2). These residues were in the same region to the binding sites in 
Adamalysin II, Acutolysin A and Atrolysin C (Fig. 5.1). One major difference in the 
residues involved was the presence of Asp284 in ADAMTS13 which substituted for 
the Asn in the other three M12B metalloproteases. 
Asp284 
Glu83 
Asp173 
Figure 5.2 Model of A D A M T S 1 3 based on Adamalysin II 
The A D A M T S 1 3 protein sequence was threaded through the Adamalysin II known crystal structure 
template using SwissModel^^^, revealing a putative Ca^* binding site in a homologous region to other 
M12 B family members. 
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Figure 5.3 Sequence alignment of Adamalysin II and the ADAMTS13 metalloprotease domain 
The protein sequence of Adamlysin II, shown in blue (UniPmt ID: P34179 (VMAD_CROAD)) was aligned with the protein sequence of ADAMTS13, shown in black( UniProt 
1D;Q76LX8 (ATS13_HUMAN)) using AliBee multiple alignment (Moscow)^". ' indicates residues that are ttie same between the two sequences, + indicates residues with 
similar side chains. Highlighted residues indicate those involved in a putative Ca^* binding site in ADAMTS13 compared to known Ca'* coordinating residues in Adamalysin II. 
5.3 Mutation of residues in the putative Ca^* binding site did not affect 
ADAIVITSIS activity against VWF115 
To determine the importance of the residues involved in the putative Ca^+ binding site 
of ADAMTS13, residues therein were mutated to Ala as this is an uncharged non-
polar residue. A double mutant was also made whereby both Glu83 and Asp173 
were mutated to Ala. This was done by site directed mutagenesis using the 
QuikChange® XL site-directed mutagenesis kit (Stratagene) (section 2.1.2). Mutant 
constructs were then transiently transfected into HEK293T cells (section 2.2.4) and 
protein expression was induced by addition of expression media (OPTIMEM). 
Expressed protein was concentrated and dialysed in 20mM Tris-HCI (pH7.8) 
overnight and run on SDS-PAGE with Western blotting to confirm the presence of 
ADAMTS13 protein (Fig. 5.4). ADAMTS13 ELISA was performed (section 2.6.2) to 
determine the relative concentrations of wild-type ADAMTSIS (WT ADAMTS13) and 
mutants which are shown in Table 5.1. All mutant proteins demonstrated a similar 
concentration except D173A, for which the final protein concentration was 
appreciably lower than the others. 
To determine the effect of these mutations on the rate of ADAMTS13 proteolysis of 
VWF115, InM WT ADAMTS13 or mutants E83A, D173A and D284A in dialysed 
conditioned media, was pre-incubated with 20mM Tris-HCI (pH7.8), 150ml\/l NaCI 
and 5mM CaCtg for 1 hour at 37° before the addition of I.BpM VWF115. Samples 
were then taken at progressive time points up to 3 hours and quenched with 5[il 0.5M 
EDTA before analysis using HPLC. There was no significant difference in the rate of 
proteolysis between WT ADAMTS13 and the E83A or D284A mutants However, 
there was a small delay in cleavage with mutant D173A (Fig. 5.5). 
ADAIV1TS13 
Figure 5.4 S D S - P A G E and Western blot of ADAMTS13 putative Ca^* binding site mutants 
A D A M T S 1 3 putative binding site residues were mutated by site directed mutagenesis using the 
QuikChange® XL site-directed mutagenesis kit (Stratagene) (section 2.1.2). Mutant constructs were then 
transiently transfected into HEK293T cells (section 2.2.4) and protein expression was induced by 
addition of expression media (OPTIMEM). Expressed protein was concentrated and dialysed in 20mM 
Tris-HCI (pH7.8) overnight and run on SDS-PAGE with Western blotting. Lane 1: W T ADAMTS13, Lane 
2; E83A, Lane 3: D173A, Lane 4: D284A, Lane 5: E83A/D173A. 
ADAMTS13 variant Concentration (nM) 
WT ADAMTS13 55 
E83A 68 
D173A 8 
D284A 72 
D173A/E83A 64 
Table 5.1 concentrat ions of W T ADAIVITS13 and mutants of the putative Ca * binding site in 
concentrated dialysed condit ioned media 
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Figure 5.5 Activity of ADAIV1TS13 mutants of the putative Ca * binding site in reaction wi th 
V W F 1 1 5 
I n M A D A M T S 1 3 W T A D A M T S 1 3 or mutants E83A, D173A and D284A in dilaysed conditioned media 
were pre-incubated with 20mM Tris-HCi (pH7.8), 150mM NaCI and 5mM CaClg for 1 hour at 37° before 
the addition of 1 .6| jM VWF115 . Samples were then taken at progressive time points and quenched with 
5pl 0 .5M EDTA before analysis using HPLC. 
5.4 Mutants D173A and E83A displayed a similar overall KD(app)Of 
ADAMTS13 for Ca^ ^ compared to WT ADAMTS13 
Experiments from section 4.5 were repeated with mutants D173A and E83A. 1nM 
ADAIVITSIS in dialysed conditioned media was pre-incubated with 20mM Tris-HCi 
(pH7.8), 150mM NaCI and varying concentrations of CaClg between 0 and SmIVl for 1 
hour, after which 1.6mM VWF115 was added to start the reaction. Time points were 
taken at 10 minutes and percentage cleavage of VWF115 was assessed using 
HPLC. Fig. 5.6 shows 1 of 3 experiments with similar results. WT ADAI\/ITS13 
displays an overall KQ(app) for Ca^* of ~ 75|JM, while the KD(APP) values for mutants 
E83A and D173A are -65plVI and ~51[JM respectively. These values were not 
appreciably different, and the V^ax value in each case was similar. It appeared that 
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the Ca + dependence of ADAMTS13 in reaction witli VWF115 was unchanged by 
mutation of these residues. The clustering of initial rates previously seen with WT 
ADAl\yiTS13 (section 4.5) was not seen with either E83A or D173A. These mutants 
also appeared reach a maximum rate at a lower concentration than WT 
ADAMTS13, although the KD(app) value would suggest otherwise. Of note is that these 
mutant data could not be fitted to a 2-site binding model, unlit<e the initial rates data 
for WT ADAMTS13 (section 4.5). 
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Figure 5.6 Ca^* dependence of putative binding site mutants of A D A M T S 1 3 
A representative experiment of 3, where 1nM W T ADAMTS13, mutants E83A or D173A in diiaysed 
conditioned media was pre-incubated with 150mlVl NaCI and 20mM Tris-HCI (pH7.8) and between 0 and 
5 m M CaCl2 for 1 hour at 37°C before addition of 1.6|aM VWF115 substrate. After 10 minutes reaction 
were stopped with EDTA, and V W F 1 1 5 proteolysis was quantified by HPLC, from which initial rates of 
substrate cleavage were determined. Initial rates data were plotted and KD(app) for Ca^ "^  and Vmax 
determined using Prism 4 software (GraphPad, USA). 
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5.5 Mutation of residues in the putative Ca^ + binding site altered the 
absorbance properties of ADAMTS13 with Ca^* 
The mutant constructs described in section 5.3 were also used to create a stable cell 
line of each. Plasmid DNA containing ADAMTS13 or mutant constructs E83A and 
D173A were stably transfected into HEK293 cells by Dr. C. K. Chion prior to the start 
of this project (section 2.2.3). Cells were grown for 14 days, after which they were 
induced to express ADAMTS13 by addition of expression media (OPTIMEM) and 
protein was purified using a chelating column (section 2.3). Purified protein was 
quantified by ELISA (section 2.6.2) (Table 5.2) and analysed by SDS-PAGE with 
Coomassie staining to check the purity of the ADAMTS13 preparations (Fig. 5.7). 
1pM of mutants E83A and D173A were pre-incubated with 10mM CaCl2, or 20mM 
Tris-HCI (pH7.8) for 1 hour to see if AbS28onm was equally affected as with WT 
ADAMTS13. The absorbances without Ca^'' for WT ADAMTS13, mutants E83A and 
D173A were -0.1. As seen previously with WT ADAMTS13, this value increases to 
-0.15 on incubation of the enzyme with Ca "^" for 1 hour (Fig. 5.8). However, with 
mutants E83A and D173A this value remained at -0.1 when the enzyme has been 
incubated with Ca "^" for 1 hour. This suggested that both the E83A mutation and the 
D173A mutation were inhibiting a conformational change that normally takes place 
after incubation with Ca^^ in WT ADAMTS13 under low ionic strength. 
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260 kDa-
160kDa- ADAMTS13 
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Figure 5.7 SOS PAGE and Coomass ie staining of Purified ADAMTS13 binding site mutants 
iViutations were introduced into the pcDNA3.1/ADAMTS13/myc/His expression vector by site directed 
mutagenesis, with the mutant vectors being stably transfected into HEK293 cells, and expressed into 
conditioned media. Resulting proteins were purified on a Ni^* chelating column and run on 7.5% 
polyacrylamide gel with Coomassie staining. 'Lad' shows the ladder indicating the 260 and 160kDa 
bands, with various A D A M T S 1 3 mutants all running at the same band of ~190kDa. Lane 1; W T 
ADAMTS13; Lane 2: E83A; Lane 3: D173A. 
ADAMTS13 variant Concentration ( \ x M ) 
ADAIVlTSia Wild type 5.6 
E83A 3.1 
D173A 1.2 
Table 5.2 concentrat ions of A D A M T S I S stably expressed and purified mutants 
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Figure 5.8: Abs280nm of mutants E83A and D173A with and without Ca * 
1| jM purified W T A D A M T S 1 3 or mutants E83A or D173A was incubated for 1 hour with 20mM Tris-HCI 
(pH7.8) at 37°C, before Absasonm was measured (1 hour without Ca^*). 1| jM purified W T A D A M T S 1 3 or 
mutants E83A or D173A was incubated for 1 hour with 20mM Tris-HCI (pH7.8) at 37°C in the presence 
of 10mM CaClz, before Absasonm was measured (1 hour with Ca^""). 
5.6 Mutants of the putative Ca^ + binding site displayed a marked 
difference in activity compared to WT ADAIVITS13 against full-length 
VWF 
In order to investigate further the results obtained in sections 5.3 and 5.4, the activity 
of these mutants against full-length VWF was investigated. D173A was not used in 
this experiment as its concentration was too low to accommodate the rest of the 
reactants into the mixture. 5nM WT ADAMTS13, mutants E83A, D284A and 
D173A/E83A in dialysed conditioned media was pre-incubated with 20mM Tris-HCI 
(pH7.8), 150mM NaCI and 5mM CaClg for 1 hour at 37°C before the addition of pre-
denatured VWF at a final concentration of 20|jg/ml. Samples were taken at 
progressive time points and quenched with EDTA, with subsequent analysis of VWF 
degradation by multimer gel analysis (2.7.12) and CBA assay (2.7.11). Compared to 
WT ADAMTS13, cleavage of VWF by E83A, D284A and E83A/D173A proceeded 
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significantly slower as shown by the difference in appearance of lowest molecular 
weight multimers and disappearance of high molecular weight multimers (Fig 5.9a). 
Samples were also analysed using a CBA assay which revealed that VWF in reaction 
with mutants E83A, D284A and E83A/D173A retained significantly more of its 
collagen binding ability over time than did the VWF cleaved by WT ADAMTS13 (Fig. 
5.9b), suggesting that these mutants were less effective at cleaving the full length 
substrate than the wild-type enzyme. 
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Figure 5.9 Activity of putative binding mutants of ADAMTS13 against full-length VWF 
a) Representative experiment of 3. 5nM WT ADAMTS13, mutants E83A, D284A and D173A/E83A in dialysed 
conditioned media were pre-incubated with 20mM Tris-HCI (pH7.8), 150mM NaCI and 5mM CaCIa for 1 hour at 37°C 
before the addition of pre-denatured VWF at a final concentration of 20|jg/ml. Samples were taken at various time 
points and quenched with EDTA, before analysis of VWF degradation by multimer gel analysis (section 2.7.12) b) 
Samples from a) were also analysed using a CBA assay (2.7.11). 
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5.7 New molecular model of ADAMTS13 based on the newly published 
crystal structures of ADAMTS1, 4 andS 
During this investigation, three studies were published elucidating the crystal 
structures of ADAIV1TS1, 4 and 5274-276 ||^  these studies it was shown that these 
ADAIVITS family members had a double Ca^^-binding site (Fig. 5.10). Swiss-model 
was used to model the ADAMTS13 metalloprotease domain on ADAMTS4 and 5, 
whereby the protein sequences of ADAIVITS 13 and these other ADAMTS family 
members were first aligned to check that the degree of sequence similarity was 
suitable for modelling, and then the ADAMTS13 protein sequence was threaded 
through the template crystal structures [PDB:3b8z (ADAMTS5), PDB: 3b2z 
(ADAMTS4)]. Fig. 5.11a shows the new molecular model of ADAIVITS 13 based on 
the crystal structures of ADAMTS4 and 5. Here we can see the difference between 
the new model and the model previously shown in Fig. 5.1 lb, based on the structure 
of Adamalysin II. The main difference between these models is in regard to the new 
predicted position of the Asp166 residue much closer to the putative Ca^^ binding site 
(Fig. 5.11a) in a similar position to Asp353 of ADAMTS5 (Fig. 5.10a) and Asp304 in 
ADAMTS4 (Fig. 5.10b) which are both involved in coordination of two ions in a 
double Ca^^ binding site. Fig. 5.12 shows the alignment between ADAMTS5 and 
ADAMTS13, showing the original putative Ca^+ binding site residues in yellow and 
also the new Asp residue (pink) demonstrated to contribute to coordination of double 
Ca "^" binding site in ADAMTS5. 
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a) 
Asp474 
u270 
Asp360 
Zn^ + in 
active site 
b) 
Asp426 
Cys4Z3 
Aspsll 
Zn^* in 
active site 
Figure 5.10 Crystal structures of ADAWITSS and ADAMTS4 metalloprotease domains showing 
double Ca^* binding site 
Published crystal structures of the metalloprotease domains of ADAMTS5 (PDB;3b8z) (a) and 
ADAMTS4 (PDB: 3b2z ) (b). Shown are the homologous residues involved in coordinating the two 
ions in the double binding site (pink), and the active site ion (grey). Structures are displayed 
using Pymol software (De Lano scientific, USA). 
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a) 
Zn2+ in 
active site 
b) 
Asp264 
AspfeO Cys28f~ 
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Figure 5.11 Predicted model of the ADAIVITS13 metalloprotease domain based on two different 
known crystal structures 
ADAMTS13 metalloprotease domain modelled on a) ttie known crystal structures of ADAMTS4 and 5 
(PDB: 3b2z and 3b8z respectively) b) the known crystal structure of Adadmalysin II (PDB: 11 AG). Both 
models made using Swiss-model as described in section 2.8. Circled in red is Asp166, showing its 
different position in the two models 
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Figure 5.12 Sequence al ignment of ttie ADAMTS5 and ADAMTS13 metalloprotease domains 
Ttie protein sequence of ADAMTS5, st iown in green (UniProt 1D:Q9UNA0 (ATS5_HUMAN)) was aiigned witti tfie protein sequence of ADAMTS13 ( UniProt ID:Q76LX8 (ATS13_HUMAN)) using 
AliBee muitipie al ignment (IVIoscow)^^. * indicates residues tfiat are ttie same, + indicates similar side ctiains. Yellow tilghllghted residues indicate those involved in a putative double Ca^* binding 
site (previously shown in Fig. 5.3). Asp166 in ADAMTS13 is highlighted in pink, while neighbouring residues which are capable of coordinating a Ca^' ion are highlighted in blue. 
5.8 Further mutation in a possible double Ca^ "^  binding site did not alter 
the activity of ADAMTS13 against VWF115 
To determine tiie importance of further possible residues involved in the new putative 
double Ca^* binding site of ADAMTS13, residues therein were mutated to Ala as this 
is an uncharged non-polar residue. IVIutant constructs N162A, E164A and D166A had 
already been made as part of another investigation (section 6.2), and so WT 
ADAMTS13 and mutant constructs were transiently transfected into HEK293T cells 
as previously described and protein expression induced by addition of expression 
media (OPTIIVIEIV!). Expressed protein was concentrated and dialysed overnight in 
20mM Tris-HCI (pH7.8) at 4°C. Dialysed conditioned media of the mutants and WT 
ADAMTS13 was run on SDS-PAGE with Western blotting to confirm the presence of 
ADAMTS13 protein (Fig. 5.13). Table 5.3 shows the concentrations of each mutant 
protein calculated by ELISA as previously described in 2.6.2. To assess the effect of 
these mutations on ADAMTS13 activity, 1nM transiently expressed ADAIVtTS13 was 
pre-incubated with 20mM Tris-HCI (pH7.8), 150mM NaCI and 5mM CaCk before the 
addition of 1.6nM VWF115. Samples were taken at progressive time points up to 3 
hours and the reaction stopped with 5^1 0.5M EDTA. ADAMTS13 mutants N162A, 
E164A and D166A all showed no significant difference in rate of VWF115 proteolysis 
compared to WTADAMTS13 (Fig. 5.14). 
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ADAIV1TS13 
Figure 5.13 SDS-PAGE and Western blotting of ADAMTS13 mutants of a newly predicted double 
Ca^* binding site 
Mutant constructs N162A, El64A and D166A had been made as part of another investigation (section 
6.2), and so WT ADAMTS13 and mutant constructs were transiently transfected into HEK293T cells as 
previously described and protein expression induced by addition of expression media (OPTIMEM). 
Expressed protein was concentrated and dialysed overnight in 20mM Tris-HCI (pH7.8) at 4°C, Dialysed 
conditioned media of the mutants and WT ADAMTS13 was run on SDS-PAGE with Western blotting. 
Lane 1: WTADAMTS13, lane 2: N162A, Lane 3: E164A, Lane 4: D166A. 
ADAMTS13 variant Concentration (nM) 
Wild type 24.0 
N162A 12.2 
E164A 16.6 
D166A 16.1 
Table 5.3 Concentrations of WT ADAMTS13 and mutants of a putative double Ca binding site 
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Figure 5.14 Activity of further mutants of the predicted double binding site against VWF115 
Representative experiment of 3. 1nM transiently expressed WT ADAMTS13 and mutants N162A, 
E164A and D166A were pre-incubated with 20mM Tris-HCI (pH7.8), 150mM NaCl and 5mM CaClg for 1 
hour at 37°C before the addition of 1.6nM VWF115. Samples were taken at progressive time points and 
the reaction stopped with EDTA, after which VWF115 cleavage was assessed using HPLC. 
5.9 dependence of further binding site mutants was similar to 
WT ADAIVITS13 in reaction with VWF115 
To determine the effect of these mutations on the dependence of ADAMTS13 
proteolysis of VWF115, InM transiently expressed ADAMTS13 Wild-type or mutants 
N162A, E164A and D166A were pre-incubated with 20mM Tris-HCI (pH7.8), 150mM 
NaCI and between 0 and 8mM CaCIa for 1 hour at 37° before the addition of 1 .BpM 
VWF115. Samples were then taken after 10 minutes and quenched with EDTA 
before analysis using HPLC. There was no significant difference in the Ca 
dependence of proteolysis of VWF115 between WT ADAMTS13 and the N162A, 
El64A and D166A mutants (Fig.5.15a). When analysed using a 1-site binding model, 
the KD(app) for Ca^ for each mutant is shown in Table 5.4 (1-site binding). Considering 
the results in section 5.4, these data were re-analysed using a 2-site binding model. 
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Again, N162A, E164A and D166A showed no significant difference in Ca^* 
dependence compared to WT ADAMTSIS (Table 5.4, 2-site binding). 
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Figure 5.15 dependence of putative double Ca *^ binding site mutants 
Representative experiment of 3. 1nM transiently expressed WT ADAMTS13 or mutants N162A, E164A 
and D166A In dialysed conditioned media was pre-lncubated with 20mM TrIs-HCI (pH7.8), 150mM NaCI 
and between 0 and 8mM CaClg for 1 hour at 37° before the addition of I.GjjM VWF115. Samples were 
then taken after 10 minutes and quenched with 0.5pl 0.5M EDTA before analysis using HPLC. 
Percentage cleavage was used to calculate initial rates at different concentrations, from which the 
KD(app) was determined using GraphPad Prism. 
1 -site binding 2 site-blnding 
^D(app) KD(app)1 KD(app)2 
Wild-type 70|_ilVI ±20 eOjaiVl ± 8 540|aM ± 85 
N162A 110iiM ±17 78IJM ± 9 670[aM ±50 
E164A 82^M ± 20 56nM ±25 620(aM ±26 
D166A 89iiM ±13 45[JM ±15 690[aM ±55 
Table 5.4 Ko^ pp) values for different ADAMTS13 mutants derived from initial rates plotted using a 
'1-site binding' or '2-site binding' model in Prsim 4 software (Graph Pad, USA). 
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5.10 ADAMTS13 activity against full-length VWF was reduced in mutants 
N162A and E164A of the putative double Ca^ "^  binding site 
In order to ascertain whether the results obtained with the mutants of the newly 
predicted double binding site in reaction with VWF115 could be repeated in a 
full-length assay, the activity of these mutants with full-length VWF was investigated. 
5nM transiently expressed WT ADAMTS13, mutants N162A, E164A and D166A 
were pre-incubated with 20mM Tris-HCI (pH7.8), 150mM NaCI and 5mM CaClg for 1 
hour at 37°C before the addition of pre-denatured VWF at a final concentration of 
20|jg/ml. Samples were taken at various time points and quenched with EDTA, 
before analysis of VWF degradation by multimer gel analysis (section 2.7.12) and 
CBA assay (2.7.11). 
Compared to WT ADAMTS13, D166A activity was normal against full-length VWF 
(Fig. 5.16a and b). However, both mutants N162A and El64A cleaved VWF 
significantly slower than WT ADAI\/ITS13 as shown by the more gradual 
disappearance of high molecular weight multimers. These results were confirmed in 
the CBA assay which demonstrated that VWF in reaction with N162A and E164A 
retained significantly more of its collagen binding activity than either WT ADAMTS13 
orD166A(Fig. 5.16b). 
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Figure 5.16 Activity of putative double binding site mutants against full-length VWF 
a) Representative experiment of 3, where 5nM transiently expressed WT ADAMTS13, mutants N162A, 
E164A and D166A in dilaysed conditioned media was pre-incubated with 20mM Tris-HCI (pH7.8), 
150mM NaCI and 5mM CaClg for 1 hour at 37°C before the addition of pre-denatured VWF at a final 
concentration of 20|jg/ml. Samples were taken at progressive time points and quenched with EDTA, 
before analysis of VWF degradation by multimer gel analysis (2.7.12) and b) CBA assay (2.7.11). 
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5.11 Discussion 
The ADAMTS13 metalloprotease domain has often been modelled on the known 
crystal structure of Adamalysin II, since, until recently, this was the closest M12B 
family member for which the crystal structure had been elucidated (Fig. 5.1 and 5.2). 
The four residues revealed by this modelling and sequence alignment (Fig. 5.3) to be 
likely candidates to coordinate a Ca^^ ion were Glu83, Asp173, Asp284 and Cys281. 
A key difference between this putative site and that of Adamalysin II was an Asp 
residue at position 284 in ADAMTS13 as opposed to an Asn residue at position 200 
in Adamalsyin II. Despite that these are different residues, they had both been 
reported to be involved in Ca^^ binding sites. Mutation of residues in this region, 
however, produced no obvious effect in activity assays against VWF115 (mutant 
D173A appeared to be slightly less active but this may have been due to lower 
expression levels, as the double mutant showed no significant decrease in activity) 
(Fig. 5.5). This result was unexpected as the site was widely suggested to be 
involved in Ca^^ binding, and has been demonstrated to be absolutely required 
for ADAMTS13 function (Chapters 3 and 4). When the dependence of two of 
these mutants, E83A and D173A, was investigated, there was, again, no significant 
difference in KD(app) values compared to WT ADAMTS13 when the data was analysed 
using a 1 -site binding model (Fig. 5.6). However, when the data were analysed using 
a 2-site binding model, the results were significantly different to WT ADAMTS13 
where two distinct KD(app) values had been observed. With mutants E83A and D173A, 
no higher KD(app) values were observed, suggesting the elusive second binding site 
revealed in a 2-site binding model with the WT ADAMTS13, had been abolished by 
these mutations. Although I am suggesting no major role of site 1 in cleavage of the 
small VWF substrate, I cannot completely exclude some contribution. Based on the 
above results, if there was such a contribution, it would account for no more than 
20% of total activity. 
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My findings are, however, interesting in light of the results from section 5.5 and 5.6, 
which suggested that mutations in this region were having an effect on both the 
structure of the enzyme and its activity against the full-length VWF substrate. Fig. 5.8 
demonstrated that the absorbance change observed with WT ADAMTS13 on 
incubation with Ca^^, could not be seen with either mutants E83A or D173A. This 
result suggested that these mutations have blocked the conformational change. 
Mutations in this region also had a significant effect on the activity of ADAMTS13 
against full-length VWF (Fig. 5.9). These data suggested that this region is important 
for ADAMTS13 interaction with a longer VWF substrate mediated through a 
conformational change in the enzyme. This may bring different ADAMTS13 domains 
into contact with the VWF molecule, enhancing the fit between enzyme and 
substrate, and allowing more efficient proteolysis to occur. It is possible that we did 
not see this effect with VWF115 as it is a short substrate which may not require 
interaction with other ADAMTS13 domains to be fully cleaved. 
During this study the crystal structures of the metalloprotease domains of three other 
ADAMTS family members were published, namely ADAMTS1, 4 and 5. The crystal 
structures of ADAMTS4 and 5 were shown in Fig. 5.10. Because these are much 
more closely related to ADAMTS13, having a much higher degree of sequence 
similarity, ADAMTS 13 is now preferentially modelled on these structures instead of 
Adamalysin II. An interesting finding in the elucidation of these structures was the 
presence of a double Ca^^ binding site in the region equivalent to the putative site 
discussed above. Adamalysin II and the other M12B family metalloproteases shown 
in Fig. 5.1 all coordinate a single ion in this region. There were two main 
features of this site which were different between Adamalysin II and ADAMTS4/5. 
Firstly, Asn200 in Adamalysin 11 was replaced by an Asp residue in the equivalent 
position in both ADAMTS4 and 5. The main difference between these two residues in 
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terms of Ca^* coordination is the number of oxygen atoms they can contribute to a 
site. Asn can potentially contribute two oxygen atoms, one from its carboxyl group 
and one from its non-charged polar side chain, while Asp can potentially contribute 
the same oxygen from its carboxyl group but two oxygens from its negatively charged 
side chain. This extra oxygen contributes to the coordination of the second Ca^* ion, 
as shown in Fig. 5.10. The second feature of this site which allows two Ca^^ ions to 
bind is an extra Asp residue at position 304 in ADAMTS4 and 353 in ADAMTS5, 
which is not found in the equivalent position in Adamalysin II. This region is part of an 
alpha helix in Adamalysin II, whereas in ADAMTS4 and 5, it is a loop region, 
providing greater flexibility and ease of movement to coordinate a Ca^^ ion. 
The new model of ADAMTS13 based on the newly published structures predicted a 
double Ca^^ binding site in this region because of these two features which are 
common to ADAMTS4, 5 and 13 (Fig. 5.11). In light of this observation it was 
reasonable to predict that another residue aside from Giu83, Asp173, Cys281 and 
Asp284 may contribute to coordination of two Ca^^ ions in this region, namely an Asp 
residue around position 165/166. Searching the ADAMTS13 sequence revealed 
many residues around this region which may be involved in Ca^ *^  binding: Asn 162, 
Glu164, Asp165, Asp166, Asp168 (depicted in Fig. 5.12). Residues Asn162, Glu164 
and Asp166 had already been mutated to Ala at this stage of the investigation for 
reasons outlined in section 6.2, and so they were investigated for Ca^* dependence. 
As we can see from Fig. 5.14, these mutants demonstrated no significant difference 
in activity compared to WT ADAMTS13 against VWF115. Ca^^ dependence and Vmax 
also appeared unchanged when analysed using both 1 -site and 2-site binding 
models (Fig.5.15 and Table 5.4). This initially suggested that none of these residues 
were involved in Ca^^ coordination. However, two of these mutants, N162A and 
E164A, displayed significantly reduced activity against full-length VWF (Fig. 5.16). 
D166A demonstrated normal activity against the full-length substrate compared to 
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WT ADAMTS13, which was unexpected considering that this was the key residue 
predicted to be involved in coordination of second ion in this putative double 
Ca^^ site (Fig. 5.11 and 5.12). However, Asn162 and Glu164 could be contributing to 
coordination instead. Further investigation of acidic and polar residues in the 
vicinity is required to elucidate which particular residues may be involved in 
coordination of two Ca^* ions. Most important is mutation of residues Asp165 and 
Asp168 to Ala, as either of these may be the preferred acidic ligand to Aspl 66. 
The possible role of this Ca^* binding site, if fully elucidated, may be to stabilise 
folding. The connector loop just beyond this site may position the disintegrin domain 
close to the active site at the other end of the metalloprotease domain upon Ca "^" 
binding, which is thought to be the case in ADAMTSI^^"^. This speculation is 
supported by the absorbance data (section 5.5) which showed that a conformational 
change was abolished by mutation in this site. This would, again, suggest that Ca "^" 
binding to this site was causing a large conformational change such as the one 
mentioned above. Absasonm is dependent on aromatic residues, as previously stated. 
Within this proposed double Ca^ binding site was a Trp residue at position 283. Trp 
residues affect Abs280nm most strongly out of all the aromatic residues, and so may 
have largely contributed to an absorbance change within this region if it was being 
moved a significant distance as a result of Ca^^ binding. Another observation 
supported the theory of the connector loop repositioning the disintegrin domain on 
binding of Ca^. That is that in the new model of the ADAMTS13 metalloprotease and 
disintegrin domains, a cluster of aromatic residues could be seen at the interface 
between the two domains (Fig. 5.17). Since the metalloprotease and disintegrin 
domains of ADAMTS4 and 5 were crystallised with this state would represent 
the end result of a conformational change caused by Ca^ binding to this site. The 
new interaction of these aromatic residues is highly likely to cause a dramatic change 
in AbS280nm. The creation of an aromatic interface such as this, combined with a 
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dramatic change in position of Trp283, may explain the large change in absorbance 
as a result of binding. Further purified binding site mutants would need to be 
made in order to test this hypothesis further, as well as looking at the effect of 
mutating the binding site Trp, and other aromatic and charged residues at the 
aromatic interface. 
Trp 283 
Connector loop 
Tyr 304 
Tyr 305 
Putative 
binding site 
Figure 5.17 Model of ADAIVITS13 metalloprotease and dlsintegrin domains 
Predicted structure of the metalloprotease and disintegrin domains of ADAMTS13. Shown are: the putative Ca^* 
binding site, the connector loop between the two domains, 2 Tyr residues in the disintegrin domain (yellow), a Tyr 
(yellow) and Phe (orange) residue in the metalloprotease domain. Also shown are charged residues which may 
contribute to the aromatic interface interaction (negatively charged residues in red and positively charged residues in 
blue). 
There also exists a splice variant of ADAMTS13 (isoform 3) (uniprot: Q76LX8-3). It 
has a feature of interest for this site, in that it is missing residues 275-305, which 
include Cys281 and Asp284. A function for this isoform has not been assigned and 
its frequency in the population is not known, but it would be potentially interesting to 
investigate further the influence of mutating not only this Ca^^ binding site, but also 
disrupting the disulfide bond of which this Cys residue partakes. 
165 
Chapter 6 
Identification and characterisation of a functional Ca^ ^ binding 
site in ADAMTS13 
6.1 Introduction 
Whatever the possible role of the putative double binding site described in 
chapter 5, it is clear from the results presented therein that this is not the site 
responsible for the overall Ko(app) of ADAMTS13 for of ~70nM. It was therefore 
necessary to search for another site. The possibilities for the location of this site are 
vast considering the size and the variety of domains in ADAMTS13, but the only 
models available to search for possible sites apart from in the sequence are those 
from the crystal structures of the metalloprotease domains of other closely related 
metalloproteases. At the start of this investigation, the closest model available was 
that of Adamalysin II (section 5.1). 
6.2 Molecular modelling yields potential sites of Ca^ ^ interaction in the 
ADAMTS13 metalloprotease domain 
As previously stated, Adamalysin II is known to coordinate a Ca^^ ion in its 
metalloprotease domain specifically through residues Glu9, Asp93, Cys197 and 
Asn200 (Fig. 5.1a). The ADAMTS13 metalloprotease domain is predicted to 
coordinate Ca^ "^  using similar residues (Fig. 5.2). However, further investigation and 
modelling on new crystal structures revealed that this site may be part of a double 
Ca2+ site (section 5.7). This site will be designated site 1 from this point on. The 
availability of crystal structures such as Adamalysin II is helpful for identifying 
possible structural similarities, and particularly for locating other possible 
binding motifs in ADAMTS13. Inspection of different Ca^+ binding sites in other 
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proteases and the manner in which residues are generally arranged around the ion, 
reveals a pattern of coordination. Figure 6.1 illustrates 4 examples of this 'classic 
arrangement' with the red parts of the residues representing the negatively charged 
oxygen atoms, which will coordinate with the positive ion. These are all Ca^^ binding 
sites, and so in the search for alternative sites in ADAMTS13, this 'classic 
arrangement' was sought. 
The position of amino acid residues around a ion is such that the charged 
oxygen atoms point inwards towards the ion, creating a pocket of negative charge in 
which the ion can 'sit' (Fig. 6.1), and also creating a centre of high hydrophobicity 
contrast (see section 1.4.1). The model of the ADAMTS13 metalloprotease domain 
(based on Adamalysin II) was viewed using Pymol software (DeLano Scientific, USA) 
on a 'surface' setting. Here, surface clusters of negative charge were initially sought 
by colouring all oxygen atoms red, so clusters of negative charge would appear as 
dense patches of red on the surface (Fig. 6.2a). Once a surface cluster had been 
identified, the domain was viewed using the setting of 'side chains - spheres' which 
allowed side chains to be viewed alone, which meant that only oxygen atoms from 
negatively charged and polar side chains could be seen in red. This was relevant as 
Ca^* binding sites are much more likely to involve the side chains of Asp, Glu and 
Asn than the carbonyl oxygen of any other amino acid (section 1.4.1). 
Figure 6.3a shows a site (termed site 2) very close to the previously mentioned 
predicted Ca^ binding site (site 1), and is comprised of residues Asn162, Asp165, 
Asp166 and Asp 168. There is also a Glu residue at position 164, although in the 
model its negative side chains are facing away from the potential 'pocket' of negative 
charge. Asn 162, Glu164 and Asp166 were mutated to Ala by site directed 
mutagenesis (section 2.1), and transiently expressed in HEK293T cells (section 
2.2.4). Mutant proteins were tested for activity and Ca^^ dependence in Chapter 5. 
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Figure 6.3b shows a site (termed site 3) fairly close to the active site, made up of 
residues from a classic Ca^^-binding loop. Again, the negative side chains point in 
towards a potential 'pocket' of negative charge. Figure 6.3c shows a site (termed site 
4) away from either the Zn "^" ion or predicted ion, and figure 6.3d shows a site 
(termed site 5) extremely close to site 1. Figure 6.3e shows a site (termed site 6) 
involving residues far away from each other in sequence, but close to each other in 
predicted structure. This may suggest a site where a positive ion can bind to stabilise 
the structure of a domain by bringing residues from different parts of the amino acid 
sequence together along with two or more water molecules. 
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Figure 6.1: Four examples of Ca * coordinating residue arrangements 
Ca^* binding sites viewed in Pymol (DeLano scientific, USA) illustrating residues only a) Psychrophilic 
alkaline protease from a Pseudomonas species, b)Thermolysin, c) Matrix Metalloprotease 8 (MMP8), d) 
Stromelysin. Tiie residues are shown in stick format and the red coloured ends represent their 
negatively charged oxygen atoms. The MMPs have three Ca^"^binding sites; not all oxygens coordinate 
Ca^ "^  ions; Carbonyl groups can also coordinate Ca^. 
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a) 
Cluster of 
negative charge' 
b) 
Cluster of acidic 
side chains 
Figure 6.2 ADAIVITS13 metalloprotease domain model of surface charge and side chains 
a) The ADAMTS13 metalloprotease domain model (based on Adamalysin II) was viewed using Pymol 
'surface' mode (oxygen atoms appear in red). A surface cluster on negative charge is circled in yellow, 
b) as a) but the mode is 'side chain - spheres', and a cluster of acidic side chains (2 oxygen atoms 
each) is circled in yellow. 
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a) Site 2 b) site 3 
c) Site 4 
e)Site 6 
AapleS 
Asp168 
Asm 62 
.Tilt135 
Glu)38 Leu134 
d) site 5 
AsplBZ _ Pro186 
G l u 2 1 2 ^ flsp182 
GlylTO 
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\ Asp135 
G1U154 
^^ G^ln269 
Figure 6.3: Possible sites of interaction within the metalloprotease domain of ADAMTS13 
On the left of each pair in a) to e) is the model of the metalloprotease domain of ADAMTS13 (based on Adamalysin II) showing the predicted Ca'* ion in pink and the catalytic 
Zn^* ion in the active site in blue. The residues coloured red show the location of possible Ca'* interaction sites and the images on the right hand side show these residues in 
detail, particularly showing the predicted coordination of their negatively charged oxygen atoms (red tips), made using Pymol software (DeLano scientific, USA). 
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Site 3 is of special interest as it appears to be similar to a site found in some MMPs 
e.g. MMPS, the metalloprotease domain of which is shown in a similar orientation to 
ADAMTS13 metalloprotease domain in Fig. 6.4, highlighting the possible position of 
a coordinated Ca^ ion. 
a)MMP8 
Zn^+in the 
active sites^ 
b) ADAMTS13 
Possible 
Zn in the 
active s i t 
Site 1 
Figure 6.4 Comparison of the metalloprotease domain of MMPS and the predicted 
metalloprotease domain structure of ADAMTS13 
a) MMP 8 (PDB 20Y2) is oriented showing the ion close to the active site, b) ADAMTS13 
metalloprotease domain is shown in the same orientation with residues shown also. Both are displayed 
using Pymol software (DeLanp scientific, USA). Also illustrated in both is the ion in the active site. 
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6.3 Molecular modelling based on the ADAMTS4 and 5 metalloprotease 
domains further suggests that site 3 may be a Ca^* binding site 
The recently reported crystal structures of ADAMTS4 and 5 were used to generate a 
revised model for the ADAMTS13 metalloprotease domain (section 5.7). Based on 
this model it was clear that the site previously designated site 2 (Fig. 6.3a), may be 
part of a double Ca^^ binding site, also involving residues from site 1. When 
modelled using ADAMTS4 and 5 metalloprotease domain structures, some of the 
other suggested Ca"" binding sites also appear to have a different conformation. Site 
4 now has a conformation such that the oxygen atoms are no longer facing inward 
towards a central region, so are unlikely to be coordinating a cation in this space (Fig. 
6.4a). Site 5 is similarly composed of much more dispersed residues in the new 
model that are unlikely to be able to coordinate a cation due to the distance between 
the residues (Fig. 6.4b). Site 6 now shows far more dispersed residues although the 
Glu and Asp are facing more towards each other (Fig. 6.4c). However, there are no 
other residues in the surrounding area of the new model that would contribute to this 
site, and with a maximum of 3 oxygens being donated to this site through the 
residues, the other oxygen atoms would have to be provided by water, which would 
be energetically unfavourable. Site 3, however, still demonstrated potential as a Ca^^ 
binding site since the residues were still facing each other, even though Asp187 and 
Pro186 seem quite far away from the other two residues involved. In favour of this 
site is the Ca^^ ion revealed in the ADAMTS5 structure. 
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Figure 6.5 New predicted residue conformation of previously predicted Ca * binding sites 
Predicted residue conformation of sites predicted to be involved in binding based on the Adamalysin II crystal 
structure, now modelled using ttie known crystal structures of ADAMTS4 and 5. a) site 4, b) site 5, c) site 6, d) site 3. 
All viewed using Pymol software (DeLano scientific, USA). 
6.4 Expression of site 3 mutants of ADAMTS13 metalloprotease domain 
To determine the importance of the residues involved in the predicted site 3 Ca^* 
binding site of ADAMTS13, residues therein were mutated to Ala as this is an 
uncharged non-polar residue. This was done achieved by site directed mutagenesis 
using The QuikChange® XL site-directed mutagenesis kit (Stratagene) (section 2.1). 
Mutant constructs were then transiently transfected into HEK293T cells (2.2.4), and 
transfected cell lines were induced to express protein by addition of expression 
media (OPTIMEM). Expressed protein was concentrated and dialysed overnight in 
20mM Tris-HCI, and run on SDS-PAGE (2.6.4) with Western blotting with the anti-
ADAMTS13 (TSP2-4 depleted) antibody (2.6.6) (Fig. 6.6). Table 6.1 shows the 
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concentrations of each mutant protein calculated by ADAMTS13 ELISA (section 
2.6.2). 
190kDa 
ADAMTS13 
Figure 6.6 SDS-PAGE with Western blotting of ADAMTS13 site 3 mutants 
ADAI\/1TS13 site 3 mutants in concentrated dialysed conditioned media were run on SDS-PAGE sung 
7.5% gels (section 2.6.4). The presence of ADAMTS13 was confirmed by Western blotting with the anti-
ADAMTS13 (TSP 2-4 depleted) antibody (section 2.6.6). 
ADAMTS13 mutant Concentration (nM) 
W T A D A M T S 1 3 45 
E184A 32 
D187A 35 
E212A 28 
Table 6.1 ADAMTSIS site 3 mutants concentration determined by ADAMTS13 ELISA 
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6.5 ADAMTS13 site 3 mutants have significantly reduced activity against 
VWF115 compared to WT ADAMTSIS 
In order to assess the effect of site 3 mutations on the activity of ADAMTS13, 1nM 
WT ADAIV1TS13 or mutants E184A, D187A or E212A in concentrated dialysed 
conditioned media were pre-incubated with 20mi\/i Tris-HCi, 150mM NaCI, pH 7.8, 
and 5mM CaCIa for 1 hour at 37°C before the addition of 1.6iil\/l VWF115. Samples 
were taken at progressive time points, and the reaction quenched with Spl 0.5M 
EDTA before analysis using HPLC (section 2.7.3). E184A proteolysed VWF115 at an 
equivalent rate compared to WT ADAIV1TS13 (Fig. 6.7). D187A and E212A, however, 
had markedly reduced activity against VWF115 compared to WT ADAMTS13. 
lOOn 
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•WT ADAMTS13 
•E184A 
•D187A 
•E212A 
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Figure 6.7 Activity of ADAMTSIS site 3 mutants against VWF115 
Representative experiment of 3, in wtiich InlVl ADAI\/1TS13 in concentrated dialysed conditioned media 
was pre-incubated with 20mM Tris-HCI, 150mM NaCI, pH7.8, and 5mM CaCIs for 1 hour at 37°C before 
the addition of I.epM VWF115. Samples were taken at progressive time points, and the reaction 
quenched with 5pl 0.5M EDTA before analysis using HPLC (section 2.7.3) to determine percentage 
cleavage of VWF115. 
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6.6 ADAMTS13 site 3 mutants have severely altered Ca^ ^ dependence in 
reaction with VWF115 compared to WT ADAMTS13 
In order to assess the effect of site 3 mutations on the dependence of 
ADAMTS13, 1nM WT ADAMTS13 or mutants E184A, D187A or E212A in 
concentrated dialysed conditioned media was pre-incubated with 20mM Tris-HCI, 
150mM NaCi, pH 7.8, and concentrations of CaClg between 0-8mM for 1 hour at 
37°C before the addition of 1.6|iM VWF115. Samples were taken at 20 minute time 
points for WT ADAMTS13 and E184A, and 2 hour time points for D187A and E212A 
given the massively decreased rate of proteolysis (Fig. 6.7). For these latter mutants, 
a long incubation with VWF115 was required to obtain 15-20% cleavage required for 
accurate determination of KD(app)- The reactions were quenched with 5|il 0.5M EDTA 
before analysis of cleavage using HPLC (section 2.7.3). Fig. 6.7 demonstrated that 
E184A had similar activity to WT ADAMTS13 towards VWF115. However, the Ca^* 
dependence of that activity was appreciably altered. It was observed that the curve of 
E184A initial rates with increasing Ca^^ concentration was less steep than WT 
ADAMTS13 (Fig. 6.8) and Table 6.2 demonstrated that the KD(app) increased almost 
4-fold to ~250|aM, compared to ~72iiM for WT ADAMTS13. This suggests a reduced 
Ca^* affinity. Even more dramatic are the effects of mutations D187A and E212A, 
which not only severely reduced activity of ADAMTS13 against VWF115 as shown by 
the reduced Vmax of initial rates from ~0.3nMs"^ for WT ADAMTS13 to -0.1 nMs"^ for 
D187A and ~0.06nMs"^ for E212A (Fig. 6.8), but also dramatically increased the 
KD(app) of the enzyme for Ca^^ from ~72(iM of WT ADAMTS13 to ~520|iM (~8-fold 
increase) and ~720|iM (a 10-fold increase) for mutants D187A and E212A, 
respectively, indicating an appreciable reduction in Ca^^ affinity and dependence 
(Table 6.2). 
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Figure 6.8 Ca * dependence of ADAIVITS13 site 3 mutants in reaction with VWF115 
Representative experiment of 3, in which 1nM WT ADAMTS13 or mutants E184A, D187A and E212A in 
concentrated dialysed conditioned media was pre-incubated with 20ml\/l Tris-HCI, 150mM NaCI, pH7.8, 
and varying concentrations of CaCIa between 0-8mM for 1 hour at 37°C before the addition of 1.6|_iM 
VWF115. Samples were taken after 20 minutes for WT ADAMTS13 and E184A, and after 2 hours for 
D187A and E212A, based on results from section 6.5. The reactions were quenched with 5^1 0.5M 
EDTA before analysis of cleavage using HPLC (section 2.7.3 ). 
ADAMTS13 variant Ko(app) (JJM) V,^ax(nMs') 
Wild-type 72 ± 2 1 0.3 ±0 .04 
E184A 250 ± 45 0.28 ±0 .05 
D187A 520 ± 35 0.1 ±0 .02 
E212A 720 ± 60 0.06 ±0 .01 
Table 6.2 dependence of ADAIVITSIS site 3 mutants 
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6.7 ADAMTS13 site 3 mutants have reduced activity against full-length 
VWF compared to WT ADAMTS13 
In order to see if tine results obtained with the site 3 mutants in reaction with VWF115 
could be repeated in a full-length VWF assay, 5nM WT ADAMTS13, mutants E184A, 
D187A and E212A in concentrated dialysed conditioned media were pre-incubated 
with 20mM Tris-HCl, 150mM NaCl, pH7.8, and 5mM CaCl2 for 1 hour at 37°C before 
the addition of pre-denatured VWF at a final concentration of 20ijg/ml. Samples were 
taken at progressive time points and quenched with 5|al 0.5M EDTA, before analysis 
of VWF degradation by multimer gel analysis (section 2.7.12) and CBA assay 
(section 2.7.11). Mutants D187A and E212A proteolysed VWF significantly slower 
than WT ADAMTS13 which was apparent from the slower disappearance of high 
molecular weight multimers and the slower appearance of low molecular weight 
multimers (Fig. 6.9a), while mutant E184A cleaved the substrate at a similar rate to 
WT ADAMTS13. This was confirmed by the CBA assay, demonstrating that VWF 
proteolysed by mutants D187A and E212A retained its collagen binding ability for 
longer suggesting these mutants acted less efficiently. VWF in reaction with mutant 
El 84A had significantly reduced collagen binding ability compared to VWF in 
reaction with D187A and E212A, further confirming that E184A behaves similarly to 
WT ADAMTS13 at high Ca "^" concentrations. 
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Figure 6.9 Activity of ADAMTS13 mutants of the site 3 binding site in reaction with VWF 
Representative experiment of 3. a) 5nM WT ADAMTS13, mutant E184A, D187A and E212A in dialysed 
conditioned media were pre-incubated with 20mlVI Tris-HCi, ISOmiVl NaCI, pH7.8, and 5mM CaCl2 for 1 
hour at 37°C before the addition of pre-denatured VWF at a final concentration of 20pg/ml. Samples 
were taken at progressive time points and quenched with EDTA, before analysis of VWF degradation by 
multimer gel analysis (section 2.7.12). b) Samples from a) were also analysed using a CBA assay 
(section 2.7.11). 
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6.8 ADAMTS13 site 3 mutant, D187A, has severely altered Ca^* 
dependence compared to W T ADAMTS13 in reaction with full-length 
V W F 
In order to assess qualitatively the Ca^* dependence of D187A in reaction with full-
length VWF, assays were set up as in section 6.7, but with increasing 
concentrations. Purified plasma-derived VWF (section 2.5) was incubated with 1.5M 
Gdn-HCl at 37°C for 1hour. The denatured VWF was then added at a final 
concentration of 20iig/ml to 5nM WT ADAMTS13 or mutant D187A in concentrated 
dialysed conditioned media, pre-incubated for 1 hour with 150mM NaCl2,20mM Tris-
HCl, pH7.8, and varying concentrations of CaCIa between 0 - 5mM. Samples were 
taken at progressive time points and quenched with EDTA, before analysis of VWF 
degradation by multimer gel analysis (section 2.7.12) and CBA assay (section 
2.7.11). Compared to WT ADAIVITSI3, mutant D187A showed significantly altered 
Ca^^ dependence. This was apparent from the gradual increase in low molecular 
weight multimers between 500 and lOGOjiM, with no significant decrease in high 
molecular weight multimers (Fig. 6.10a). These results reflected those found for the 
short substrate VWF115. VWF in reaction with WT ADAIVITSI 3 displayed decreasing 
collagen binding ability with increasing Ca^^ concentration, whereas VWF in reaction 
with D187A retained most of its collagen binding ability even at high Ca^* 
concentrations (Fig. 6.1Gb). This data supported the multimer gel analysis(Fig. 6.10a) 
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Figure 6.10 Ca^* dependence of D187A in reaction with full-length VWF 
Representative experiment of 3. 5nM WT ADAMTS13 or D187A in concentrated dialysed conditioned 
media was pre-incubated with 20mM Tris-HCI, 150mM NaCI, pH7.8 and varying concentrations of CaCIa 
between 0-5mM for 1 hour at 37°C before the addition of VWF (denatured with 1.5M Gdn-HCI) at a final 
concentration of ~20pg/ml. The reaction was incubated for 2 hours at 37°C after which samples were 
taken and quenched with 5pi O.SfVl EDTA. Samples were analysed using multimer gel analysis (section 
2.7.12) (a) and CBA assay (b) (section 2.7.11). 'RP' denotes the multimer pattern of reference plasma, 
while '-AD13' denotes the multimer pattern of VWF in the reaction before the addition of ADA[\yiTS13 in 
the presence of 5mM CaClg. 
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6.9 Absorbance of D187A under low ionic strength is appreciably 
increased by addition of Ca^^ 
Mutant construct PCDNA3.1-ADAMTS13-D187A was stably transfected into HEK293 
cells by Rens De Groot as previously described (section 2.2.3) and stably transfected 
cell lines were grown out over -14 days before enhancement] of protein expression 
by addition of expression media (OPTIMEM). Expressed protein was concentrated 
and purified by affinity chromatography (section 2.3.2). Fig. 6.11 shows the 
purified fraction of the mutant protein generated before ELISA using SDS-PAGE 
(section 2,6.4), Coomassie staining (section 2.6.4) and Western blotting (section 
2.6.6), and the concentration obtained by ADAMTS13 ELISA (section 2.6.2). The 
absorbance of purified mutant D187A was assessed using l i iM enzyme measured at 
280nm with no present in reaction buffer containing 20mM Tris-HCl, pH7.8. At 
the same time lOmM CaCIa was added to a IjaM mutant D187A solution in 20mM 
Tris-HCl, pH 7.8, and the absorbance immediately measured so there was no pre-
incubation with Ca^. 1|aM mutant D187A in 20mM Tris-HCl, pH7.8, was then pre-
incubated with 5mM CaCl2 for 1 hour at 37°C. At the same time 1|aM mutant D187A 
was pre-incubated with 20mM Tris-HCl, pH7.8, alone for 1 hour at 37°C to see if the 
absorbance would remain the same after 1 hour pre-incubation with no Ca^^. The 
absorbance measured for D187A in the presence and absence of Ca^ "^  at low ionic 
strength is the same as WT ADAMTS13 (Fig. 4.9), with Ca^+ causing a large increase 
in absorbance, showing the site responsible for this, and hence a conformational 
change, has not been affected by the D187A mutation (Fig. 6.12a). This change in 
absorbance was also shown to occur over time between 20 and 40 minutes 
incubation (Fig. 6.12b). 
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200KDa 
148KDa 
'190KDa 
D187A ~1.3|iM 
Figure 6.11 SDS-PAGE with coomassie staining and Western blotting of purified mutant D187A 
Purified mutant D187A was analysed using SDS-PAGE with coomassie staining and western blotting. 
Lane 1: ladder. Lane 2: Coomassie stain under non-reducing conditions, demonstrating a 
slngle~190kDa band. Lane 3: Western blot using antl-ADAMTS13 (TSP2-4) depleted antibody. 
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6.12 Absorbance of purified mutant D187A under low ionic strength conditions 
a)The absorbance of l n M purified mutant D187A was measured at 280nm with no present in 
buffer containing 20mlVI Tris-HCI, pH7.8. At the same time lOmM CaClg was added to 1|aM mutant 
D187A in 20mlVI Tris-HCI, pH7.8, and the absorbance immediately measured so there was no pre-
incubation with Ca^^ (shown in the 'no pre-incubation' column). 1|iM mutant D187A was then pre-
incubated with 10mM CaClg in 20mM Tris-HCI, pH7.8, for 1 hour at 37°C. At the same time 1 |iM mutant 
D187A was pre-incubated with 20mM Tris-HCI, pH7.8, alone for 1 hour at 37°C (shown in the ' Ihr pre-
incubation' column). n=4 b) The absorbance change in a) was measured over time. lOmM CaClg was 
added to lnM purified mutant D187A in 20mM tris-HCI, pH7.8 and the absorbance measured every 
minute for 1 hour. Representative experiment of 3.j 
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6.10 Discussion 
The data presented in chapter 5 revealed that the putative binding site of 
ADAMTS13 (site 1) was not the site responsible for the overall Ca "^" dependence of 
ADAMTS13 activity (KD(app) ~70(iM) aganst VWF115. Another site was therefore 
sought. Searching the ADAMTS13 metalloprotease domain (based on Adamalysin II) 
yielded many possible candidates for cation interaction near the surface of the 
domain (Fig. 6.3). The similarity between site 3 and a Ca^^ binding site in MMP8 
supported the hypothesis that this particular site may be involved. Mutation within this 
site severely decreased the activity of ADAMTS13 against VWF115 (Fig. 6.7), with 
substitution mutants D187A and E212A demonstrating the greatest reduction in 
activity. Examining the dependence of these mutants further confirmed that 
mutation of Asp187 and Glu212 to Ala decreased the V^ax from -0.3 to -0.1 for 
D187A and -0.06 for E212A (Table 6.2). More interestingly though, is that for all the 
tested mutants of this site (E184A, D187A and E212A), the KD(app) of ADAMTS13 for 
Ca^^ had been appreciably increased up to -10 fold with mutant E212A. This 
suggests that mutations D187A and E212A may be inhibiting Ca^"' binding to this site, 
as it can only bind at very high concentrations. Furthermore, these mutations are 
inhibiting the proper functioning of the enzyme even when Ca "^" has bound, since the 
Vmax is vastly reduced in both cases. Interestingly, the mutant E184A has a reduced 
affinity for Ca^* (KD(app) ~250|aM) but the Vmax is restored to WT ADAMTS13 levels by 
high Ca^^ concentrations. This would suggest that mutation of Glu184 is mildly 
inhibiting Ca^^ binding to this site, but once it is bound, Ca^* allows the enzyme to 
function normally (Vmax -0.28 compared to -0.3 for WT ADAMTS13). 
These results were extended by assaying the activity of these mutants against full-
length VWF (Fig. 6.9). At high Ca^+ concentration, mutants E184A and WT 
ADAMTS13 displayed similar activity, while D187A and E212A displayed greatly 
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reduced activity. Tine results from Fig. 6.8 and Table 6.2 are supported, at least semi 
quantitatively by Fig. 6.10a. Here, disappearance of high molecular weight multimers 
and appearance of low molecular weight multimers occurs between 50-200nM Ca^'" 
in WT ADAMTS13, whereas there is no significant decrease in high molecular weight 
multimers seen with mutant D187A, suggesting that these multimers are not being 
proteolysed by the enzyme. There is a gradual increase in low molecular weight 
multimers between 500-1 OOOuM, which would support the Koopp) of mutant D187A for 
Ca^^ of ~520|iM against VWF115. The CBA assay (Fig. 6.10b) further confirms this. 
The data from VWF115 and full-length VWF studies strongly suggest that site 3 is the 
high affinity binding site in ADAMTS13 responsible for the Koopp) of ~70[iM. 
It can be concluded that site 3 and site 1 act independently based on the absorbance 
studies in section 6.9. Here, it was demonstrated that mutant D187A displays the 
same change in Absgsonm on addition of Ca^^ under low ionic strength as WT 
ADAMTS13 (6.12a) even though its activity is greatly reduced in comparison. It also 
takes between 40-60 minutes for the absorbance change to occur fully, as was 
observed with WT ADAMTS13. 
Aligning the metalloprotease domain protein sequences of ADAMTS13 and other 
ADAMTS family members reveals an interesting variation. In most other members, 
there are 2 Cys residues that form an internal disulphide bond (Fig. 6.13). It would 
appear from this observation that this loop adjacent to the active site may be held in 
a stable conformation by the disulphide bond generally present in ADAMTS 
metalloproteases. In ADAMTS13, these Cys residues are not present, suggesting 
that a Ca^ ion may be substituting for a disulfide bond in this site. ADAMTS13 would 
require Ca^^ for this loop to be stabilised, providing a rational for the absolute 
requirement of ADAMTS13 for for efficient enzyme function. This contention is 
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supported by MMP8, in whicli the equivalent loop also lacks a disulfide bond and is 
held in a stable conformation by a Ca "^" ion (Fig. 6.4). 
Site 3 Glu212 
Active 
Site 
ADAMTS13 
ADAMTSL 
ADAMTS2 
ADAMTS3 
ADAMTS4 
ADAMTS5 
ADAMTS6 
ADAMTS7 
ADAMTS8 
ADAMTS9 
ADAMTSIO 
ADAMTSl2 
ADAMTSl4 
ADAMTSl5 
ADAMTSl6 
ADAMTSl7 
ADAMTSl8 
ADAMTSl9 
VLYITRFDL-ELPDGNR—QVRGVTQLGGACSPTWSCLIT-EDTGFDLGVTIflHEIGHSFGIiEHDG 
AILFTRQDLSG-SQT—gOTLGMADVCTVCDPSRSCSVI-EDDGLQAAFTT^ 
AIFLTRQDF-GPSGM QGYAPVTGMCHPVRSCTLNHED-GFSSAFWA 
AIFLTRQDF-GPAGM QGYAPVTGMCHPVRSCTLNHED-GFSSAFVVA 
AILFTRQDLGG-VST—GOTLGMADVGTVCDPARSCAIV-EDDGLQSAFTA;! 
AILFTREDLSG-HHS—BDTLGMADVGTICSPERSCAVI-EDDGLHAAFTVA 
AVLITRYDIB-TYKN-KPRGTLGLASVA:GMCEPERSCSIN-EDIGLGSAFTM 
AILLTRKDLj-AAMN-RpBETLGLSHVAGMCQPHRSCSIN-EDTGLPLAFTyA 
AILLTRQNF%-QEGL--BDTLGVADIGTICDPNKSCSyi-EDEGLQAAHTliA 
AVLLTRQDIS-RAHD-K-fflDTLGLAELGTfCDPYRSCSIS-EDSGLSTAFTM 
AVLITRYDlS-IYKN-KpBGTLGLAPVQGMCERERSCSVN-EDIGLPQAFTIis 
AVLLTRKDIS-AGFN-RPSETLGLSHLSGMCQPHRSCNIN-EDSGLPLAFTIA 
WFLTRQDFG-PSGM QGYAPVTGMCHPLRSCALNHED-GFSSAFVI^ 
AILFTRQDI^-ATT—HDTLGMADVGTMCDPKRSCSVI-EDDGLPSAFTTA 
AILLTGLDIS-SWKNE-PSDTLGFAPISGMCSKYRSCTIN-EDTGLGLAFTI^ 
HELGHVFNMPHDD 
HETGHVLGMEHDG 
HETGHVLGMEH3G 
HELGHVFNMLHDN 
HEIGHLLGLSH 
HEIVHNFGMNH 
HELGHSFGIQHDG 
AVFVTRTDFS-VHKDE-PSDTVGIAYLGGVCSAKRKCVLA-EDNGLNLAFTI^HELGHNLGMNH 
AILLTGFDIS-SWKNE-PHDTLGFAPTSGMCSKYRSCTIN-EDTGLGLAFTIAHESGHNFGMIH 
AILITRKDFB-VHKDE-PADTVGIAYLSGMCSEKRKCIIA-EDNGLHLAFTIJIHEMGHNMGINH 
DD 
DG 
HELGHVLSMPH 
HELGHVFNMPH 
HEIGHTFGMNH 
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HETGHVLGMEH 
HELGHVFNMPH 
HESGHNFGMIH 
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OG 
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DN 
Figure 6.13 Alignment of ADAIVITSI3 family members 
Protein sequences of ADAMTS13 and other family members were aligned to demonstrate the 2 Cys 
residues found in most family members. In yellow are homologous regions and the 2 Cys residues in 
site 3 are shown in blue. Glu212 is highlighted as well as the active site in all ADAMTS 
metalloproteases. 
However, after investigation of the newly published crystal structure of ADAMTS5, it 
is apparent that this ADAMTS family member also binds a Ca^^ ion in this region, as 
does ADAMTS4^^'^ (Fig. 6.14). Two of these residues involved in Ca^+ binding are 
conserved in ADAIVITS family members. In ADAMTS13 these are Asp 182 and 
Glu212. Glu212 has been demonstrated to be important for Ca^+ binding to this site, 
but Asp182 has not yet been investigated. The other residues contributing to Ca^^ 
coordination in ADAMTS4 and 5 are non acidic and are contributing though their 
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carbonyl backbone. The way ADAMTSIS is modelled on ADAMTS4 and 5 suggests 
that the Ca^ ion in this site may be largely coordinated by non-acidic residues 
through their carbonyl oxygens (Fig. 6.14a), but this model also places Asp187 and 
Giu184 far away from the Ca^^ ion. An informative method to try and assess the 
likelihood of being coordinated in the manner suggested by modelling is to 
measure the predicted bond length between the coordinating oxygen and the ion 
itself. Pymol software (Delano scientific, USA) achieves this without further 
manipulation of the model. As we can see from Table 6.3, ADAMTS5 calcium-oxygen 
bond lengths in this site are well within the narrow range expected of a binding 
site of 2.1-2.7 A (section 1.4.1). The revised model of the ADAMTSIS 
metalloprotease domain, however displays no calcium-oxygen bond lengths within 
this range in this predicted coordination arrangement (Table 6.3). It was also 
observed that this Ca^ ion in ADAMTS5 is being coordinated by 5 oxygen atoms 
from surrounding residues and so at least 1 water must be contributing to the site 
also (since Ca^* cannot be coordinated by only 5 oxygen atoms (section 1.4)). In 
MM8, however (Fig. 6.4a), the Ca^^ ion is coordinated by 6 oxygen atoms all from 
surrounding residues, 3 of which are from acidic residues. These observations are 
important as acidic residues provide greater hydrophobicity contrast to the site, which 
would exert a stronger attraction for Ca^ "^  and hence tighter binding (section 1.4). The 
observation that all the oxygen atoms contributing to the site are from surrounding 
residues instead of water would also suggest a high affinity of the site for Ca^^ 
(section 1.4). These observations combined with the fact that both Glu184 and 
Asp187 do not coordinate the Ca^^ ion in this site in the homology model, despite 
their demonstrated role in the Ca^ dependence of ADAMTS13, suggest that this 
predicted model is incorrect with regards to this binding site. 
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a) ADAMTS13 
Aspigy 
Arg190 
Leu183 
Iu212 
Van 92 
b) ADAMTS5 
Leu370 
Thr378 
Figure 6.14 Site 3 binding site in ADAIVITS13 and its equivalent in ADAMTS5 
a) The ADAMTS13 metalloprotease domain was modelled on the known crystal structure of the 
ADAMTS5 and 4 metalloprotease domains, showing site 3 and predicted coordinating residues. The 
Ca^* ion is shown in pink, and the in the active site is shown in grey, b) The same site is shown in 
ADAMTS5. Both are viewed using Pymol software (De Lano scientific, USA). 
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The likely residue arrangement with regard to Ca^+ in this site would involve Asp 182, 
Leu183, Glu184, Asp187, Vail 92 and Glu212. This would provide 5 oxygens from a 
continuous sequence and 1 from another region, demonstrating typical type 2 Ca^* 
binding site coordination. Classification of this site as type 2 would explain the 
affinity found^"^^. 
In ADAMTS5, the type of residues involved and the fact that at least 1 water is 
involved in coordination, suggests that it may be of lower affinity than in ADAMTS13. 
This could only be fully elucidated by repeating experiments performed on 
ADAIVITS 13 with ADAMTS5 and its substrate. However, whatever the reason 
binds to this site in ADAIVITS family members containing a disulfide bond in this 
region, this loop cannot be stabilised in any other way in ADAMTS13 other than by a 
Ca^ ion binding. Perhaps in ADAMTS4 and 5 the loop is partially stabilised by a 
disulfide bond and partially by a ion binding. 
ADAMTS13 predicted site 3 ADAIVITS5 site 3 equivalent 
Residue Distance to (A) Residue Distance to (A) 
Asp182 1.95 Asp369 2.26 
Leu183 1.76 Leu370 2.34 
Arg190 2.75 Cys376 2.30 
Vail 92 3.08 Thr378 2.39 
Glu212 2.76 Glu398 2.32 
Table 6.3 predicted Ca-oxygen bond lengths in the ADAMTS13 site 3 C a * binding site compared 
to ADAMTS5 
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Kinetic analysis of the reaction between WT ADAMTS13 and VWF115, and D187A 
and VWF115 revealed a possible mechanism of action of this high affinity 
binding site. Time course analysis, performed by Rens de Groot, revealed Kcat/K^ 
values of -1.24 x10 M s ^ for WT ADAMTS13 and VWF115, This was reduced to 
-0.1 x10®M'^ s"^ for mutant D187A (Table 6.4). For WT ADAMTS13, the Km for 
VWF115 was 1.29|aM and Kcat was 1.31s'\ The corresponding values for D187A 
were 4.32|iM and 0.31 s \ The increase in Km suggests that the mutation in D187A 
affects the functional binding affinity between the substrate and the active site of the 
enzyme. The reduction in Kcat also suggests a reduction in substrate turnover, while 
the 13-fold reduction in catalytic efficiency is an overall measure of the decrease in 
proteolytic activity of the enzyme. 
These results link a mutation in this binding site to a reduction in functional 
substrate binding activity. This suggests that when Ca "^" binds to this site and 
stabilises this loop region, the substrate can then be optimally placed in the active 
site for efficient proteolysis. 
ADAMTS13 K c a l / K m , 10®M"'s"' 
Michaelis Menten 
K m , jjivi K c a t , S- , K o a t / K m , 10®M"^ S"^  
Wild-type 1.24 ±0.1 1.29 1.31 1.02 
D187A 0.1 ± 0.02 4.52 0.31 0.07 
Table 6.4 : Kinetic analysis of wild-type ADAMTS13 and mutant D187A proteolysis of VWF115 
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Chapter 7 
Conclusions and Future Directions 
7.1 Conclusions 
The aim of this thesis, initially, was to clarify the functional role of Ca^*, Zn^^ and 
other cations in ADAMTS13 and then to attempt to identify sites of interaction with 
Ca^\ A number of divalent cations were investigated for their ability to enhance 
ADAMTS13 activity against VWF115. The best understood was Zn^"", for which a 
KD(app) of ~1.5[iM was derived. This is in the same range as the value reported 
previously^®" and is well below the free Zn "^" ion concentration in plasma of ~15nM^^^. 
Interestingly, this value is high, considering that thorough dialysis of ADAMTS13 in 
conditioned media does not remove the Zn "^" ion, but does remove all traces of Ca^"", 
which binds to ADAMTS13 with an overall KD(app) of ~70|aM. The reason for this high 
Kdopp) remains unknown. Ba '^" was also found to affect ADAIVITSIS activity, but was 
not an efficient substitute for Ca^ "^  and bound with an appreciably lower affinity 
(~1.4ml\/l). 
It was demonstrated in this thesis that increasing Ca^* concentrations enhanced the 
rate of proteolysis of VWF115 by ADAMTS13. More importantly, this was also the 
case for ADAMTS13 in reaction with the full-length substrate, indicating the 
likerequirely physiological imprtance of for ADAMTS13 function, as previously 
reported^°®'^ ®®. The KD(app) I obtained (~70|iM) of ADAMTS13 for Ca "^" in reaction with 
VWF115 is in good agreement with that found previously using a short substrate^®". 
In my experiments this was confirmed, at least qualitatively, in full-length VWF 
assays, demonstrating that the overall KD(app) is well below physiological Ca^* 
concentrations. The result that the Ca^ dependence of ADAIVITS13 appeared the 
same, independent of substrate length, was not in agreement with previously 
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published data^®° which reported a Koopp) of ~5|al\/l in reaction with full-length VWF, 
and the reason for this discrepancy remains unclear. 
An observation in this thesis, not previously reported in the literature, is that 
ADAMTS13 requires a long pre-incubation time with Ca^ to be fully active. Without 
pre-incubation with Ca^* there is a lag phase, during which the enzyme is functioning 
sub-optimally. However, in most activity assays of ADAMTS13 previously performed, 
no pre-incubation of the enzyme with the reaction was mixture was described, 
although time points were long enough into the reaction that incomplete Ca^ binding 
at the start would probably not have appreciably affected the result^®". Also reported 
for the first time in this study is that Ca^* causes a change in Absggonm of ADAMTS13, 
indicative of a conformational change under low ionic strength conditions. It is 
unclear at this stage why the change in Abs280nm is abolished at high ionic strength, 
although a plausible explanation may lie in the ability of high ionic strength in the 
local environment of Trp residues to alter their absorbance potential. NaCl and other 
salts have been observed to have an effect on the emission spectra of Trp 
previously^^®"^®°. Alternatively, high ionic strength conditions may be inhibiting a Ca^*-
induced conformational change, or at least reducing its effect so that no change in 
AbS28onm Can be observed. It remains possible that a less pronounced conformational 
change might be seen with more thorough analysis using alternative methods (see 
section 7.2.1). Ca^"'-induced conformational changes have been previously reported 
to be reduced in magnitude by high ionic strength conditions^® '^^ ®^. The time of pre-
incubation with Ca^ required for efficient activity and the incubation time required for 
a change in AbS280nm to occur appeared similar. It is tempting to speculate that the 
time required for a possible Ca^+ dependent conformational change is functionally 
related to the lag time in activity. Lag phases in enzyme activation attributable to a 
conformational change from an inactive to an active state have been previously 
reported in other enzymes^®^. There are two other results that may support a 
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functional relationship. Firstly, it is demonstrated that the change in Abs28onm, 
occurred at high Ca^^ concentrations, with an EC50 value of ~ SSOpM. In determining 
the overall KD(app) of ADAMTS13 for Ca^^ in reaction with VWF115, initial rates 
between 200-600[aM did not increase. At Ca^^ concentrations of 800|il\/l upwards, a 
further, less pronounced increase in activity was observed, suggestive of further 
activation by high Ca^* concentrations. This further activation may be attributable to a 
induced conformational change. A second observation in support of the 
correlation between conformational change and pre-incubation time requirement is 
from the site 1 mutants. In the determination of KD(app) values for mutants E83A and 
D173A, no further increase in activity was seen with higher concentrations, with 
Vmax being reached at ~200iil\/l. The results on these mutants could not be fitted to a 
2-site binding model. These mutants also displayed no change in Absaaonm with 
under low ionic strength conditions, suggestive of a lack in conformational change, or 
at least a less pronounced change that could not be detected using the current 
method. Despite these data, the effects of these mutants on ADAMTS13 activity 
appeared minimal, at least in reaction with VWF115. Full-length assays, however, 
revealed that these mutations did, indeed, affect ADAI\/ITS13 activity against VWF. 
Taken together, a tentative model can be proposed based on these observations in 
which Ca^* causes a conformational change in the enzyme mediated by binding to 
site 1, which is required for efficient activity of the enzyme physiologically, but without 
which, ADAMTS13 can cleave VWF115 efficiently. Indeed, it has been recently 
reported that Arg349 in the disintegrin domain must interact with Asp1614 in VWF for 
effiecient cleavage to occur^ ®®. This requires a particular orientation of the 
metalloprotease domain and disintegrin domains of ADAMTS13 which may be 
achieved by Ca^* binding to site 1. VWF and ADAMTS13 were reported to have 
extensive exosite interactions with VWF A-domain binding sites in the spacer, 
cysteine-rich and TSP-1 domains^^^. The conformational arrangement of these non-
catalytic domains would therefore be important to the efficient function of the 
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enzyme. Thus, a conformational change induced by Ca^ binding may help to 
stabilise the interaction of ADAMTS13 with its large substrate, especially in the face 
of shear stress forces, which may otherwise be able to disrupt the binding interaction. 
However, further studies of a possible conformational change under physiological 
ionic strength need to be conducted to test and strengthen this hypothesis. 
At the start of the investigation, the site predicted to be responsible for the functional 
response of ADAMTS13 to Ca "^" was thought to be composed of Glu83, Asp173, 
Cys281 and Asp284, termed site 1. Recently published crystal structures of other 
ADAMTS family members revealed a common feature of ADAMTSI, 4 and 5 of a 
double binding site in the 'site 1' position instead of a single Ca^^ binding site, 
previously predicted for all three from modelling on Adamalysin 11^ '^^ '^ ^^ . In these initial 
ADAMTS family models, the Asn residue at position 200 in Adamalysin II is replaced 
by an Asp residue at the equivalent position. In ADAMTS13, at least, this was 
thought to be of small consequence as Asn and Asp are both widely demonstrated to 
be able to coordinate 032+155,183,257 yi'ig subsequent discovery of a double 
binding site in three members of the ADAMTS family demonstrated a new role of this 
Asp residue. Due to the acidic nature of its side chain, it was able to contribute two 
oxygen atoms to a double site, rather than just the one oxygen that Asn was 
able to provide^ '^^ '^ ^®. A new Asp residue appeared, from the crystal structures of 
ADAMTS1,4 and 5, to be contributing three oxygen atoms to the site as well as the 
previously identified residues. This new arrangement allowed one Ca^^ ion to be 
coordinated by six oxygen atoms from surrounding residues and one oxygen from 
water at the corners of a pentagonal bipyramid. This arrangement includes four 
acidic residues, providing a high degree of hydrophobicity contrast (section 1.4.1). 
The other Ca^* could be coordinated by five oxygen atoms from acidic residues and 
two water molecules. This new Asp residue was found in ADAMTSI 3 using 
sequence alignment with ADAMTS5, corresponded to Asp166, although there were 
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other acidic or polar residues found in the vicinity (Asn162, Glu164, Asp165, 
Asp168). The mutant D166A, however, cleaved both VWF115 and full-length VWF at 
similar rates to WT ADAMTS13, and it is therefore possible that surrounding acidic 
residues may instead be involved in the double Ca^ site. This double Ca^* site is 
rare in metalloproteases, although it has been observed in other types of enzyme. 
One such enzyme is cytosolic phospolipase A2, in whose C2 domain two Ca^* ions 
are bound in close proximity^®'^. Sites capable of binding multiple ions are a 
feature of C2 domains and they achieve this through positive cooperativity. Despite 
the formidable charge repulsion between bound divalent cations, two or more ions 
can therefore bind at the same site, the second binding with higher affinity than the 
first. Charge repulsion would be a similar problem in ADAMTS13 and other ADAMTS 
family members containing this feature, and ADAMTS13 may also use positive 
cooperativity to accommodate two Ca^* ions in this site. More direct binding studies 
would be needed to ascertain whether or not this is the case. 
My investigation revealed the presence of a new binding site in ADAMTS13. 
Designated site 3, it was predicted to comprise residues Glu184, Asp187 and Glu212 
by experimental analysis, and residues Asp182 and Val192 or Leu183 by modelling. 
The predicted structure modelled on ADAMTS4 and 5 displays incorrect Ca-oxygen 
bond lengths and so the exact residues involved will need to be identified either by 
further mutation of residues within the site or by crystal structure resolution. This site 
was shown to be responsible for the overall KD(app) of ADAMTS 13 for by 
mutation of residues in this site, which resulted in an appreciably increased KD(app) 
values and appreciable decreased V^ax values. The latter value demonstrated that 
mutations in this site are having a severe effect upon ADAMTS activity. This was the 
case for both the short VWF substrate, VWF115, and the full-length substrate. It was 
also observed that site 3 binds Ca^ independently of site 1, as mutant D187A still 
demonstrated an appreciable change in Abs28onm on incubation with Ca^^ under low 
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ionic strengtii conditions, whereas mutants of site 1 still displayed high affinity 
functional response to Ca^ and comparable activity to WT ADAMTSIS . Site 3 was 
first identified as a possible candidate for Ca^* binding because of structural similarity 
between the ADAMTS13 metalloprotease domain model and the known crystal 
structure of MMPS. This site was subsequently found in ADAMTS4 and 5 also, 
despite the presence of a disulphide bond stabilising the structure of the loop 
involved. On examination of various enzymes in the Metzincin superfamily, it appears 
that a disulphide bond in this region is unique to ADAMTS family members but a Ca "^" 
ion in this region is more commonly seen. Many MMPs were found to harbour a Ca "^" 
ion in an equivalent loop near the active site cleft on elucidation of their crystal 
structures, and in all cases were type II binding sites (section 1.4.1). The Metzincin 
superfamily can be subdivided into many different smaller families, but those that 
have been characterised at a structural level include seven: astacins, reprolysins, 
serralysins, matrix metalloproteases, snapalysins, leishmanolysins and pappalysins 
A topology scheme of the metalloprotease domain of the representative 
structures of each of these families has been made (Fig. 7.1). From these it appears 
that the site corresponding to Ca "^" binding site 1 in ADAMTS13 is also found in 
MMPs, again between the third and fifth beta sheets as in Adamalysin II (7.1e and f). 
This would suggest a common evolutionary origin since convergent evolution is 
reported to be rare in Ca^^ binding sites, with loss being far more common among 
distantly related family members^®®. Two Ca^ ions in this region, however, appears 
to be a feature of ADAMTS family members alone, and has not been previously 
reported prior to the elucidation of the crystal structures of ADAMTS4 and 5. A 
binding site corresponding to site 3 in ADAMTS13 is found in three families of 
Metzincins: snapalysins (FigT.ld), MMPs (Fig. 7.1 e), and reprolysins (Fig. 7.If). In 
Adamalysin II, however, this site does not exist, but my results and the crystal 
structures of the ADAMTS family metalloprotease domains demonstrate that this site 
is a feature of some reprolysins at least. This also implies a common evolutionary 
198 
origin and it has been suggested that the snapoiysin family may represent the 
structure of the common ancestor of all Metzincins^®®. A disulphide bond in this 
region, however, is unique to the ADAMTS family. Further study of Ca "^" binding sites 
in the Metzincins is required to elucidate how MMPs, snapolysins and ADAMTS 
metalloproteases came to bind Ca^^ in this region so close to the active site. 
The crystal structures of ADAMTS4 and 5 provide the most accurate model of the 
ADAMTS13 metalloprotease domain to date. The superimposition of these three 
models illustrates the extent of the sequence similarity between the Ca^ binding 
sites described (Fig. 7.2). Site 1 (Fig. 7.2a) in all three structures appears identical in 
orientation and residues involved. Site 3 (Fig. 7.2b) in the predicted model of 
ADAMTS13, as previously described, includes residues Asp187 and Glu184 but they 
do not appear to contribute to binding in this model as their acidic side chains 
are pointing away from the Ca^ ion. The superimposition demonstrates that the loop 
that contains these residues in ADAMTS13 appears to adopt the conformation of the 
equivalent loop in ADAMTS4 and 5 due to the presence of a disulphide bond in the 
latter models. In ADAMTS13 there is no disulphide bond in this region as Cys327 in 
ADAIV1TS4 is replaced by Arg190 in ADAMTS13. As such there are no free Cys 
residues in this loop region which could pair up to stabilise the loop. Because there is 
no structural reason why this loop would adopt such a closed conformation in 
ADAMTS13, it is reasonable to conclude that residues Asp187 and Glu184 may 
adopt a conformation that enables them to contribute to a functional Ca "^" binding 
site. 
This proposed mechanism of Ca^ interaction with ADAMTS13, involving one 
functional Ca^ binding site and a double site capable of inducing a conformational 
change in the enzyme, is a tentative model based on my own results and on the 
available literature on closely related crystal structures as well as general features of 
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Ca binding sites. Note that in the discussion of chapter 5, page 161, I also consider 
that site 1 could conceivably influence direct cleavage. Additional studies will be 
required to substantiate such a suggestion. A more refined model will undoubtedly 
emerge through crystallisation of the ADAMTS13 metalloprotease domain and other 
more quantitative studies of ADAMTS13 in reaction with full-length VWF. 
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Figure 7.1 Topology scheme of each of the Metzincin representative structures 
a) astacin, b) aeruginolysin, representative structure of tine Serralysins, c) leishmanolysin, d) Streptomyces 
caespitosus, of the snapalysins, e) MMP8, f)Adamalysin II. Circled in green is the position in which a Ca^* ion is seen 
in the crystal structures of ADAMTS4 and 5, and where site 3 is positioned in ADAMTS13, g) utilysin or the 
pappalysins. Taken from Gomis-Ruth (2009)^ . Labelled are the Zn^* and Ca^* ions. 
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a) 
Asp284 
Asp474 
Asp426 
Cys281 
Cys471 
Cys423 
Asp173 
Asp360 
Asp311 
Glu83 
Glu270 
Glu221 
Asp166 
Asp353 
Asp304 
b) 
Arg190 
Cys376 
Cys327 
Glu184 Leu183 
Leu370 
Leu321 
Asp187 Asp182 
Asp369 
Asp320 
Glu212 
Glu398 
GIU349 
7 
Van 92 
Thr378 
Thr329 
Figure 7.2 Superimposition of ADAI\/ITS4, 5 and 13 binding sites 
a) Site 1 in ADAMTS13 superimposed on tlie equivalent site in ADAMTS4 and 5, witti identical residues involved. 
ADAMTSIS is shown in grey, ADAMTS4 in pink and ADAMTS5 in blue, with residues in the corresponding colours. 
Ca^* is shown in green, b) as for a) but site 3 is shown. 
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7.2 Future work 
7.2.1 Studies of the conformational change of ADAIVITSIS 
The absorbance studies described in this thesis are limited as only one wavelength 
was used (280nm), whereas in other absorbance studies to measure conformational 
changes in proteins, a spectrum of different wavelengths is employed^®^. More widely 
used methods to observe conformational changes in a protein are by fluorescence or 
circular dichroism (CD) spectroscopy. Trp and Tyr were previously described to be 
the main residues responsible for absorbance of a protein at 280nm, and they are 
also natural fluorophores^®®. Trp has a high sensitivity to electronic excitation upon 
absorption of light over a range of wavelengths, mainly due to its indole moiety. 
Fluorescence emission occurs when the electronic excited state of the fluorophore 
returns to the ground state by emitting photons. The resulting fluorescence emission 
occurs at longer wavelengths than that of excitation because of energy loss from 
relaxation in the excited state. Fluoresence can be used as a measure of protein 
conformation because of the ability of the environment immediately around the 
fluorophore to affect its electronic excited state^®®'^ ®°. A fluorescence emission 
spectrum is usually measured between 300 and 400nm, with excitation at 295nm, 
creating a curve which may then be altered by Ca^^ binding, and subsequently 
causing a conformational change^®'*. Using ANS is a more indirect method of 
measuring conformational change involving fluorescence measurements^®®. ANS is a 
(ipohilic fluorescent dye which binds to hydrophobic patches on the surface of 
proteins, which changes its fluorescent properties. As a conformational change 
occurs, more or less hydrophobic patches may be accessible and so degree of 
conformational changes can be measured by fluorescence intensity of ANS. 
In circular dichroism (CD), the parameter measured is the difference in absorbance 
for left and right circularly polarised light. CD is an absorption phenomenon, and so 
the chromophores that contribute to a spectrum are the same as those contributing to 
conventional absorption spectrum^^\ The near-UV (340-255nm) CD bands of 
proteins (deriving from Trp, Tyr, Phe and Cys) reflect the tertiary and quaternary 
structure of the protein. The far-UV CD bands (deriving from peptide bond 
absorption) reflect the secondary structure of the protein. CD spectroscopy is widely 
used in the study of proteins because the CD spectra are sensitive to molecular 
conformation^®®'^ ®°'^ ® .^ It has particular features which would be useful for detection of 
a conformational change in ADAMTS13 in that it is extremely sensitive to changes in 
conformation (so could be used to study local conformational effects of Ca^^ binding 
to site 3), and a wide range of solvent conditions is accessible to study with very 
small amounts of protein required. 
7.2.2 Direct binding studies 
For many Ca^* binding proteins, direct binding studies can be performed using 
chromophoric chelators whose absorbance or fluorescence is Ca^* dependent. A 
mixture of equal amounts of chelator and protein is titrated with Ca^^ and binding to 
the chelator can be measured spectroscopically^®°. The Ca^* binding constants of the 
protein are derived by fitting the absorbance or fluorescence as a function of total 
Ca "^" concentration. This kind of study can only be done if the Ca^ binding site in 
question has roughly the same affinity for Ca "^" as the chelator, so that Ca "^" ions are 
evenly distributed between protein and chelator. However, most chromophoric 
chelators of Ca^ have very high affinities in the nM range e.g. Quin-2, 5N-
BAPTA^®°'^ ® .^ ADAMTS13 has an overall KD(app) of ~70(iM, so these chelators cannot 
be used. Another, rarely used, chelator of Ca^^ is Furaptra^®^ with Kd for Ca^^ of 
much closer to the Ca^^ affinity of ADAMTS13. This may be close enough 
to provide an accurate method of determining the direct binding affinity of 
ADAMTS13for Ca^\ 
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Another method to study binding in ADAMTS13 directly is through electrospray 
ionisation mass spectrometry (ESl-MS). ESI-MS can provide information about metal 
ion partitioning and the sequence of metal ion binding^®". Metal- bound and metal-
free protein have different mass spectra, depending on how many Ca^* ions are 
bound, with each Ca^^ adding 40Da to the molecular weight of the protein species^®". 
The mass spectra can be determined at various concentrations and thus the 
binding affinity can be determined. One drawback of this method is that it can only be 
achieved accurately with a protein <30kDa. The molecular weight of ADAMTS13 is 
190kDa, but the metalloprotease domain alone is only ~28kDa. 
7.2.3 Further investigation of site 1 
The exact nature of site 1 as a functional binding site in ADAMTS13 has 
remained semi-elusive during this investigation. This has been mainly due to the lack 
of involvement of this site in ADAMTS13 interaction with VWF115, the substrate on 
which kinetic studies of Ca^ "^  enhancement of ADAMTS13 were done. From the 
results presented in this study, it appears that the full-length substrate may provide 
more answers if an accurate determination of binding affinity of ADAMTS13 in 
reaction with VWF can be achieved. In the studies performed previously^®", KD(app) 
was determined by densitometric analysis of the 350kDa VWF band. This could be 
achieved in a similar manner here to determine the Ca "^" dependence of ADAMTS13 
against VWF. 
Further mutation of residues in the potential double Ca^^ binding site is required to 
ascertain exactly which residues are involved in coordinating this site. It appears that 
Asp166 may not be involved, but mutants N162A and E164A display an appreciably 
reduced rate of activity against full-length VWF. Mutants D165A and D168A could 
also be made to identify which residue exactly is providing oxygen atoms to both 
Ca^* ions corresponding to Asp365 in ADAMTS5. Stable cells lines of all mutants in 
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this double site would be useful to make to test their Absasonm or to use in new assays 
to determine the conformational change more accurately (section 7.2.1). A disulphide 
bond could also be engineered in this site to observe whether or not still affects 
the site and induces a conformational change, or whether ADAMTS13 becomes 
locked in a stable conformation. It would be useful to examine pre-incubation time 
requirements for mutants of this site to ascertain whether or not the lag phase 
observed in ADAMTS13 activity without prior incubation with Ca^ is due to the 
conformational change in the enzyme caused by Ca "^" binding and associating slowly. 
7.2.4 Further investigation of site 3 
There is a discrepancy between my results of the residues involved in this binding 
site and those predicted by the model of the ADAMTS13 metalloprotease domain 
based on ADAMTS4 and 5. Further residues in this site could be mutated to identify 
exactly which residues are involved at a functional level, combined with direct binding 
studies (section 7.2.2). Again, a disulphide bond could be engineered in this site by 
mutating selected residues to Cys, to see if Ca^^ dependence of this site is abolished, 
but activity maintained. Both mutants D187A and E212A in reaction with VWF115 
demonstrated residual activity, it would be necessary to determine whether this 
activity could be attributed to binding to site 1 and contributing to activity or 
whether site 3 had not been completely knocked out, and so some residual 
enhancement of the enzyme was still possible. A double or triple mutant of this site 
would help ascertain which scenario was responsible for this residual activity. As well 
as making mutations in both sites at once to try to completely abolish activity if it is 
the latter scenario. 
205 
7.2.5 Investigation of other domains in ADAIVITSI3 
Studies so far have concentrated on the metalloprotease domain of ADAMTS13 as 
this was the only domain for which a model could be made. CUB domain 1 is 
homologous to the CUB domain 1 of procollagen C-proteinase 1 with a high degree 
of sequence similarity between them, the latter of which has been found to contain a 
Ca "^" binding site^®®, and the residues involved are conserved in ADAMTS13. This 
site could be investigated for Ca^ "^  dependence by mutating residues therein and 
repeating the assays carried out in Chapters 5 and 6. 
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Chapter 9 
Appendices 
Appendix 1: Vectors and Primers 
Vector name Description 
pcDNA3.1 ADAMTS13 Wild type ADAIVITS13 with a myc His C-
terminus tag 
PCDNA3.1 ADAMTS13 N162A Protease domain ADAMTS13 mutant 
PCDNA3.1 ADAMTS13 E164A Protease domain ADAi\/lTS13 mutant 
PCDNA3.1 ADAMTS13 D166A Protease domain ADAIVITS13 mutant 
PCDNA3.1 ADAMTS13 E212A Protease domain ADAIVITS13 mutant 
pcDNA3.1 ADAMTS13 E83A Protease domain ADAIV1TS13 mutant made by 
Dr. Alain Chan Kwo Chion 
pcDNA3.1 ADAMTS13 D173A Protease domain ADAMTS13 mutant made by 
Dr. Alain Chan Kwo Chion 
pcDNA3.1 ADAMTS13 D284A Protease domain ADAMTS13 mutant made by 
Dr. Alain Chan Kwo Chion 
pcDNA3.1 ADAMTS13 
E83A/D173A 
Protease domain ADAI\/ITS13 mutant made by 
Dr. Alain Chan Kwo Chion 
pcDNA3.1 ADAMTS13 D187A Protease domain ADAMTS13 mutant made by 
Rens de Groot 
pcDNA3.1 ADAMTS13 El 84A Protease domain ADAMTS13 mutant made by 
Rens de Groot 
pETlOO VWF115 115aa peptide VWF fragment with a N-terminal 
His tag and Xpress epitope 
pET100VWF76 76aa peptide fragment with a N-terminal His 
tag and Xpress epitope. Made by Dr James 
Crawley 
Table 9.1: Vector constructs generated. 
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Primer name Amino acid 
changed 
Direction Primer Sequence (5' to 3') 
ADAMTS13-
N162A 
N to A Forward GCCAGACCATCGGCCCTGAG 
GACGACAOGG 
ADAMTS13-
N162A 
N to A Reverse CCGTGTCGTCCTCAGGGCCG 
ATGGTCTGGC 
ADAMTS13-
E164A 
E to A Forward GACGATCAACCCTGCGGAGG 
ACAGGGATCG 
ADAMTS13-
E164A 
Eto A Reverse GGATCCGTGTCGTCGGCAGG 
GTTGATGGTC 
ADAMTS13-
D166A 
D to A Forward CAACCCTGAGGACGGCAGGG 
ATCCTGGCC 
ADAMTS13-
D166A 
D to A Reverse GGCCAGGATCCGTGGCGTCC 
TCAGGGTTG 
ADAMTS13-
E212A 
Eto A Forward GTGGCTGATTACCGCGGACA 
GTGGGTTGGAG 
ADAMTS13-
E212A 
E to A Reverse GTGGAAGGGAGTGTGGGGGG 
TAATGAGGGAG 
ADAMTS13-
E83A 
Eto A Forward GGGATGGTAGAGGTGGGGGT 
GGGGGTG 
ADAMTS13-
E83A 
Eto A Reverse GGGTAGGATGTGGAGGAGGA 
GGGGGAG 
ADAMTS13-
D173A 
D to A Forward GATGGTGGGGATGGTGGGGT 
GGTGGTGTATATG 
ADAMTS13-
D173A 
D to A Reverse GTAGGAGGGGTAGGAGGGGA 
GGAGGAGATATAG 
ADAMTS13-
E83A/D173A 
Eto A 
D to A 
Forward Sub cloning E83A insert into 
D173A vector 
ADAMTS13-
E83A/D173A 
E to A 
D to A 
Reverse Sub cloning E83A insert into 
D173A vector 
ADAMTS13-
D187A 
D to A Forward GGTGTGGGGGTTAGGATGAG 
GGGCGTGCAGGTGAAGGTAG 
T 
ADAMTS13-
D187A 
D to A Reverse GGAGCTGGGGGTTAGGAGGA 
GGGAAGTGGAGGTGAAAGG 
ADAMTS13-
E184A 
EtoA Forward G G GATGGTAGAGCTGG GG GT 
GGGGGTG 
ADAI\/ITS13-
E184A 
Eto A Reverse GGGTAGGATGTGGAGGAGGA 
GGGGCAC 
Table 9.2: Primers used to generate vector constructs in table 1 
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Appendix 2: Buffers 
Buffers for Agarose gel electrphoresis 
5XDNA loading buffer; 0.125% (w/v) xylene cyanol, 0.125% (w/v) bromophenol blue, 
0.625% SDS (w/v), 20% (v/v) glycerol 
10X TBE buffer: 0.89M Tris-borate (pH8.3), 20mM EDTA. Prior to use, this was 
diluted to 1XTBE buffer with purified water. 
Buffers for SDS-PAGE eletrophoresis 
SDS-PAGE electrophoresis buffer: 25mM Tris-HCI (pH8.3), 192mlVI Glycine, 0.1% 
(w/v) SDS 
2X protein loading buffer: 150mM Tris-HCI(pH6.8), 20% (v/v) glycerol, 4% (w/v) SDS, 
0.125% (w/v) bromophenol blue 
Buffers for Native PAGE gel electrophoresis 
NativePAGE sample buffer: 50mM BisTris, 6N HCI, 50mM NaCI, 10% w/v Glycerol, 
0.001% Ponceau S 
NativePAGE running buffer: 50mM BisTris, 50mM Tricine, pH6.8. 
NativePAGE Cathode buffer: 0.1% Coomassie G-250 in 250ml pure water 
PBS buffer 
Dissolve 5 PBS tablets (Sigma) to 1 litre of distilled H2O 
Transfer Buffer 
25mM Tris-HCI (pH8.4), 182mM glycine, 20% (v/v) methanol 
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Appendix 3: Broth and agar 
LB Broth ( 500 ml) 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCI 
2XYT Broth (1L) 
1.6% (w/v) bacto-tryptone, 1% (w/v) bacto-yeast extract and 0.5% (w/v) NaCI 
SOC medium 
2% (w/v) bacto-tryptone, 0.5%(w/v) bacto-yeast extract, 10mM NaCI, 2.5mM KCI, 
10mM MgCIa, 10mM MgS04, 20mM Glucose 
LB agar (250ml) 
1% (w/v) bacto-tryptone, 0.5% (w/v) bacto-yeast extract, 1% (w/v) NaCI, 1.5% bacto-agar 
(The components of each medium are dissolved in ultra-pure water and autoclaved) 
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THROMBOSIS AND HEMOSTASIS 
A functional calcium-binding site in the metalloprotease domain of ADAMTS13 
Michelle D. Gardner / Chan K. N. K. Ch ion/ Rens de Groot / Anuja Shah / James T. B. Crawley/ and David A. Lane' 
'Department of Haematology, Imperial College London, London, United Kingdom 
ADAMTS13 regulates the multimeric size 
of von Willebrand factor (VWF). Its func-
tion is highly dependent upon Ca^+ ions. 
Using the initial rates of substrate 
(VWF115, VWF residues 1554-1668) prote-
olysis by ADAMTS13 preincubated with 
varying concentrations, a high-
affinity functional ADAIVITS13 Ca^+-
binding site was suggested with Kpiapp) of 
80 (jiM ( ± 1 5 ixlVI) corroborating a previ-
ously reported study. When GluBS or 
Asp173 (residues involved in a predicted 
Ca^+-binding site in the ADAMTSI3 metal-
Introduction 
loprotease domain) were mutated to ala-
nine, Ca2+ dependence of proteolysis of 
the substrate was unaffected. Conse-
quently, we sought and identified a candi-
date Ca^+-binding site in proximity to the 
ADAMTS13 active site, potentially com-
prising Glu184, Asp187, and Glu212. Mu-
tagenesis of these residues within this 
site to alanine dramatically attenuated the 
KD(app) for Ca2+ of ADAMTSIS, and for 
D187A and E212A also reduced the V^ax 
to approximately 25% of normal. Kinetic 
analysis of the Asp187 mutant in the 
presence of excess Ca^+ revealed an ap-
proximately 13-fold reduction in specific-
ity constant, kcat/Km, contributed by 
changes in both Km and kcat- These re-
sults were corroborated using plasma-
purified VWF as a substrate. Together, 
our results demonstrate that a major influ-
ence of Ca^+ upon ADAI\/ITS13 function is 
mediated through binding to a high-
affinity site adjacent to its active site cleft. 
(Blood. 2009;113:1149-1157) 
von Willebrand factor (VWF) is a large multidomain glycoprotein 
that circulates in plasma as covalently associated multimers of 
varying size (2-40 VWF units). ' VWF has 2 major hemostatic 
functions: (1) to form a bridge between the damaged vessel wall 
and platelets; and (2) as a carrier protein for factor VIIL'-^ The first 
hemostatic event following disruption of the endothelium involves 
VWF binding to exposed matrix proteins. Normally, VWF circu-
lates in plasma in a globular form. However, once bound to 
subendothelial collagen, the shear forces exerted by the flowing 
blood cause VWF to unfold and in turn adopt an elongated 
conformation. In this form, VWF binds to the GPIb-IX-V receptor 
complex on the surface of circulating platelets, resulting in their 
tethering and the ultimate formation of a primary platelet plug.'-^ 
Large V W F multimers are more adhesive than smaller forms 
because they contain more platelet- and collagen-binding sites and 
more readily unravel in response to shear forces. V W F multimers 
are synthesized intracellularly in a 2-stage process—first by 
dimerization in the endoplasmic reticulum and then by multimeriza-
tion of these dimers in the Golgi apparatus.'' Following their 
secretion from endothelial cells, VWF multimers can be converted 
to a smaller, less adhesive form by the plasma metalloprotease, 
ADAMTS 13.5-10 
ADAMTS13 is expressed predominantly in the liver." It has 
also been shown to be expressed in hepatic stellate c e l l s , i n 
platelets,'^ by cultured endothelial c e l l s , a n d by glomerular 
podocytes.'^ It is secreted into the blood as an active enzyme and 
circulates at a plasma concentration of approximately 5 n M , " '''-'® 
ADAMTS13 cleaves VWF at a single site in its A2 domain at the 
Tyr l605-Met l606 bond." '^ ' Physiologically, this can only occur 
once V W F has first been unraveled in response to rheologic shear 
forces. In vitro, cleavage of multimeric VWF by ADAMTS 13 
requires denaturants or flow/shear to enable access of the metallo-
protease to the A2 domain scissile bond.^ The lower-molecular-
weight VWF multimers that arise following proteolysis exhibit 
reduced adhesive potential. ' In this way, ADAMTS 13 modulates 
VWF platelet-tethering function. 
The domain structure of ADAMTS 13 comprises a metallopro-
tease domain, disintegrin-like domain, thrombospondin type 1 
repeat, cysteine-rich domain, and spacer domain, characteristic of 
all ADAMTS family members. Thereafter, 7 additional throm-
bospondin type 1 repeats occur, followed by 2 C-terminal CUB 
d o m a i n s . T h e VWF-cleaving function of ADAMTS 13 is highly 
dependent on divalent cations.^" This is demonstrated by the 
observation that EDTA, which chelates such metal ions, renders 
ADAMTS 13 completely inactive. A major reason for this is the 
removal of the active site Zn^^ ion. The coordination of a Zn^+ ion 
in the active site is essential for hydrolysis of the target peptide 
bond.® Like all ADAMTS family members, ADAMTS 13 contains a 
characteristic active site motif in the metalloprotease domain that 
consists of 3 histidine residues that coordinate the catalytic Zn^* 
ion. This sequence (HEXXHXXGXXHD) is highly conserved 
among all family members.® 
In addition to Zn^+, Ca^+ is also critical for the proteolysis of 
VWF by ADAMTS 13.^ 0.23 ^ potential Ca^+-binding site in the 
ADAMTS 13 metalloprotease domain has been predicted, based on 
its homology with adamalysin 11.®-^ '' In this model of ADAMTS 13, 
a single Ca-+ ion is proposed to be coordinated by Glu83, Asp 173, 
Cys281, and Asp284 in the metalloprotease domain. However, 
although its importance may have been assumed, the functionality 
of this site has yet to be demonstrated. The exact contribution of 
Ca^+ to ADAMTS 13 function has not been fully elucidated. Early 
studies provided some insight into the role of divalent cations in 
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ADAMTS13 function. However, there also exist conflicting data: 
Tsai suggested that possibly only trace amounts of Ca?'*' were 
sufficient for full ADAMTS13 activity.^® Furl an et al suggested that 
whereas 10 mM Ca^+ or Sr^+ appreciably activated ADAMTS 13, 
10 mM Ba^+ maximally activated the enzyme.^' This latter conten-
tion suggested that ADAMTS 13 might be unique among metallo-
proteases in its preference for Ba^"^ over Ca^+. Perutelli et al 
reported efficient cleavage of the recombinant VWF A2 domain by 
ADAMTS 13 without the addition of metal ions .^ Anderson et al 
carried out the first systematic experimental investigation of the 
role of Ca^+ in ADAMTS 13 f u n c t i o n . I n that study, the authors 
reported an overall Kn(app) of 4.8 (xM ( ± 3.0 (xM) for the Ca^+ ion 
dependence of ADAMTS 13 function using multimeric VWF as a 
substrate in the presence of denaturants. The authors also used a 
fluorescent peptide substrate, FRET-VWF73 (a short recombinant 
VWF A2 domain fragment^''), to study ADAMTS 13 metallopro-
tease metal ion dependence. Their results demonstrated that 
ADAMTS 13 activity was undetectable in the absence of both Zn^* 
and Ca^+ ions, and that ADAMTS 13 was markedly enhanced by 
Ca^+ ions. A Ko^app) of approximately 60 p,M for Ca^+ for the 
proteolysis of FRET-VWF73 by ADAMTS 13 was reported. To 
endeavor to rationalize the discrepancies between different pub-
lished reports, and to more fully characterize the functional 
Ca^"^-binding site(s) in ADAMTS 13, we have examined the 
molecular basis of the Ca^+ dependence of ADAMTS 13 activity. In 
this report, we provide evidence for the presence and location of a 
high-affinity functional Ca^+-binding site in the ADAMTS 13 
metalloprotease domain. 
Methods 
Expression and purification of recombinant ADAMTSI3, VWF, 
and VWF115 
Recombinant purified human wild-type ADAMTS 13 with a C-terminal 
Myc/His tag expressed in HEK293 cells was prepared and purified as 
previously described.^^'^" Mutagenesis of potential Ca^^-binding residues 
was performed using the Quikchange site-directed mutagenesis kit (Strat-
agene. La Jolla, CA) according to the manufacturer's instructions. All 
vectors were verified by sequencing. Wild-type ADAMTS 13 and its 
mutants were also expressed transiently in HEK293T cells using linear 
polyethylenimine (Polysciences, Warrington, PA) for transfection. Prior to 
use, both fully purified ADAMTS 13 and transiently expressed ADAMTS 13 
in conditioned media were extensively dialyzed in 20 mM Tris (pH 7.8) 
using double deionized water (to ensure the absence of trace concenfrations 
of any divalent cations). The ADAMTS 13 concentration was determined 
using a specific in-house ADAMTS 13 enzyme-linked immunosorbent 
assay (ELISA), as previously described." The VWF A2 domain fragment, 
VWFl 15 (spanning VWF residues 1554-1668) was expressed, purified, and 
quantified as previously described for use as a specific ADAMTS 13 
metalloprotease domain substrate.^' Full-length VWF was purified from 
plasma and quantified as previously described.'' 
ADAMTS13 activity assays 
For time-course analysis of VWF 115 proteolysis, 20 nM purified recombi-
nant ADAMTS 13 or 1 nM of expressed ADAMTS 13 in conditioned media, 
both in 20 mM Tris-HCl (pH 7.8), 150 mM NaCI, and 0 to 8 mM CaCl; (as 
indicated) were preincubated at 37°C for 1 hour without VWFl 15 (unless 
otherwise stated). Thereafter, 1.6 (iM VWFl 15 was added to start the 
reaction followed by incubation at 37°C. At different time points, 60 p-L 
subsamples were removed, and reactions were stopped with 5 p.L 0.5M 
EDTA. VWFl 15 proteolysis was quantified by high-performance liquid 
chromatography (HPLC) as previously described.^' For investigation of 
metal ion dependence, reactions were set up as above, except ADAMTS 13 
in dialyzed conditioned media was preincubated for 1 hour at 37°C in 
20 mM Tris-HCl (pH 7.8), 150 mM NaCI, and 10 mM metal ion (CaCl2, 
BaCli, MgClz, NiS04, MnCl?, or CUSO4). The specificity constant, kca/Km, 
of wild-type ADAMTS 13 and mutant with D187A (at 5 mM Ca-"*") were 
also determined from time-course experiments with the substrate concentra-
tion below 1.0 p,M, as described.® Michaelis-Menten plots were then used 
to determine individual and k^ at values.^' 
To determine the Ca^+ dependence of ADAMTS 13, the KD(app) (ie, the 
cation concentration required for a half maximal response [V„,ax/2]) was 
derived. For this, activity assays were set up as above using a range of Ca^+ 
concentrations (0-8 mM). Thereafter, early time points (0-10 minutes) were 
taken so that the proteolysis reactions were in the linear part of the 
time-course curve (ie, less than 15% VWFl 15 proteolysis). HPLC was used 
to quantify VWFl 15 cleavage, from which the initial rate of substrate 
proteolysis was determined. Data were fitted to parabolic plots, and the 
K,)(app) for Ca^+ was determined by Graph Pad Prism 4 software (GraphPad, 
San Diego, CA) using the following equation: Y = (V^a^ X [Ca-+]/ 
(Kocapp) + [Ca^"^])), where Yis the initial rate of VWF115 proteolysis. 
The Zn2+ dependence (KD(app)) of ADAMTS13 was determined as in 
the equation except that ADAMTS 13 was pretreated with EDTA and then 
extensively dialyzed and equilibrated into 20 mM Tris (pH 7.8) and 
150 mM NaCI. This was then preincubated with 5 mM CaCl2 prior to 
adding VWFl 15 in the presence of a range of Zn-+ concentrations 
(0-100 p.M). After 5 to 10 minutes, reactions were stopped, and the initial 
rates of VWFl 15 proteolysis were determined before derivation of the V,„ax 
and Kotapp), as described. 
To ensure that our expressed ADAMTS 13 was fully bound to Zn-+, samples 
were treated with 15 mM EDTA for 30 minutes, dialyzed in 5 L 20 mM Tris-HCl 
(pH 7.8) for 4 hours, dialyzed again in 5 L 20 mM Tris-HCl with 500 |xM ZnCli 
for 4 hours, and finally equilibrated in 5 L 20 mM Tris-HCl and 150 mM NaCI 
for 4 hours. The initial rate of VWFl 15 cleavage was compared with 
ADAMTS 13 that had not been treated with EDTA. Time-course reactions 
demonstrated that the initial rate for ADAMTS 13 treated with EDTA was 
0.23 nMs~' compared with 0.25 nMs~' for ADAMTS 13 not subjected to EDTA 
and cation resupplementation. The V^ a^x was also restored to its previous level by 
this protocol. These experiments demonstrated that resupplementation of divalent 
cations reversed the effect of EDTA. They also indicate that ADAMTS 13 freshly 
expressed into conditioned media already contains Zn^ "*" in the active site. 
Therefore, in all assays (except those examining Zn-+ dependence) it was 
assumed that after dialysis the ADAMTS 13 remained fully coordinated to Zn-"*" 
but that all bound Ca-+ had t)een removed at the start of the experiment. 
Purified plasma-derived VWE was also used as a substrate for 
ADAMTS 13, using a previously reported activity assay.-' For this, VWF 
was incubated with 1.5 M guanidine-HCI at 37°C for I hour. The denatured 
VWF was then diluted at least 10-fold to a final concentration of 80 nM into 
150 mM NaCI, 20 mM Tris-HCl, and 5 mM CaCh buffer, in which 5 nM 
ADAMTS 13 had been preincubated for 60 minutes. The reaction was 
incubated at 37°C for I hour before quenching with 10 p-L 0.5 M EDTA. 
The cleavage products were detected by multimer gel analysis and 
collagen-binding assay as previously described. 
Molecular modeling of ADAMTS13 metalloprotease domain 
ADAMTS 13 metalloprotease domain was modeled using its sequence homol-
ogy to adamalysin II and the coordination for the crystal structure of this 
domain-'' (protein database file name HAG) using the SWISS-MODEL server.^ 
Models were manipulated using Pymol software (Delano Scientific, Palo Alto, 
CA). Areas of dense surface negative charge were sought, and amino acids were 
identified that may comprise putative Ca-+ binding sites. 
ADAMTS13 UV absorbance 
To measure Ca^"'"-dependent conformational changes in ADAMTS 13, the 
absorbance at 280 nm UV light (AbS28o) by fully purified wild-type 
ADAMTS 13 or ADAMTS 13 E83A, DI73A, and DI87A mutants was 
measured using a UV-160I spectrophotometer (Shimadzu, Kyoto, lapan). 
For this, I p-M ADAMTS 13 in 20 mM Tris-HCl (pH 7.8) was incubated 
with varying concentrations of CaCl2 (0-8 mM) in the presence or absence 
of 150 mM NaCI. Abs2st) was measured every minute for 60 minutes. Data 
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Figure 1. dependence of the VWF115 proteoly-
sis by ADAMTS13. (A) 20 nM purified ADAMTS13 in 
150 mM NaCI, 20 mM Tris-HCI (pH 7.8) was preincu-
bated with 5 CaCl2 for 60 minutes (+ Preinc), 0 min-
utes {-Preinc), or in the absence of CaCl2 (-Ca^-^) 
before addition of 1.6 |j.M VWF115 substrate. Reactions 
were Incubated at 37*^ and stopped with EDTA, and 
VWF115 cleavage was quantified by HPLC. (B) The 
reaction conditions were as in panel A, but initial rates of 
substrate proteolysis by fully purified ADAMTS13 were 
determined as a function of preincubation time with 5 mM 
CaClg. (C) Reactions were set up again as in panel A, 
except that tlie concentration of CaCl2 was vaned and the 
Ko(app) i ± SD; n = 4) was derived for purified AD-
AMTS13. (D) 1 nM of ADAMTS13 in dialyzed conditioned 
medium was used under identical conditions to that used 
in panel C, and the (± SD; n = 4) was again 
derived. (E) 1 nM of ADAMTS13 in dialyzed conditioned 
medium was studied as in panel A, except that preincuba-
tion was performed in the presence of 10 mM (final 
concentration) of CaCl2, BaCig, MgCl2, NiS04, IVInClg, or 
CUSO4. (F) 1 nM ADAMTS13 was pretreated with 15 mM 
EDTA to remove the Zn^+ ions, dialyzed and equilibrated 
in 150 mM NaCI, 20 mM Tris-HCI (pH 7.8), 5 mM CaClg, 
and varying concentrations of ZnCl2 between 0 and 
100 fxM for 60 minutes at 37°C before addition of 1.6 (xM 
VWF115 substrate. Reactions were stopped with EDTA 
after 10 minutes and proteolysis analyzed by HPLC, from 
which a KD(app) for Zn^+ of 1.5 jxM {± 0.6 |jlM) was 
derived. 
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were fitted to a sigmoidal dose response curve using Prism software 
(GraphPad), from which the half maximal response (EC50) was determined. 
Results 
Ca^+ dependence of ADAMTSIS-mediated proteolysis of 
VWF115 
To first assess the Ca^+ dependency of ADAMTS13, time-course 
experiments were conducted. Initial experiments (Figure lA-C) 
used fully purified ADAMTS13. Under the assay conditions used, 
almost no proteolysis of V W F l 15 substrate occurred using puiified 
ADAMTS13 unless Ca^+ ions were added to the reaction buffer 
(Figure lA) . This showed that purification and dialysis of 
ADAMTS13 was able to remove essentially all functional Ca^+, 
but it did not remove the active site-bound Zn^+ (known to be 
essential for any activity), and that any trace divalent metal ions in 
the buffers used were unable to appreciably activate the protease. In 
time-course reactions in the presence of Ca^+ set up without prior 
preincubation with this cation before the addition of VWFl 15, we 
detected a "lag phase" in VWFl 15 proteolysis, whereas this was 
not evident when ADAMTS13 was preincubated with Ca^+ for 
1 hour prior to the addition of VWFl 15 (Figure I A). To confirm 
this finding, and to determine the optimal Ca^+ preincubation time 
required to "activate" ADAMTS13, the initial rate of VWF115 
proteolysis was titrated as a function of Ca^+ preincubation time. 
These results confirmed that Ca^+ ions do not fully activate 
A D A M T S 1 3 immediately. Indeed, the full activation of 
ADAMTS13 by Ca^+ took 40 to 50 minutes, even at high Ca^+ 
concentrations (5 mM) much higher then the previously reported 
suggesting that complete association of this cation takes 
place comparatively slowly (Figure IB). 
To investigate further the Ca^+ dependence of purified 
ADAMTS13, the influence of Ca^+ concentration upon the initial 
rate of V W F l 15 proteolysis was determined. Following 1 hour of 
preincubation of ADAMTS13 with varying concentrations of Ca^+ 
(0-5 mM), VWFl 15 was added and reactions were stopped after 
5 or 10 minutes. To ensure accurate kinetic analyses, initial rates of 
V W F l 15 proteolysis were determined from samples with less than 
15% substrate cleavage. Using purified ADAMTS13, a mean 
( ± SD; n = 4) Ko^app) for Ca^+ of 80 |xM ( ± 15 ixM) was deter-
mined (Figure IC). This value is in good agreement with the data 
reported by Anderson et al (60 ± 25 p.M) using FRET-VWF73.2'' 
Using ADAMTS13 that had been expressed in conditioned me-
dium, concentrated and then thoroughly dialyzed, a very similar 
value of 70 |xM ( ± 20 puM) was obtained (Figure ID). It was 
noted, however, that despite the similarity in these Ko(app) values, 
the maximal activity (V^^) of purified ADAMTS13 was apprecia-
bly lower than that of ADAMTS13 in dialyzed conditioned media 
(compare Figure IC and ID). Moreover, lower ADAMTS13 
antigenic concentrations in conditioned media (1 nM compared 
with 20 nM) were needed to proteolyse the substrate at a similar 
rate. This reduced V ^ ^ was attributed to loss of activity during 
purification (indeed, determination of k^ai and K,,, values of 
ADAMTS13 in conditioned media containing Ca^+ produced 
estimates of k^a/K,,, that were approximately 10-fold increased 
compared with values we have published using purified 
ADAMTS13^' ; see below). This reduction in V^ax was a potential 
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obstacle for ttie comparison of responses of fully purified mutants 
(see below) to Ca^+. Consequently, the Ca^+ induced functional 
responses of wild-type and mutant ADAMTS13 against substrate 
( V W F l l S and full-length VWF) proteolysis were subsequently 
compared using extensively dialyzed conditioned media samples 
rather than purified material. 
The activity of ADAMTS13 in the presence of different metal 
ions was also determined. This demonstrated that Ca^"^ is the most 
potent activating divalent cation out of 6 (Ca^+, Ba^+, Mg-+, Mn^+, 
Ni^+, and Cu-+) tested (Figure IE). Ba^+ was the only other metal 
ion to have any appreciable effect on ADAMTS13 activity, which 
is compatible with prior reports in the literature.^® It has been 
suggested that Ca^+ and act synergistically with respect 
to ADAMTS 13 activity.2'' To explore the Zn^+ dependence of 
activity, ADAMTS 13 in selected experiments was pretreated with 
EDTA to remove all cations as described in "Methods," preincu-
bated with 5 mM Ca^+, then titrated with . Figure IF 
demonstrates an absolute requirement of Zn^+ for activity. Fitting 
the results of Figure IF to the equation in "Methods" revealed a 
Kd(app) of 1.5 |j,M ( ± 0.6 jjlM). 
Ca^+ induces a conformational change in ADAMTS13, but only 
under low-ionic-strength conditions 
To examine the possibility of conformational changes induced by Ca^^ 
ions, the change in Absigo of purified ADAIVITS13 was examined over 
time in the presence of 5 mM Ca^^. We detected a large change in 
Abs2go of ADAMTS 13 in response to Ca^+, but only in the absence of 
NaCl. At 0 minutes, ADAMTS 13 Abs28o was the same in all samples. 
However, in the presence of Ca^+, the Abszgo had increased markedly 
over the course of 1 hour, whereas it remained unchanged in the absence 
of Ca^+ or in the presence of 150 mM NaCl (Figure 2A). These data are 
indicative of a conformational change in response to Ca^^ binding that 
alters the relative exposure/orientation of surface residues such as Trp, 
Tyr, and Phe. Further analyses revealed that this change in absorbance 
occurs slowly, with the Absiso increase only detectably starting after an 
approximately 20-rninute lag phase, and reaching completion after 
approximately 50 minutes (Figure 2B). Using a 1-hour preincubation 
time, the Ca^ "*" concentration dependence of this change was titrated 
(Figure 2C), revealing an ECso value of 880 p.M, which is appreciably 
higher than the kineticaUy derived Kpf^pp)value of 70 to 80 (xM for 
VWF115 proteolysis (Figure 1C,D). The change in AbS28o induced by 
Ca^+ could conceivably be attributed to aggregation of the sample. This 
possibility was discounted by electrophoresis of ADAMTS 13 on a 
native PAGE gel in the presence and absence of NaCl and CaCl;, which 
showed that ADAMTS 13 migrated as a distinct band (data not shown). 
These observations, together with the need to omit NaCl to observe the 
conformational change, suggests that the influence of Ca^^ observed in 
Figure 2 is mediated through a distinct site to that determining the 
high-affinity proteolysis response observed in Figure 1. 
Modeling of ADAMTS13 metalloprotease domain 
As there are no structural data on ADAMTS 13 to date, modeling of 
the ADAMTS 13 metalloprotease domain using the known adama-
lysin II structure was done to search for putative Ca^+-binding 
sites. From this, the Ca^^-binding site predicted by Zheng et al'' is 
apparent (Figure 3A). This putative Ca^"^-binding site involves 
Glu83, Aspl73, Cys281, and Asp284 in ADAMTS 13, and is called 
Site 1. Glu83 and Asp 173 are perfectly conserved. Cys281 is 
predicted to coordinate Ca^+ through its carbon backbone rather 
than the amino acid R-group. This site is on the opposite side of the 
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Figure 2. Ca^+ causes a change in absorbance of ADAMTS13, but only in 
low-ionic-strength conditions. (A) The AbSsao (± SO) of 1 |.iM of purified AD-
AMTS13 in 20 mM Tris-HCI (pH 7.8) with or without 10 mM CaCl2, and with or without 
150 mM NaCl, was measured at 0 minutes and 60 minutes after the addition of CaCI; 
and/or NaCl. (B) Change in AbSgso of 1 p,M ADAMTS13 in 20 mM Tris-HCI (pH 7.8) 
and 10 mM CaCl2 over 60 minutes. (C) Change in Absjso of 1 p.M ADAMTS13 in 
20 mM Tris-HCI (pH 7.8) prelncubated for 1 hour with 0 to 5 mM CaCl2. From these 
data, the EC50 was derived. 
metalloprotease domain to the active site and is highly conserved in 
matrix metalloproteinases (MMPs). 
Two further potential Ca^+-binding sites (called Site 2 and Site 
3) were also identified based on the presence of clusters of Asn, 
Asp, and Glu residues (Figure 3B,C). Site 2 is located relatively 
close to Site 1, and involves residues in proximity on a contiguous 
sequence potentially involving a combination of Asn 162, Glul64, 
Asp 165, Asp 166, and Asp 168. Site 3 is located on the other side of 
the metalloprotease domain to Site I and Site 2, adjacent to the 
active site cleft involving Aspl87 and Glu212, and either Asp l82 
or Glu l84 (Figure 3C). G lu l84 and Asp 187 are not conserved, 
whereas Asp 182 and Glu212 are well conserved among the 
ADAMTS family. 
The Ca^+-induced change in absorbance of ADAMTS13 under 
low-ionic-strength conditions is lost by mutation of Site 1 
To investigate the functional response of Site 1 to Ca^"^, 
2 ADAMTS 13 single-point mutants, E83A and D173A, were 
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Figure 3. Identification of putative Ca^+-binding sites in ADAMTS13 metallopro-
tease domain by homology modeling. (A-C) The ADAMTS13 metalloprotease domain 
was homology-modeled using the crystal structure of adamalysin II (1 lAG). Structures are 
depicted in cartoon format. Zrf + ion and 3 active-site His residues are shown in blue. 
(A) Site 1 predicted to involve E83, D173, C281, and D284 is shown in red. Ca^+ ion also 
present In adamalysin II oystal structure in a homologous site Is shown as a red sphere. 
(B) Putative SiW 2 is in proximity to Site 1 (shown in red) and may involve residues N162, 
E164, D165, D166, and D168, which are highlighted in green. (C) Putative Site 3 Is located 
on the opposite side of the metaNoprotease domain to SIW1 arxj Site 2 (shown in red arxj 
green, respectively) and lies adjacent to the acbve-site defL Site 3 may involve residues 
D182, El 84, D187, and E212, which are shown in purple. 
generated to disrupt Ca^+ binding to tliis site (Figure 3A). These 
mutants were then tested for functional Ca^ "^  dependence using the same 
assays used previously to characterize wild-type ADAMTS13. The 
E83A and D173A mutants showed an overall for Ca^+ of 65 |xM 
and 51 |xM, respectively (Figure 4A), which is very similar to the data 
Time (mins) 
Figure 4. Mutagenesis of Site 1 abolishes the Ca^Nnduced conformational 
change in ADAMTS13 observed under low-ionic-strength conditions. Analysis 
of putative Site 1 residue mutants. (A) 1 nM ADAMTS13 wild-type, E83A, or D173A in 
150 mM NaCI and 20 mM Tris-HCI (pH 7.8) was preincubated with 0 to 5 mM CaClg 
for 60 minutes at 37"C before addtion of 1.6 VWF115 substrate. After 10 min-
utes, reactions were stopped with EDTA, and VWF115 cleavage was quantified by 
HPLC, from which initial rates of substrate proteolysis were determined. Initial rates 
are plotted as a function of Ca^+ concentration, from which the Ko{mpp) was derived. 
(B) The AbS28o (± SD) of 1 jxM purified ADAMTS13 ( • ; WT), E83A ( • ) , or D173A ( • ) 
in 20 mM Tris-HCI (pH 7.8) plus or minus 10 mk^  CaCl2 was measured at 0 minutes 
arxj 60 minutes after the addition of CaClg. (C) Change in Absggo of 1 ADA^^TS13 
{WT), E83A, and D173A in 20 mM Tris-HCI (pH 7.8) and 10 mM CaGl2 over 
60 minutes. 
derived for wild-type ADAMTS13. In the absence of NaCl, however, 
neither of these mutants exhibited any change in Abs28o in the presence 
or absence of 5 mM Ca^+, even after 1 hour (Figure 4B,C). Even when 
Ca^+ was increased to 8 mM, we detected no change in Abs28o for either 
of these mutants (data not shown). These data revealed that the 
Ca^+-induced absorbance change detected under low-ionic-strength 
conditions in wild-type ADAMTS13 had been abolished by either of the 
E83A or D173A substitutions and was therefore mediated by Site I. 
They also suggest that whereas these residues most likely bind Ca^+, 
this does not appreciably influence substrate cleavage under normal 
ionic conditions. 
Site 2 is not a functional Ca^^-binding site 
From our molecular modeling, the putative Ca^+-binding site 
called Site 2 (Figure 3B) could potentially involve several residues 
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Figure 5. Putative Site 2 is not a high-affinity functional binding site. Analysis of 
putative Site 2 mutants. 1 transiently expressed ADAMTS13 (WT) or E164A or 
D166A Site 2 mutant in 150 mM NaCI and 20 mM Tris-HCI (pH 7.8) were preincu-
bated with 0 to 8 mM CaClsforGO minutes at 37°C before addition of 1.6 p,M VWF115 
substrate. After 10 minutes, reactions were stopped with EDTA, and VWF115 
cleavage was quantified by HPLC, from which initial rates of substrate proteolysis 
were determined. Initial rates are plotted as a function of Ca^^ concentration, from 
which the Ko^ mpp) was determined. 
in a short sequence spanning residues 162 to 168 of the metallopro-
tease domain. To determine whether Site 2 corresponded to the 
high-affinity functional Ca^+-binding site, El64A and D166A 
mutants were generated and the Ca^+ dependence of VWF115 
proteolysis was analyzed (Figure 5). From the initial rate of 
VWF115 cleavage data, we derived Krxapp) values that were very 
similar to those derived for wild-type ADAMTS13 (Figure 5). The 
lack of any functional deficit in either the E164A or D166A mutants 
strongly suggested that Site 2 is not a functionally important 
Ca^"^-binding site. 
Site 3 is the functional high-affinity Ca^+-binding site and is 
essential for full ADAMTS13 activity 
The putative Ca^+-binding site, called Site 3, is predicted to involve 
residues Asp 182 or Glul84, Asp 187, and Glu212 (Figure 3C). We 
made E184A, D187A, and E212A substitutions because 2 of these 
residues are unique to ADAMTS13 (Glul84 and Asp 187) among 
the ADAMTS family, and one is highly conserved (Glu212). 
Following generation of E184A, D187A, and E212A mutants, we 
measured the Ca^+ dependence of VWF115 cleavage. As before, 
wild-type ADAMTS 13 showed a characteristic Ko(^p) for Ca^+ of 
72 |j,M. The E184A mutant exhibited a that was very similar 
to wild-type ADAMTS 13 (Figure 6A). However, it was clear that it 
had reduced Ca^+ dependence, as observed by the shift of the curve 
to higher concentrations of Ca-+. We derived a Ko^ app) value of 
242 |xM (as compared with the 72 ^iM derived for wild-type 
ADAMTS 13). This suggested that the binding of Ca^+ to the 
high-affinity site had been compromised by this mutant rather than 
abolished. The data for D187A and E212A mutants were more 
Site 3 
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mu timers 
VWF 
cleavage produdis 
Figure 6. Site 3 Is a high-affinity functional Ca^^-binding 
site and is critical for ADAMTS13 activity. (A) Analysis of 
putative Site 3 mutants. 1 nM transiently expressed 
ADAMTS13 (WT), E184A, D187A, or E212A Site 
3 mutants in 150 mM NaCI and 20 mM Tris-HCI (pH 7.8) 
were preincubated with 0 to 5 mM CaCl2 for 60 minutes al 
37°C before addition of 1.6 (iM VWF115 substrate. After 
lOmnutes, reactions were stopped with EDTA and 
VWF115 cleavage was quantified by HPLC, from which 
initial rates of substrate proteolysis were determined. 
Initial rates are plotted as a function of Ca^+ concentra-
tion, from which the Ko{mpp) was derived. (B) The AbS28o 
(± SD) of 1 ixM purified ADAMTS13 D187A mutant in 
20 mM Tris-HCI (pH 7.8) in the absence ( • ) or presence 
(M) of 10 mM CaClp was measured at 0 minutes and 
60 minutes after the addition of CaClg. (C) Change in 
AbS2Bo of 1 p.M purified ADAMTS13 (WT) or D187A 
mutant in 20 mM Tris-HCI (pH 7.8) and 10 mM CaCI? over 
60 minutes. (D,E) Plasma-derived purified full-length VWF 
was pretreated with 1.5 M guanidine-HCI to denature the 
protein and then added to a preincubating mixture of 
5 nM wild-type or D187A mutant, 150 mM NaCI, 20 mM 
Tris-HCI (pH 7.8), and varying CaCl2 concentrations 
between 0 and 5 mM. The reaction was incubated at 
37°C for 60 minutes before quenching with EDTA. 
Samples were analyzed by collagen-binding assay to 
assess the ability of the remaining VWF in the sample to 
bind human collagen type III (D). Samples were also run 
on a 1.4% agarose gel with subsequent Western blotting 
to detect VWF multimefic composition (E). 
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Table 1. Kinetic analysis of wild-type ADAMTS13 and mutant D187A ADAMTS13 proteolysis of VWF115 
Time course (n = 3), 
k„i/Km, 10= M- 's - ' 
Michaelis-Menten 
ADAMTS13 Km, IJ.M kcal, S-' kcai/Km, 10= 
Wild-type 1.24 i 0.10 1.29 1.31 1.02 
D187A 0.10 ± 0.02 4.32 0.31 0.07 
dramatic (Figure 6A). Both mutants showed appreciably reduced 
Vmnx (3- and 4-fold, respectively). Furthermore, for each mutant, 
the Kocapp) was appreciably altered, at 520 p,M for D187A, and 
720 |xM for E212A (Figure 6A). This strongly suggests that the 
binding of Ca^+ to the high-affinity site has been greatly attenuated 
or abolished in these mutants. 
To examine the contribution of this high-affinity Ca^^-binding 
site to the proposed conformational change induced in 
ADAMTS13 under low ionic conditions in the presence of Ca^+, 
absorbance studies were performed with the D187A mutant under 
low-ionic-strength conditions, as before. The conformational change 
in response to incubation with Ca^+ remained the same as 
wild-type ADAMTS13 (Figure 6B,C), consistent with this effect 
being mediated by the low-affinity Site 1. This suggests that the 
2 potential Ca^+-binding sites have independent effects. 
To investigate possible mechanisms by which Ca^^ occupancy 
of Site 3 influences ADAMTS13 proteolysis of VWF115, kinetic 
investigations were carried out using wild-type and mutant 
ADAMTS13 with VWF115 in the presence of 5 mM Ca^" .^ 
Time-course analysis (n = 3) carried out with 0.85 nM wild-type 
ADAMTSI3 and VWF115 ( < I (xM) revealed values of 
1.24 (± 0.10) X 10^ M~ ' s~ ' , whereas this was reduced to 
0.10 (± 0.02) X 10®M~'s~' for the D187A mutant (Table 1). 
Michaelis-Menten constants, K^, and the turnover number, kcat, 
were determined by titration with increasing and saturating amounts 
of substrate (Table 1). For wild-type ADAMTS13, the for 
VWF115 was found to be 1.29 |xM and k^a, to be 1.31 s" ' . The 
corresponding values for the D187A mutant were 4.32 |xM 
and 0.31 s" ' . 
The D187A mutant was further investigated in full-length VWF 
assays to determine the influence of this mutation, and hence this 
site, with the physiologic substrate. Plasma-purified VWF (pre-
treated with guanidine-HCl) was incubated with both wild-type 
ADAMTS13 and D187A mutant preincubated with varying Ca^+ 
concentrations (0-5 mM). Figure 6D shows the analysis of these 
samples using a collagen-binding assay. VWF after incubation with 
wild-type ADAMTS13 had greatly reduced collagen-binding func-
tion when compared with VWF treated with D187A mutant. The 
VWF cleavage products were also analyzed on a multimer gel 
(Figure 6E). This clearly shows a difference between wild-type 
ADAMTS13 and D187A mutant in both the rate of proteolysis (as 
shown by a greater number of high-molecular-weight bands after 
time with the mutant compared with wild-type ADAMTS13) and 
also the Ca^+ dependence (with low-molecular-weight bands 
appearing at much higher Ca-+ concentrations in the mutant 
(500-1000 |xM) than with wild-type ADAMTS13 (50-200 puM). 
Discussion 
In the present study, we aimed to characterize the Ca^+ dependence of 
the functional activity of ADAMTS 13. Here, we report for the first time 
that Ca^+ ions do not fully activate ADAMTS 13 immediately upon 
addition, with fuU activation occurring only after 40 minutes of incuba-
tion with Ca^+ ions. This has obvious implications for the design of 
functional assays for ADAMTS 13, which should allow time for 
equilibration of the protease and Ca-^ ions. We also demonstrate that 
Ca^+ and Zn^+ ions have independent roles in protease activity, with 
both ions absolutely required for expression of activity. The requirement 
for Zn^+ ions is no surprise in view of its known role in the ADAMTS 
family, forming an essential part of the active center. It is also known that 
Ca^+ is needed for optimum activity, but there have been disparate 
findings on its importance, and the mechanism for Ca^'^'-induced 
activation has not been flilly addressed before. The speculation in the 
literature about possible functional Ca^"^-binding sites in ADAMTS 13^^^ 
have not before been subjected to formal evaluation of their roles. The 
homology model of the ADAMTS 13 metalloprotease domain, based on 
the crystal structure of adamalysin H, identified a putative Ca^"^-binding 
site (Site 1) in ADAMTS 13 predicted to be coordinated by Glu83, 
Aspl73, Cys281, and Asp284 (Figure 3A).® These residues are broadly 
conserved among ADAMTS family members and other metalloprotein-
ase domains. For this reason, Ca-+ binding to this site may also be a 
common feature of ADAMTS proteins.^' The present study found that a 
response (change in absorbance) to occupancy of this site by Ca-+ could 
be measured, but only under low-ionic-strength conditions. This re-
sponse was attributed to a conformational change in the metalloprotease 
domain of ADAMTS 13. Absorbance measurements of mutants of this 
potential site to which Ca^+ had been added under low-ionic-strength 
conditions showed no changes in AbS28o over time (Figure 4B,C), or 
with increasing ion concentration (data not shown), suggesting that the 
Ca-^-dependent conformational change had been ablated in these 
mutants. Together, these results strongly suggest that Glu83 and Asp 173 
(in conjunction with Cys281 and Asp284) comprise a potential low-
affinity Ca-+-binding site in ADAMTS 13. Gerhardt et al identified a 
double Ca^^ site in ADAMTS 1'^  in the region corresponding to the 
low-affinity Site 1 in ADAMTS 13, which is also present in ADAMTS4 
and ADAMTS5.^^ The double Ca^"^-binding site appears to be a unique 
feature of ADAMTS family metalloprotease domains, although whether 
all members of this family bind 2 Ca^+ ions at this site remains to be 
established. It is thought that in ADAMTS 1, this double site may help 
stabilize/mediate folding and reorientation of a polypeptide loop connect-
ing the metalloprotease and disintegrin-like domains. This appears to 
position the disintegrin-like domain close to the active site at the other 
end of the catalytic domain.^^ This is also thought to be the case in 
ADAMTS4 and 5.^ Conceivably, such a conformational change may 
contribute to the Ca^+-dependent Abs28() changes seen with 
ADAMTS 13 under low ionic conditions. This process might involve 
repositioning of the more C-terminal domains to align with the active 
site of the metalloprotease. For this reason, it has been suggested that the 
disintegrin-like domain in ADAMTS 1 could represent an auxiliary 
substrate binding surface and so be directly involved in substrate 
recognition.^^ Although the large conformational changes observed in 
Figures 2, 4, and 6 are largely inhibited by NaCl, it remains to be 
determined whether more discrete changes still occur and might 
contribute to the multiple interactions required for ADAMTS 13 func-
tion. It must be considered though that short substrate (VWF115) 
proteolysis is largely unaffected by this site, which is demonstrated by 
the essentially unaltered Ca^+ dependence of VWFl 15 proteolysis on 
mutagenesis of residues Glu83 and Asp 173 (Figure 4A). 
nsG 
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Figure 7. Alignment of ADAMTSl 3 Ca^+-binding site 
with other ADAMTS family members. ADAMTS13 met-
alloprotease domain (residues 171-234) were aligned 
with corresponding regions of other ADAk^TS family 
members. Regions of amino acid conservation are high-
lighted in gray. The active site amino adds are boxed/ 
labeled. High-affinity Ca^^-binding residues in 
ADAMIS13 are labeled with arrows. The Cys residues in 
all ADAMTS family members except ADAMTSZ, 3, 13, 
and 14 that pair to form a disulphide bond are highlighted 
in black boxes. 
The evidence for the presence and importance of a high-affinity 
functional binding site is compelling. Prior to the present study, 
despite data highlighting the importance of Ca^+ for ADAMTS 13 
function, there was no indication based on functional studies as to 
the location of a Ca^^-binding site within the ADAMTS 13 
metalloprotease domain. Inspection of the homology model, to-
gether with sequence conservation between ADAMTS family 
members and MMPs, helped identify 2 candidate high-affinity 
sites; Site 2 predicted to involve residues Glul64 and Asp 166 (in 
conjunction with one or more of Asnl62, Aspl65, and Aspl68; 
Figure 3B), and Site 3 predicted to involve residues Asp 187 and 
Glu212 in conjunction with Asp 182 or Glul84 (Figure 3C). The 
suggestion of Site 3 was supported by comparison of the 
ADAMTS 13 metalloprotease domain homology model with 
the crystal structure of MMFS,^' from which clear similarities in 
this Ca^+-binding site can be seen. The present study demonstrates 
that mutating Site 3 residues in ADAMTS 13 to alanine attenuates 
high-affinity Ca^+-induced functional activity (Figure 6A), strongly 
suggesting that they comprise the high-affinity Ca^^-binding site. 
Interestingly, the D184A mutant did not alter the V^ax of 
ADAMTS 13 for VWF115 proteolysis, but it did increase the 
Kocapp)- For this reason, it appears that this mutation reduced the 
affinity for Ca^+ at this site, rather than abolished binding 
completely. This suggests that this residue does not have a major 
role in Ca^ "^  coordination, and that nearby Glul82 is more likely 
the residue that fulfills this function (Figure 7). Conversely, the 
D187A and E212A mutants exhibited both a markedly increased 
Kocapp) and a reduced Vmax- Together, these observations are 
suggestive of an appreciable or even a complete loss of Ca^+ 
binding to the high-affinity Site 3. This result is supported at least 
semiquantitatively by Figure 6D and 6E, which shows decreased 
activity of the D187A mutant compared with wild-type 
ADAMTS 13 against full-length VWF. Despite the large influence 
of mutating this site on Ca^+ functional responses, ADAMTS 13 
still exhibited some residual concentration-dependent response to 
Ca^+ in reaction with VWF115. Whether the residual activity 
represents the function of another distinct functional Ca^+-binding 
site remains to be determined. It is clear, though, that the majority 
of the effects that Ca^+ has upon ADAMTS 13 cleavage of 
VWF115 is mediated through binding to this high-affinity site. 
Further support for a site-specific Ca^+ functional role was 
provided by mutation of Site 2 of ADAMTS 13 (involving similarly 
charged residues, Glul64 and Asp 166). These substitutions had no 
effect upon ADAMTS 13 function or its Ca^+ dependence (Figure 
5). The data presented in this manuscript also suggest that the high-
and low-affinity sites respond to Ca^+ independently. For example, 
the Site 3 D187A mutant ADAMTS 13 still exhibited Ca-^-
dependent changes in Abs^go over time under low ionic conditions 
(Figure 6B,C). 
Inspection of the proposed high-affinity site of ADAMTS 13 and 
comparison of the residues involved with the equivalent region in 
other ADAMTS family members reveals an interesting variation. 
In most of the other ADAMTS metalloproteases, there are 2 Cys 
residues that form an internal disulphide bond (Figure 7). It seems, 
therefore, that this loop adjacent to the active site may be held in a 
stable conformation by the disulphide bond that is present in most 
ADAMTS family members. In ADAMTS 13, these Cys residues 
are not present. Consequently, in ADAMTS 13 this loop may be 
held in a stable/active conformation by a Ca-+ ion, which provides 
a rationale for the functional importance of this site. This conten-
tion is corroborated by MMP8, in which the equivalent loop that 
(like ADAMTS 13) also lacks a disulphide bond, and appears to be 
held in a stable conformation by a Ca^+ ion." 
During the preparation of this manuscript, 3 papers were 
published that describe the crystal structures of the metalloprotease 
domains of ADAMTS 1 ,^ 5 ADAMTS4,^ and ADAMTS5.3"8 Those 
involving ADAMTS4 and ADAMTS5 report a Ca^+-binding site in 
a similar position to Site 3 in ADAMTS 13, although here, there is 
also a disulphide bond present. The disulphide bond will stabilize 
the loop, with a bound calcium ion perhaps also contributing. 
Further kinetic analysis of the reaction between wild-type 
ADAMTS 13 and VWF115, and D187A and VWF115 revealed a 
possible mechanism of action of this high-affinity Ca^+-binding site. 
Time-course analysis carried out with wild-type ADAMTS 13 and 
VWF115 revealed kgat/K^ values of 1.24 (± 0.10) X 10*^  M" 's" ' , 
whereas this was reduced to 0.10 (± 0.02) X 10®M~'s^' for the 
D187A mutant (Table 1). For wild-type ADAMTS 13, the K,^  for 
VWF115 was found to be 1.29 |xM and k^ ai to be 1.31 s~'. The 
corresponding values for the D187A mutant were 4.32 |i,M and 0.31 s"' . 
The increase in implies that the mutation of D187A affects the 
functional binding affinity between the substrate and the active site of 
the enzyme. The reduction in k^ ai points to a reduction also in substrate 
turnover, while the 13-fold reduction in catalytic efficiency provides an 
overall measure of the decrease in proteolytic activity of the mutated 
enzyme. These results directly link the mutation of a residue in a 
Ca^"^-binding site to a reduction in functional substrate binding and 
activity, suggesting that Ca^+ in this site may normally serve to stabilize 
this loop region such that the substrate is optimally placed in the active 
site for efficient proteolysis. Intriguingly, in ADAMTS4 and 
ADAMTS5 there is no residue homologous to Asp 187 in ADAMTS 13, 
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while the homologous residue to Glu212 is present, as it is in all 
ADAMTS family members and most MMPs. Since it is evident that 
Aspl87 is important to activity and calcium binding in ADAMTS 13, 
this different coordination of Ca^+ may be necessary for the Ca^+ ion to 
stabilize the whole loop by itself, as there is no disulphide bond to aid in 
this function. If so, ADAMTS 13 may be more dependent on Ca^+ for 
function than other ADAMTS metalloproteases. 
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